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Introduction
1. Hematopoiesis
1.1 Origin of blood cell formation
Hematopoiesis is the process of proliferation, differentiation and maturation of all different types 
of blood cells (Figure 1).  The primary organs involved in hematopoiesis during embryogenesis 
are the yolk sac and the fetal liver1,2.  The yolk sac is responsible for the primitive erythropoiesis, 
which begins during the first 3 to 6 weeks of gestation in humans and 7 to 7.5 days of gestation in 
mice.  At the early stage of embryo development, yolk sac blood islands are formed which support 
the differentiation of the primitive erythroblast and endothelial cells.  The primitive erythroblasts 
enter the newly formed vascular network, where they continue to divide, differentiate and 
acquire hemoglobin3.  Primitive hematopoiesis is mainly restricted to the erythroid lineage.  The 
cells are large, nucleated, and contain early embryonic globin chains not found in later stages of 
development.  The process continues until approximately day13 in mice when the hematopoietic 
stem cells (HSC) inhabit fetal liver to take over the role as the primary hematopoietic organ until 
birth4,5.  Erythroid cells formed in the fetal liver are enucleated and morphologically similar to 
those found in adult, with the exemption to hemoglobin chains.  The spleen and the thymus also 
are implicated in hematopoiesis during this period to support the differentiated lymphoid cells in 
fetal and adult period.  The fetal hematopoiesis progresses towards the definitive hematopoiesis 
when the HSCs migrate towards newly developed long bones.  In humans the bone marrow is 
the primary organ of hematopoiesis.   The adult definitive hematopoiesis takes place around the 
time of birth, and is a life long lasting process. 
1.2 Hematopoietic stem cells
The hematopoietic cascade of different blood lineages originates from a single common cell the 
hematopoietic stem cell.  HSCs are characterized by unique properties of self-renewal, and the 
capacity to proliferate and differentiate into progenitors of each of the different blood cell lineages 
(pluripotency)6.  The occurrence of HSCs in a normal adult bone marrow is approximately 1 to 
10 cells in 100.000 cells7,8.  The sustained and steady number is achieved mainly due to self-
renewal characteristics.  The pivotal role of HSCs is to give rise to all different blood cells, 
i.e. erythrocytes, platelets, basophils, neutrophils, eosinophils, macrophages, mast cells, B-
lymphocytes, T-lymphocytes, natural killer cells, and dendritic cells9.  The ability for a single 
cell to give rise to different types of lineage specific and functionally different types of cells is 
achieved via two proposed mechanisms.  The first model anticipates that exogenous signals, 
such as ligands, interact with specific receptors to activate lineage-restricted genes in a highly 
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balanced manner10,11.  In the second model the cell fate decision is made stochastically within one 
cell cycle transit12,13.  However, up to date little is known about the molecular mechanism that 
initiates the decision process of stem cells to become a specific cell type.          
1.3 Erythropoiesis
The process of red blood cells (erythrocytes) production from a HSC via several differentiation 
steps is called erythropoiesis (Figure 2).  Colony forming unit-spleen (CFU-S) is one of the 
first experimentally defined cells that loses the ability to self-renewal but retains pluripotency. 
CFU-S may further commit towards the common myeloid progenitor (CMP) which gives rise 
to megakaryocytic/erythroid progenitor (MEP).  Morphological differences between the early 
erythroid progenitors cells cannot be established, however, the first cell from the erythroid 
Figure 1 Schematic representation of hematopoietic cascade
The very first step in hematopoietic differentiation involves a commitment of the hematopoietic stem cell (HSC) to give 
rise to multilineage progenitor (MLP) cells.   MLP give further rise to either the common myeloid progenitor (CMP) 
or common myeloid/lymphoid progenitor (CMLP).  CMP and CMLP progenitors are able to advance to granulocutes/
monocyte progenitors (GMP), as well as give rise to separate lineages: erythroid/megakaryocyte progenitors (EMP) 
or common lymphoid progenitors (CLP), respectively.  EMP continues to differentiate exclusively towards erythroid/
megakaryocytic lineage and CLP towards B-cells and T-cells.  Key hematopoietic transcriptional factors that influence 
commitment to certain lineages are depicted.       
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progenitor line that can be identified in vitro using a cocktail of growth factors and cytokines 
is burst-forming unit-erythroid (BFU-E)14.  Stimulation of an early BFU-E progenitor for 5 to 
7 days in mice and for 14-16 days in humans with erythropoietin (Epo), interleukin 3 (IL-3), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), thrombopoietin, and stem cell 
factor (SCF) gives hemoglobinized cell clusters of more than 500 erythroblasts.  BFU-E is 
the early progenitor which precedes the colony-forming unit-erythroid (CFU-E), that closely 
associates with the proerythroblast14,15.  In contrast to the BFU-E the CFU-E is Epo dependent 
but lost its dependency on other cytokines.  CFU-E is capable of full erythroid differentiation in 2 
days or 5 to 8 days, for mouse or human marrow respectively, and gives rise to small cell clusters 
containing between 8-64 well-hemoglobinized erythroid cells.  
The pro-erythroblast is the most primitive erythroid cell that can be identified morphologically. 
It is characterized by its relatively large size (14 to 19µm in diameter), large nucleus that fills 
80% of the cell, and thin circumference of basophilic cytoplasm16.   During progression to the 
next stage of differentiation i.e. the basophilic erythroblast, the cells become smaller as the 
chromatin starts to condenses, giving the nucleus a granular appearance.  The nuclear chromatin 
continues to condense, and the nucleus becomes smaller as well as the rest of the cell when 
it develops into a polychromatic erythroblast.  At this stage the accumulation of hemoglobin 
becomes detectable with histological staining procedures17.  The orthochromatic erythroblast is a 
small (8-12µm and 7-8µm in diameter in humans and mice respectively) nucleated precursor cell 
of erythrocyte, characterized by pyknotic degeneration of the nucleus due to condensation of the 
chromatin.  The nucleus decreases in size by pyknotic degeneration as the chromatin extensively 
condenses18.  The reticulocyte is the first enucleated cell in which the shrunken nucleus is 
extruded.  Reticulocytes are slightly larger in volume than erythrocytes, and contain some of 
the cytoplasmic organelles, such as ribosomes, mitochondria, and the Golgi complex.  Finally, 
mature erythrocytes have a small size, lack organelles and have a biconcave disk shape19.             
Figure 2 Erythroid lineage differentiation pathway
Erythroid/megakaryocyte progenitor (EMP) is the earliest known precursor cell that can differentiate into erythrocytes or 
megakaryocytes.  Burst forming units-erythroid (BFU-e) and colony forming units-erythroid (CFU-e) can be identified 
by morphology of the colony in a functional assay. Proerythroblast is the earliest cell of the immature forms to be 
morphologically recognizable.  The process continues until enucleation, as the cell becomes a mature erythrocyte.
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1.4 Myelopoiesis
Pluripotent hematopoetic stem cells have the ability to commit towards different lineages of blood 
cells as described above.  The process in which the stem cell gives rise and become a monocyte 
or granulocyte is termed myelopoiesis.  A granulocyte is a general term for three different types 
of cells; basophils, neutrophils and eosinophils that are characterized by presence of cytoplasmic 
storage granules20,21.   As with erythropoiesis it requires different stages of progression during 
the differentiation process.  
Neutrophil origin follows the commitment and differentiation pattern in the very early stages as 
erythroid precursors, i.e., from hematopoietic stem cell towards myeloid/lymphoid progenitor 
(MLP) followed by common myeloid progenitor (CMP).  The common myeloid progenitor cell 
becomes granulocyte/monocyte progenitor (GMP) followed by an additional narrowing towards 
terminal differentiation, as it becomes granulocyte colony-forming unit (CFU-G) (Figure 
3).  CFU-G is the first immature cell that is fully committed towards terminal neutrophilic 
differentiation and gives rise to a myeloblast.  The myeloblast is the first early progenitor cell 
that can be morphologically recognized21.  It has a very immature appearance, distinguishable 
by a large nucleus and multiple nucleoli.  Myeloblasts undergo division and maturation into 
promyelocytes.  This is the largest cell of the neutrophilic series which makes and accumulates 
large numbers of azurophilic granules in the cytoplasm22.  The neutrophilic myelocyte loses 
many of the azurophilic granules, as peroxidase-negative granules become more prominent. 
This is the last stage at which the cell has mitotic capability.  At the myelocyte stage the cell 
generates oxidation components such as the phagocyte respiratory burst oxidase (gp91phox) and 
cytochrome heavy chain, which can be used as detection indicator23.  
The last stages of the neutrophilic differentiation pathway are metamyelocytes, band-forms, 
and mature polymorphonuclear neutrophils.  These cells are non-dividing, with specific 
morphological features such as absence of nucleoli in the nucleus, presence of tertiary granules 
in the cytoplasm, and presence of a segmented nucleus in the mature neutrophil.  Late markers 
for mature neutrophils include lactoferrin (LF), neutrophil gelatinase (NG), and in mice 
the GR-1 receptor marker23. The bone marrow is the main organ that supports neutrophilic 
proliferation and maturation.  Within the bone marrow neutrophils are found in two functionally 
different compartments, a proliferating compartment and a storage compartment.  The actively 
proliferating neutrophil precursor cells (myeloblast through myelocyte) are localized in mitotic 
or proliferating compartment.  In the maturation storage compartment more differentiated cells 
are found; metamyelocyte, band, and mature neutrophils24.  The polymorphonuclear neutrophils 
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enter the blood circulation where they function for the next 24 to 48 hrs before death or loss25.  
2. Transcription factors in hematopoietic development 
2.1 Introduction to transcription factors
Transcription factors are proteins which posses the ability to recognize and bind to specific 
short DNA base sequences and regulate transcription of genes26-29.  The sites are identified via 
specific motifs present within the transcription factor, the DNA binding domains30-32.  Common 
domains in transcription factors that are involved in DNA binding are zinc fingers (C
2
H
2
, C
4
, or 
C
6
)33,34 , helix-turn-helix (two α helices and a short extended amino acid chain between them), 
leucine-zipper (two α helices joined together)35, and helix-loop-helix  (similar to leucine-
zipper structure)36 motifs.  Although the motifs might differ between transcription factors, the 
role remains the same, which is specific DNA sequence recognition followed by control and 
regulation of gene expression.  This is achieved by binding to promoter regions, frequently a 
few hundred basepairs upstream of the major transcription start site of a gene, to either inhibit 
or activate transcription. 
Although physical interaction between DNA and the transcription factor is essential, this 
interaction is not solely responsible for its activity.  Other specific functional domain(s) present 
within the transcription factors are required to accomplish the protein’s functions26. Transcription 
factors in general are known to form complexes with other proteins, critical for their function. As 
a result these interacting proteins can regulate transcription factor function.  These co-factors, or 
protein complexes may influence the fate of transcription factors from being either a repressor or 
an activator37-40. Transcription factors may undergo posttranslational modifications.  Eukaryotic 
proteins are modified by a stable modifications, such as disulfide formation, glycosylation, and 
lipidation, that allows the protein to form the correct structure and proper functional state41. 
Furthermore, many other covalent modifications may occur transiently but they play important 
roles in regulating the protein biological function.    
The most common covalent modifications are phosphorylation, acetylation, methylation, 
Figure 3 Schematic representation of the differentiation stages of myeloid lineage
Colony forming unit-granulocyte (CFU-G) is the first committed immature progenitor cells that give rise to mature 
neutrophils.  During differentiation the cell undergoes morphological changes such as granulation and nucleus 
segmentation.  The neutrophil has a lifespan of about 3 days.
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sumoylation and ubiquitination29,42.  These modifications may take place at a single site, but also 
at multiple sites41.  The complexity of protein modifications is not only restricted to the type 
of modification at a given residue, but also by the fact that the same residue can be modified 
in many different ways43-45.  Posttranslational modification of transcription factors appears to 
play an important role as it influences the expression of the target genes.  The most well studied 
transcription factor that may undergo many different modifications, thereby affecting its function 
and regulation, is the tumor suppressor factor p53 46. 
The fate of uncommitted progenitor cells towards fully functional lineage specific cells has in 
recent years mainly been studied in the light of extrinsic (growth factors or stroma) or intrinsic 
(stochastic) signals12,13,47,48.  Although both signals have a major influence on the cell’s fate, the 
importance of transcription factors should not be overlooked, as they are key molecules that 
influence the expression of genes that regulate committed mature cell development. 
2.2 Transcription factors in erythroid development
GATA1.  The transcription factor that plays a major role in erythroid lineage development 
and differentiation is GATA1.  GATA1 is a member of a zinc finger transcription factor 
family containing 6 members.  GATA1 is required not only for the proper development of the 
erythroid, but also for the megakaryocytic and eosinophilic lineages.  The identification of 
GATA1 was accomplished by recognizing a specific transcription factor that was able to bind 
the β-globin 3’ enhancer sequences in chicken and human49,50.  GATA1 recognizes and binds a 
specific DNA consensus sequence, (A/T)GATA(A/G), via its C
4
 zinc finger domains51-53.  The 
expression of GATA1 is restricted to erythrocytes, megakaryocytes, eosinophils, and mast cells, 
54-57.  The importance of GATA1 as a key regulator in erythropoiesis was demonstrated both 
in vitro and in vivo.  Embryonic stem (ES) cells deficient in GATA1 by gene disruption were 
capable to contribute to all different tissues, including white blood cells. However, there was 
no contribution towards mature red blood cells58.  In accordance with the in vitro observations, 
GATA1 -/- mice showed embryonic lethality between day E10.5 and E11.5, due to profound 
anemia54,59.  Characterization of the cell stage in the absence of GATA1 revealed a block of 
differentiation at the proerythroblast stage60.  Other mouse models with partial disruption of 
the GATA1 gene showed that GATA1 levels played a pivotal role in control of erythroid cell 
development61,62.  The finding that GATA1 is a key factor in erythroid development may indicate 
the direct role of its target genes in erythropoiesis.  The abundance of GATA consensus sequences 
in the genome that can be found in the promoters of many genes does not reflect its real target 
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genes.  The most well studied direct targets of GATA1 are the genes encoding α and β-globins, 
the heme biosynthesis enzymes ALAS2, ALAD, and HMBS, ABC mitochondrial erythroid 
(ABCme), erythropoietin (Epo), Epo receptor (EpoR), the anti apoptotic protein Bcl-
XL
, and 
the transcription factors GATA2, EKLF, and TAL149-51,63-70.  In addition, interactions of GATA1 
with other transcription factors or co-factors have been shown to influence the expression of 
GATA1 target genes.   Putative target genes may either be repressed or activated.  GATA1 is able 
to form homo-dimers via its N- or C-terminal zinc finger.  The dimerization plays an important 
role in self-regulation, as shown in the zebrafish model 71.  A very important partner of GATA1 
isolated in a yeast two-hybrid screen is Friend of GATA1 (FOG1)72.  The interaction occurs via 
the N-terminal zinc finger domain of GATA1, and plays an essential role during erythroid and 
megakaryocytic differentiation73.  Ablation of the GATA1 domain required to form a complex 
with FOG1 inhibits the progression towards erythroid terminal differentiation.  Depending on 
the promoter context FOG1 can either stimulate or represses GATA1 activity at the promoter 
level.  PU.1 has been demonstrated to act as a binding partner of GATA1 and inhibits GATA1 
binding to DNA. In addition, it has been reported that GATA1 prevents c-Jun from forming a 
complex with PU.174.   These interactions may be of great importance in the decision making of 
precursors to develop either into the myeloid or into the erythroid lineage.  Other proteins that 
have been reported to interact with GATA1 are the tumor suppressor protein retinoblastoma (Rb) 
erythroid Krüppel-like factor (EKLF), LIM-only protein (LMO2), and P300/CBP75-77.
GATA2.  The second hematopoietic member of the GATA family was identified by Yamamoto 
and colleagues based on the sequence homology with GATA178.  GATA2 contains a C-
terminal DNA binding zinc finger domain and an N-terminal zinc finger involved in protein-
protein interaction similar to the other GATA family members79. The expression of GATA2 is 
restricted to hematopoietic stem cells, hematopoietic early progenitors, and endothelial cells79. 
Constitutively active GATA2 supports proliferation and blocks terminal erythroid differentiation 
of erythroid precursor cells80,81.  The expression and tight regulation of GATA2 depends on 
cooperation with GATA1.  The level of GATA2 must decrease when the GATA1 level increase 
to allow erythroid terminal differentiation.  The importance of GATA2 in the erythroid lineage 
was demonstrated by ablation studies of GATA2 in vivo.  GATA2 -/- mice are embryonic lethal 
at day E10-11 due to defective primitive and definitive erythropoiesis82,83.  In vitro differentiation 
using GATA2 null ES cells implies a key role for GATA2 in maintenance and/or proliferation of 
hematopoietic precursors cells84.   
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EKLF.  The erythroid Krüppel-like factor (EKLF) belongs to a large family of transcription 
factors that is characterized by a common arrangement of the zinc fingers, as previously found 
in the Drosophila Krüppel protein85.  The three C
2
H
2
 zinc fingers of EKLF are positioned at the 
C-terminal part of the protein.  In addition, the protein contains two transactivation domains 
(TD) within the proline rich region domain spanned along a major part of the protein86,87. 
EKLF was isolated from mouse a erythroleukemia cell line, and the expression is restricted 
to the erythroid lineage88-90.  The mRNA transcript of EKLF is present as early as E7.5 in the 
developing embryo, and continues to be expressed in the adult spleen91.  This indicates that both 
primitive and adult hematopoietic cells express EKLF and that its expression is required for the 
survival and maturation of erythroid cells.  The zinc finger domain of EKLF specifically binds 
the DNA sequence 5’-CCACACCCT-3’88.  The specificity of the binding and its target genes was 
demonstrated in β-thalassemia patients, as mutations in the EKLF DNA binding site of β-globin 
promoter region strongly decrease the expression of β-globin chain92-94.  
The role of EKLF in vivo was addressed using EKLF -/- mice89,90.  The homozygous null mice 
die at E14, which indicates that primitive erythropoiesis, is not severely affected, as the embryos 
are able to survive until fetal liver erythropoiesis takes over.  At a later stage (E12), fetal 
erythropoiesis is impaired resulting in severe anemia.  
NF-E2.  The nuclear factor E2 (NF-E2) is a heterodimeric basic-leucine zipper (b-Zip) 
transcription factor95,96.  The two subunits of NF-E2 are the p45 tissue-restricted subunit present 
in the erythroid, megakaryocytic, granulocytic and mast cell lineages, and a wider expressed p18 
small subunit, a member of the Maf protein family96.  The p45 subunit contains a transactivating 
domain at the N-terminus and a cap ‘n collar (cnc) domain at the C-terminus.  The p18 
subunit includes the DNA-binding motif and recognizes sites containing an AP-1 motif, 5’-
(T/C)GCTGA(G/C)TCA(T/C), however, function specificity is achieved with some additional 
basepairs upstream of the AP-1 binding motif96.  In erythroid precursors NF-E2 associates with 
the promoter of the porphobilinogen deaminase (HMBS) gene 97, α and β-globin LCR enhancer 
element95,96, and other genes involved in iron metabolism which suggests an important role in 
regulating tissue-specific gene expression98,99.   Although NF-E2 controls many genes involved 
in heme and globin synthesis, the p45 subunit of NF-E2 null mice model revealed an unexpected 
phenotype98.  The erythroid lineage was only mildly affected, but megakaryocytic development 
was impaired giving rise to a lower platelet counts.  Targeted disruption of the gene encoding for 
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the smaller subunit, p18, did not result in an overt phenotype100.  
2.3 Transcription factors in neutrophilic development
The progression/maturation process from an immature myeloblast to an active, fully differentiated 
neutrophil depends on a defined expression of an array of cell specific genes.  Regulation occurs 
via specific transcription factors that control the expression of granulocytic genes.  Amongst 
many transcription factors involved in neutrophilopoeisis, two factors that stand out are C/EBPα 
and PU.1 (Spi1).  
PU.1. PU.1 was first identified as the product of viral integration in the Spi-1 locus in Friend 
virus induced erythroleukemia101.  Insertion in the upstream 5’ region of PU.1 leads to an 
aberrant constitutive expression of PU.1 in proerythroblasts causing uncontrolled proliferation 
and block of terminal differentiation102,103.  In human and mouse PU.1 expression is observed in 
macrophages, mast cells, B lymphoids, early erythroid cells, and granulocytes but is undetectable 
in T cells101,104.  Biochemical studies further delineated specific transcriptional domains of 
PU.1105.  The N- and C-terminus consist of a transactivating region and a DNA specific binding 
region, respectively.  Distal to the N-terminal transactivation region, a proline-, glutamic acid-, 
serine-, and threonine-rich protein-protein interaction domain called region PEST is present. 
A helix-turn-helix DNA binding motif in PU.1 binds a specific purine-rich DNA sequence 5’-
AAAG(A/C/G)GGAAG-3’, nominated as the PU box106.  Homology base pairing revealed that 
PU.1 is a member of the large ETS family of transcription factors, with a common 80 amino 
acids DNA binding domain which characterizes the family107.  To gain insight into the specific 
role of PU.1 in vivo, a knockout model was established108,109.  Disruption of the PU.1 gene is 
embryonically lethal between day E17 and E18.  The PU.1 null mouse model is characterized by 
impaired development in the lymphoid, myeloid and erythroid lineage.  PU.1 overexpression in 
a transgenic model showed development and progression of erythroleukemia within few months 
after birth 110. The expression level of PU.1 in early progenitor cells, ES cells or CD34+ cells, is 
low and rises during myeloid terminal differentiation111.  The important role of PU.1 in myeloid 
cell development depends on interacting proteins112.  Granulocytic genes that have been shown 
to be targets of PU.1 either solely or in conjunction with other co-operative transcription factors 
are genes encoding for myeloperoxidase (MPO), neutrophil elastase (NE), myeloblastin (MBN), 
G-CSF receptor, GM-CSF receptor, lysozyme, a component of the phagocyte respiratory burst 
oxidase (gp91phox), tyrosine kinase c-fos, and beta 2 leukocyte integrin (CD18)13.  
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C/EBPα. CCAAT/enhancer binding protein α (C/EBPα) is a transcription factor of which its 
expression in the hematopoietic system is restricted to the myeloid lineage113.  The importance 
of C/EBPα as a key factor in granulopoiesis was demonstrated in null mice114.  Homozygous 
C/EBPα null mice showed a complete absence of mature neutrophils and eosinophils.  Other 
lineages, monocytes, macrophages, monocytes, erythrocytes, and platelets were unaffected. 
The deficiency takes place at an early stage of myelopoiesis, i.e., at the granulocyte/monocyte 
progenitor (GMP) level.  The lack of neutrophils in C/EBPα null mice indicates a pivotal role of 
this transcriptional factor as a potential regulator of its targets genes114,115.  One important gene 
that was observed to be down regulated in C/EBPα (-/-) newborn was the gene encoding for G-
CSF receptor.  However, lack of G-CSF receptor expression does not fully explain the observed 
phenotype, as G-CSF receptor (-/-) animals develop mature neutrophils, although in reduced 
numbers116.  This would indicate that additional target genes of C/EBPα play a critical role in 
neutrophil development.
C/EBPα belongs to a family of leucine zipper (bZIP) transcription factors that bind to specific 
DNA sequences117.  The domain responsible for binding DNA is located at the C-terminal part of 
the protein, in close proximity and upstream of the leucine zipper, a domain required for homo- or 
hetero-dimerization.  In addition, the N-terminus consists of two regulatory and transactivating 
domains TAD1 and TAD2118,119.  The expression level of C/EBPα is tightly controlled during 
myeloid differentiation, as shown in different myeloid cell line models120-122.       
Recently, mutations in the coding sequence of C/EBPα were found with the frequency of 9% of 
acute myeloid leukemia (AML) samples analyzed.  The phenotype observed in the knockout C/
EBPα animal model showed block in the granulocytic lineage, however, the mutations found in 
AML samples do not involve null mutants, but rather out-of-frame insertions/deletions or single 
point mutations in different functional domains of C/EBPα123,124.   
AML1. The expression of AML1 is mainly restricted to myeloid and lymphoid lineages during 
differentiation, but also includes early precursor cells125-127.  AML null mice do develop primitive 
hematopoiesis lack definitive hematopoiesis.  In vitro differentiation of null ES cells also failed 
to contribute towards hematopoietic lineage specific progression128.  AML1 is a DNA binding 
transcription factor and binds TGT/cGGT consensus sequence via the runt N-terminus DNA 
binding domain129.   The binding between AML1 and DNA occurs also indirectly, via other 
Ets family members, such as MEF, Ets-1, PU.1 and C/EBPα and synergistically enhance 
transcription130-132. 
c-Myb. The transcription factor c-myb was identified in a retroviral screen133,134.  Structurally, c-
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Myb possesses two important domains, an N-terminal DNA binding domain and a transactivating 
domain localized more centrally135,136.  The expression level of c-myb in hematopoietic precursor 
cells is high and gradually decreases as the cell progresses towards maturation137.  The control 
of c-myb expression is important especially during myeloid differentiation, as inhibition of c-
myb negatively influences the proliferation, while over-expression reduces growth arrest during 
terminal erythroid and myeloid differentiation138-141.  c-Myb knockout embryos die at E15.5 
due to lack of lymphoid, myeloid, and erythroid lineages142.  A more indirect role of c-Myb in 
myeloid development is achieved via co-operation with other factors such as members of the 
AML1 family and C/EBPα143,144.  In addition, c-Myb is able to regulate the expression of c-Myc, 
c-kit, and Flt3145.  These findings indicate that multiple indirect mechanisms exist by which c-
myb controls myeloid development.
2.4 Transcription factors in AML
Transcription factors play a very important role in the pathogenesis of acute leukemia.  Alteration 
or disruption of transcription factors in AML affects the normal cell cycle and differentiation of 
developing cells.  Transcription factors are highly regulated during normal cell development, and 
follow a specific pattern of expression and interaction with other regulatory proteins.  However, 
the same transcription factors are frequently involved in AML, such as Evi1/AML1 in t(3;21), 
AML1/ETO in t(8;21), PZLF/RARα in t(11;17) or PML/RARα in t(15;17)146.   Deregulation of 
transcription factors and consequently progression towards leukemia can be due to two different 
mechanisms.  The first model implies a quantitive change, where the inappropriate silencing 
or/and aberrant expression leads to loss or gain of function, respectively.  The second model 
involves mutations where the corresponding proteins either become truncated or chimeric 
proteins are generated with altered functional properties.  Those alterations play a crucial role in 
neoplastic progression146. 
Acute Myeloid Leukemia (AML) is a malignant disease of hematopoietic precursors in the 
bone marrow and blood.  The diseases can occur in a variety of ways, perturbing the normal 
physiological process of different blood lineages to proliferate, differentiate, or undergo apoptosis. 
Due to different factors affecting development of AML, patients show heterogeneous offset of 
the disease.  In the majority of cases the chromosomal alteration determine the outcome and 
progress of the disease.  The disease can be simply characterized into 3 major groups: favorable 
[t(8,22), t(15,17) and inv16], 60-80% survival) intermediate (representing normal karyotypes 
40% survival) and unfavorable (other clonal cytogenetic abnormalities, 20% survival)147.  
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EVI1 (ecotropic virus integration 1) is an oncogene involved in translocation or inversion on 
human chromosome 3, t(3;3)(q21;26) or inv(3)(q21;q26) respectively148.  AML with aberrant 
expression of EVI1 belongs to an unfavorable risk group149.  
3. Ecotropic virus integration 1 (Evi1)
3.1 EVI1, a transforming gene in AML and MDS
EVI1 was isolated and characterized from mouse retrovirally induced leukemic cell lines and 
codes for a nuclear protein of 1042 amino acids with particular motifs typical for transcription 
factors150.  Mouse Evi1 is located on chromosome 4, whereas in human EVI1 gene is located on 
chromosome 3 band q24-q28.  It consists of 12 exons with two non-coding exons, spaning over 
100 Kb of genomic sequence.  The transcript encodes for a full 145 kDa nuclear protein, but a 
shorter splice form of 88 kDa lacking zinc fingers 6 and 7 exists in human and mouse151-153.  The 
sequence between the human and mouse gene is highly conserved, and is identical for 91% at 
the nucleotide level and 94% at the amino acid level.  EVI1 has ten Krüppel-like zinc fingers 
(C
2
H
2
), of which seven are at the N-terminal part of the protein and three are more C-terminaly 
located (Figure 4).  The C and N terminal zinc finger regions are spaced by a proline rich region. 
Within the proline rich region a repression region has emerged recently which has shown to be 
responsible for EVI1 repression activity154,155.  
At the C-terminus a small acidic domain is present with unknown function to date.  Both zinc 
finger domains are able to bind to DNA. The first seven zinc fingers of EVI1 recognize the 
DNA nucleotide sequence GACAAGATAA156-158 and the three C-terminal fingers bind to the 
Figure 4 Schematic representation of ecotropic viral integration 1 (EVI-1) protein
The protein consists of several different motifs.  EVI-1 possesses ten C
2
H
2
 zinc fingers of which seven are located at 
the N-terminus and three at the C-terminus (black).  The zinc fingers structure with cysteine-histidine pairings that co-
ordinate tetrahedral binding to a single zinc atom (Zn) is depicted.  The N-terminal zinc finger can bind a specific DNA 
sequence, as does the C-terminus.    In addition, EVI-1 contains a repression domain (brick area) located between both 
zinc finger domains.  At the C-terminus a small acidic domain (white/black square) is located with unknown function.  
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GAAGATGAG DNA sequence159.  Although the EVI1 zinc fingers are capable of binding DNA, 
only one group of investigators have provided data that suggest binding to these sequences by 
the full length protein160.  Zinc fingers may not solely bind DNA sequences, but may also interact 
with other proteins.      
Spatial and temporal expression of EVI1 was demonstrated by Perkins et al158.  Using targeted 
mutagenesis the sixth exon encoding for two zinc fingers of EVI1 was disrupted .  Homozygous 
null mouse die in utero at embryonic day 10.5 and exhibit multiple developmental malformations 
i.e. widespread hypocellularity, hemorrhage, and disruption in the development of the heart, 
somites, and neural crest-derived cells161.  In adult mice the expression of Evi1 was found only 
in the kidney and in developing oocytes162. However, further analysis revealed expression in 
other organs, including spleen, heart, muscle, brain163.  The expression in blood cells has been 
controversial topic as different reports indicate either low expression or undetectable level164. 
Apart from being in mouse myeloid leukemia aberrantly expressed as a result of a proviral 
insertion, in humans it has been demonstrated that EVI1 is abnormally expressed as the result 
of chromosomal aberrations involving chromosome 3q26165.  Functional evidence that aberrant 
EVI1 expression may play a role in transformation was obtained from experiments using myeloid 
precursor cell line 32Dcl3166.  This cell line is capable of sustained proliferation in the presence of 
IL-3, but upon substitution by G-CSF 32Dcl3 cells enter a differentiation program and develop 
into mature neutrophils167.   Morishita and colleagues showed that enforced overexpression of 
Evi1 blocked differentiation of 32Dcl3 cells towards mature neutrophils but did not affect the 
proliferation capacity of cells upon IL-3 exposure168.  In contrast, other investigators found that 
overexpression of Evi1 increased proliferation of 32Dcl3 cells153,169.  Other models showed that 
inappropriate Evi1 expression in other blood lineages might have different outcomes.  Using 
the 32DEpo1 murine cell line which proliferates depending on growth factors IL-3 or EPO, 
showed that in the presence of Evi1 the cells could not be sustained in cultured upon EPO 
stimulation only170.  EpoR was shown to be a target gene for GATA-1; an important regulator 
during erythroid differentiation171-173.  As indicated above, Evi1 is capable of interacting with 
GATA-like sequences.  However both transcripts, GATA1 and EpoR, were not affected by Evi1, 
as the steady state levels of Gata1 and EpoR mRNA were equal in the Evi1 positive and negative 
cells164.  The same observation was noticed using mouse bone marrow progenitor cells, in which 
Evi1 overexpression caused a drastic reduction in the numbers of Epo sensitive colony forming 
cells164.  The data indicate that Evi1 might potentially interfere with Gata1 binding sites, however 
these data did not provide sufficient evidence that this is indeed the case.  Endogenous EVI1 
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mRNA expression levels were found in human undifferentiated erythroleukemic cell lines (K 
562, HEL, LAMA 84) and spontaneously terminal erythroid differentiation exhibiting cell lines 
(KU 812, JK-1).  No effect on erythroid differentiation of these cells was observed by EVI1174. 
Sitailo et al  demonstrated oncogenic properties in megakaryocytic lineage by Evi1.  While 
embryonic stem cells  (ES) express Evi1 at low endogenous levels, overexpression of Evi1 in ES 
cells increased the proliferation capacity of undifferentiated ES cells169.  Stimulation of ES cells 
with different cytokines bearing the Evi1 transgene resulted in a shift towards megakaryocytic 
cells.
3.2 Evi1 mouse models
As discussed earlier, different in vitro models were used to determine the role of Evi1 in 
transformation.  To study the role of Evi1 in vivo Louz et al generated the first transgenic Evi1 
animal model175.  The Evi1 gene was cloned under the murine stem cell antigen 1 promoter; Sca-
1 (Ly-6E.1)176.  Sca-1 is expressed on multipotent hematopoietic stem cells (HSC) and has been 
used as a marker for HSC in adult bone marrow and fetal liver but also in mobilized peripheral 
blood and spleen in the adult animals177-181. Although the three different lines generated in 
this study did not develop signs of leukemia during the 18 months follow up period, they 
showed decrease numbers of erythroid colony forming units (CFU-E).  Treatment of neonatal 
mice with Cas-Br-M MuLV virus to induce additional genetic “hit”, significantly increased 
leukemia progression and development in transgenic animals indicating a role of Evi1 in tumor 
progression.   
Recently, a transplantation model with retrovirally delivered Evi1 into lineage negative bone 
marrow cells showed development of myelodysplastic syndrome (MDS) in Evi1 positive 
animals182.  Interestingly, the first signs of disease developed after a period of 10 months 
post bone marrow transplantation.  In addition, transgenic animals did not develop a classical 
acute myeloid leukemia, but a myelodysplastic like disease characterized by pancytopenia, 
hypercellular bone marrow and dyserythropoesis.  The effect of transformation was proposed to 
be due to interference and repression of genes that play an important role in differentiation of red 
blood cells (EpoR) and platelets formation (c-Mpl).  In case of Evi1 positive animal both marker 
genes were down regulated.  It is of interest to notice that although the mice as mentioned earlier 
developed syndromes of MDS after 10 months, both markers were low after 4 months without 
any signs of disease.  
In this thesis we applied a novel approach to obtain an Evi1 transgenic mouse model by using 
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a specific Vav promoter restricted only to hematopoietic lineages183,184. LoxP sites upstream 
of Evi1 mouse cDNA flanked a transcriptional control sequence.  Using a mouse model that 
expressess Cre gene under the erythroid-specific β-globin gene promoter and locus control 
region185 or the promoter from the erythropoietin receptor gene186 the transgene expression is 
restricted specifically to the erythroid lineage only.
3.3 Transformation and binding molecules
Evi1’s structural domains, functions as transcriptinal repressor and diverse abilities to deregulate 
cellular processes indicate that these roles may be executed in conjunction with other proteins. 
It has been shown that Evi1 forms complexes with many different classes of proteins, which may 
play a key role in Evi1 functioning (Figure 5).    
Smad3
An important pathway that may be affected by Evi1 is the one activated by transforming growth 
factor-β (TGF-β)187. The TGF-β pathway plays an important role as a negative regulator of 
cellular growth, differentiation and apoptosis188-190.  The intracellular effectors of the TGF-β 
pathway are the members depicted as Smads.  Smad3 can regulate transcriptional activity in 
a positive or a negative manner. It has a low affinity towards Smad-binding elements (SBE) 
with the CAGAC consensus sequence191. In addition, it binds promoter regions with GC-
rich motifs192.  Due to the low DNA binding affinity, Smad3 requires cooperation with other 
sequence-specific transcription factors to bind target genes193-195.  This results in deregulation 
of Smad3 transcriptional activity and confers signaling specificity.  The direct effect of such 
de-regulation was shown in the presence of Evi1.  The repressive activity of Evi1 was achieved 
by the ability to bind via the first zinc finger domain to Smad3.  Interaction between Evi1 and 
Smad3 inhibits cells to undergo growth arrest in presence of TGF-β.  The association inhibits 
Smad3 DNA binding and negatively modulates transcriptional repression196.        
C-terminal Binding Protein (CtBP)
The repressive domain of Evi1 has been mapped within the proline-rich region197.  Within that 
region there are two motifs, PFDLT and PLDLS, both recognized by C-terminal binding protein 
(CtBP)198.  In vertebrates CtBP targets and acts as a cofactor of DNA binding transcription 
factors such as the Ikaros family members Eos199, Friend of GATA1 (FOG1)200, Ikaros201, 
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Krüppel like factor 8 (KLF8)202 and others203. The repression activity exhibited by CtBP suggests 
a critical role in a variety of different cell types and not a specific function for a certain class of 
transcriptional factors.  The interaction between CtBP1 and Evi1 was shown to be necessary for 
Evi1 transcriptional repression activity154,155.  Using mutation analysis within the Evi1 PLDLS 
motif the transcriptional repression was diminished.  Mutation within the PFDLT 
region did not affect repression capability of Evi1 to such extend as the PLDLS region154.  In 
addition the transforming ability of Evi1 was lost in RatFL cell line upon deletion PLDLS region 
of CtBP.  The region of interaction between CtBP1 and Evi1 was also shown to be presumably 
responsible for cell cycle deregulation due to increased cellular proliferation rate of 32Dcl3 
cell line153.  The data suggests that repression activity correlates with the preferential binding 
recognition between those two regions and that may influence Evi1 oncogenic activity.
Histone deacetylace family (HDACs)
Another group of co-factors that may play a role in Evi1 transcriptional repression was identified 
by Vinatzer et al204.  A member of the histone deacetylase family, HDAC-1, was shown to 
physically interact with Evi1.  HDAC-1 is a member of the HDAC class I family with three 
other members, namely HDAC-2, HDAC-3 and HDAC-8205.  HDAC-1, as all other members of 
its class, is expressed in most cell types and localizes in the nucleus206-208.  HDAC-1 is a member 
of three different protein complexes: Sin3, NuRD and Co-REST209.  Binding of HDAC-1 is 
not restricted to multi-protein complexes, as it can bind directly to DNA binding proteins, for 
instance YY1 or Rb binding protein-1210,211.  
HDAC-1 was shown to bind Evi1 at multiple sites, i.e. via the first seven zinc fingers of domain 
1, domain 2 via zinc finger eight to ten, and via the repression domain204.  Chakraborty et al153 
showed interaction between Evi1 and HDAC4 and confirmed findings of Vinatzer et al in a 
limited analysis of the first domain of zinc finger 1-7.  However, the specificity and role of the 
interaction with regard to the transformation ability of Evi1 remains elusive.
JNK1
Evi1 has a protective role in stress induced cell death by interfering with the mitogen-activated 
protein (MAP) kinase pathway212.  The first domain of Evi1 with zinc fingers 1-7 interacts with 
JNK1, and thereby inhibits activity of c-Jun.  Inhibition of JNK1 activity by Evi1 prevents stress-
induced cell death, and inhibits cell apoptosis.  The proposed model is more suitable for Evi1’s 
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role in organogenesis and morphogenesis during normal development, as no data up to date 
supports apoptosis inhibition in Evi1 mediated oncogenic progression.
Lysine Acetyltransferases (CBP and PCAF)
Two other proteins that have been shown to bind Evi1 via the proximal zinc finger domain are 
CREB-binding protein (CBP) and p300/CBP-associated factor (PCAF). These proteins belong 
to a family of lysine acetyltransferases, which play an important role in leukemia development. 
Both proteins have been shown to act as transcriptional co-activators and contain intrinsic 
histone acetyl transferase (HAT) activity213,214.  The substrates of CBP in mammals are histones, 
transcription factors, and the early region 1A (E1A) protein of adenoviruses.  PCAF has similar 
substrates namely histone 3 and 4 (H3 and H4), transcription factors, the early region 1A (E1A) 
Figure 5 Schematic representation of EVI-1 and its co-regulators binding partners 
Different EVI-1 regions have been found to be involved in interaction with several proteins.  The N-terminus zinc 
fingers of EVI-1 interact with histone deacethylases 1 and 4(HDAC1 and HDAC4), p300/CBP-associated factor (P/
CAF), methyl binding domain 3 (MBD3), c-Jun N-terminal kinase (JNK1), mothers against decapentaplegic homolog 
3 (Smad3) and the mammalian ortholog of suppressor of position-effect-variegation, SU(VAR)3-9, SUV39H1.  The 
three zinc fingers at the C-terminus are found to bind to HDAC1.  Within the repression domain two binding motifs are 
found that interact with C-terminal binding protein (CtBP1) and also with HDAC1.  The more central part of EVI-1 binds 
the CREB-binding protein (CBP).  Interaction between EVI-1 and different functional proteins play a role in affecting 
several diverse pathways.
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of adenoviruses, and in addition the HIV transcriptional activator, TAT.  In addition, CBP and 
PCAF also exhibit autoacetylation properties.
Among transcription factors that are acetylated either via CBP and/or PCAF are c-myb GATA1, 
p53, EKLF, NF-κB and others215-220.  Evi1 binds CBP and PCAF via its proximal zinc finger 
domain, however the binding site of CBP is more distal than the PCAF site153.  Acetylation of 
Evi1 is one of the first post-translation modifications reported for this protein.  This modification 
was shown to interfere with Evi1 transcriptional repression activity and nuclear organization. 
Because the modification occurs within the DNA binding motif it would be of interest to 
investigate if the modification influences the DNA binding properties of Evi1.
Methyl Binding Domain (MBD3)
In this thesis I report on the identification of a novel binding partner of Evi1, i.e. methyl-binding 
domain 3b (MBD3b).  MBD3 gene encodes for a nuclear protein with an N-terminal methyl-
binding domain.  It is the only member of methyl binding domain family (MBD1, MBD2, 
MBD4, and MeCP2) that has no affinity for methylated CpG regions in mammals221,222.  MBD3 
gene encodes the full-length protein MBD3a and a splice variant lacking the first 54 amino acids 
of the MBD motif, MBD3b.  MBD3a and b are core proteins of the histone repressor complex 
Mi2/NuRD216.
3.4 EVI1 defective expression and fusion transcripts in human disease
Inappropriate EVI1 expression in hematopoietic cells results in or at least contributes to cellular 
transformation and leukemia progression.  The expression in human AML or MDS is due to 
inversion or translocations involving the chromosome band 3q21q26 where EVI1 is located. 
The rearrangement within 3q21 caused by t(3;3) or inv(3) involves constitutively enhanced 
transcription from an enhancer of the Ribophorin I (RPN1) gene located in close proximity to 
the breakpoint223.  Other genomic rearrangements involve 3q26 locus and other chromosomal 
regions and consequently other genes.  These translocations result in production of EVI1 
containing fusion proteins.  Those fusions involve AML1, MDS1, ETV6, and RPN1 genes and 
will be discussed shortly (Figure 6).
AML1/EVI1.  The translocation (3;21)(q26;q22) was identified a decade ago in the SKH1 
chronic myelocytic leukemia (CML) cell line in addition to the already present translocation 
(9;22)(q34;q11).  The fusion involves the AML1 gene located on chromosome 21q22 and the 
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EVI1 gene on chromosome 3q26224.  Detailed analysis of the AML1/EVI1 fusion protein revealed 
the presence of a truncated N-terminal part of AML1 containing the runt domain and a full length 
EVI1 protein.  Interestingly, although it was first postulated that a 5’ non-coding region of EVI1 
is involved in this translocation, it turned out to be a novel gene called MDS1 located upstream of 
EVI1225,226.  AML1 contains two distinct well-defined domains: a runt domain at the N-terminus, 
which is highly homologous to the Drosophila segmentation gene runt and a C-terminal proline-
serine-threonine (PST) domain involved in trans-activation activity227,228.   The runt domain of 
AML1 plays an important role in heterodimerization with PEBP2β protein required to bind the 
DNA.  The PST domain is required for transcriptional activation upon complex formation with 
p300, CBP, and PCAF228.  
The role of the chimeric fusion protein was elucidated using the myeloid precursor cell line 
32Dcl3.  Overexpression of AML1-MDS1/EVI1 showed a block of differentiation upon 
stimulation with G-CSF and decreased expression of myeloperoxidase (MPO), a marker for 
neutrophilic differentiation229,230.  Although AML1 on its own is a transcriptional activator, the 
chimeric protein becomes a repressor due to the presence of EVI1.  This observation suggests 
that the fusion of AML1-MDS1/EVI1 might interfere with AML1 binding sites.  Using DNA-
binding affinity approaches the AML1-MDS1/EVI1 chimeric protein showed not only stronger 
DNA binding versus AML1 protein alone but also demonstrated that it contains a dominant 
transactivation suppressive activity.  
MDS1/EVI1.  MDS1 was identified as a part of AML1-MDS1/EVI1 fusion transcript in a 3;21 
translocation.  It encodes for a small protein with high homology to the positive regulator (PR) 
domain of the retinoblastoma-interacting zinc finger protein (RIZ)231,232, the transcriptional 
repressor BLIMP1 required for B cell terminal differentiation233,234, and the Caenorhabditis 
elegans transcription factor, Egl-43235.  The gene is located on chromosome band 3q26.2 in 
close upstream proximity, around 300kb, to EVI1236,237.  MDS1 splices into the second exon 
of EVI1 resulting in an addition of 188 amino acids to the 5’ end of EVI1.  The MDS1/EVI1 
and EVI1 expression pattern in normal man and mouse tissue163,232 and in myeloid leukemia is 
closely related238.  However, the functional role in early hematopoietic precursor cells during 
proliferation and differentiation is unclear.  MDS1/EVI1 appears to have an opposite effect as 
compared to EVI1.  EVI1 is a repressor, as shown in many different models.  On the other hand the 
MDS1/EVI1 protein does not enhance proliferation, nor does it induce a block of differentiation. 
Furthermore, MDS1/EVI1 was also shown to posses a positive growth-inhibitory effect on TGF-
β signaling pathway169,239.  
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Figure 6 Diagram of proteins involved in rearrangement with EVI-1 and generation of fusion proteins
Diagram of normal proteins, acute myeloid leukemia 1 (AML1), myelodysplastic syndrome 1 (MDS1), ets variant 6 
(ETV6), Ribophorin 1 (RPN1), and EVI-1.  The functional domains of each protein are depicted.  The vertical doted lines 
represent graphically break-point fusion junction between EVI-1 and a corresponding protein.  The arrow indicates
chromosomal breakpoints for each fusion protein as found in AML patients.      
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In addition, MDS1/EVI1 has an antagonistic effect on EVI1, and functions as a positive 
transcriptional regulator237. 
RPN1/EVI1.  A small cohort of patients (n=9) with either inv(3)(q21q26) or t(3;3)(q21;q26) 
was analyzed for the presence of the RPN1 gene as a fusion partner of EVI1, as the gene is located 
in a close proximity of the breakpoint 3q21q26240.  The analysis showed that in all but one case 
the RPN1/EVI1 fusion gene was detected and driven by the RPN1 promoter.  The RPN1 first 
exon was fused in frame to the second exon of EVI1, with the exception of one case where the 
second exon was also absent and the RPN1 first exon was fused to the third exon of EVI1241. 
ETV6/EVI1.  A less frequent fusion that is found with chromosome 3 aberrations is ETV6 
(TEL1) gene242.  ETV6 is a member of ets family transcription factors that share a conserved 
DNA binding domain243. Up to date four cases were reported where ETV6 gene was spliced and 
fused with EVI1 or MDS1/EVI1244-246.  The translocation (3;12)(q26;p13) generates either ETV6-
MDS1/EVI1 or ETV6/EVI1 fusion gene, which is inappropriately expressed by constitutive 
activation from the ETV6 promoter.  Molecular analysis of the fusion gene revealed that no 
functional domains of ETV6 were involved227,244,247.  However, the oncogenic role of the fusion 
transcripts has not been addressed any further. 
4. Regulation of gene expression and the “histone code”
The nucleus of eukaryotic cells contains the genetic information encoded by the DNA polymer. 
The DNA associate with nuclear proteins and it is stored in the form of chromatin.  The basic 
repeating unit of chromatin is the nucleosome, which is composed of 146 base pairs of DNA 
wrapped around an octamer of the core histones.  The core histone octamer is composed of two 
copies of each histone proteins, H2A, H2B, H3, and H4248.  Histones consist of globular domain 
that mediates histone-histone interaction and amino acids NH
2
-terminus (tail).   
A short, 10-60bp DNA ‘linker’ separates each nucleosome from each other resembling an 
arrangement as ‘beads-on-a-string’, and forms a chromatin fiber of 10nm in diameter.  The 
folding of chromatin undergoes further condensation into 30nm thick fibers achieved by linker 
histone H1, which interacts with the nucleosome core249.  The last level in chromatin condensation 
is formation of 100-400nm interphase fibers, or the highly compressed chromosome structures 
during methaphase250.  This high compaction of chromatin fibers prevents accessibility for 
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transcription machinery to read the nucleotide sequence, and therefore it must be dynamic and 
flexible to be able to allow unfolding and folding transition251.  
Two different forms of chromatin were established using cytological studies, transcriptionally 
active euchromatin, less dense and appearing as a relaxed structure, and transcriptionally 
silent heterochromatin, more dense and usually located at the periphery of the nucleus252.  The 
mechanisms behind the transition from euchromatin to heterochromatin and vice versa are 
poorly understood.  However, histone N terminal tails, which protrude from the nucleosome 
octamer, are subject to a variety of posttranslational modifications, such as acetylation and 
methylation of lysines (K) and arginines (R), phosphorylation of serines (S) and threonines (T), 
ubiquitylation and sumoylation of lysines (K) as well as ADP-ribosylation253,254.  The complexity 
of modification goes further, as lysine residue can be mono-, di-, or tri- methylated, and arginine 
residue can be either mono- or di-methylated255-260. 
Modification of a specific amino acid at the histone level correlates with either repressive or 
active state.  It is well established, for example, that acetylation of histone tails at H3-K4, H3-
K36 and H3-K79 is associated with transcriptional activation, and methylation at H3-K9, H3-
K27 and H4-K20 prevent transcription to occur253,261-264. 
The array of different histone amino termini modifications has led to the idea of a “histone 
code”.  It postulates that specific covalent modifications, alone or in combination, at a particular 
amino acid of the N-terminal of histone tails confer a cooperative or adverse environment for 
chromatin-associates proteins, which in turn impose distinct chromatin states from active to 
silent and influence its functional properties.  In recent years those specific histone modification 
patterns were shown to be associated with particular enzymes that can covalently modified 
histone at specific site(s).  A number of mediators and histone modifiers have been identified. 
Histone acetyltransferases (HATs), are associated with acetylation of histones by transferring 
an acetyl group to lysine residues, and thereby attract chromatin remodeling complexes253,265. 
The process is reversible by a group of enzymes that removes the acetyl group and inhibits 
transcription, the histone deacetylases (HDACs)266.  The same patterns of modification apply to 
a group of enzymes that methylate specific residue (arginine, lysine, glutamine), which dictates 
either active or silent transcription267,268.  The modification has been recently shown to be also 
reversible as the first Lysine-specific histone demethylase 1 (LSD1) was isolated269.  The number 
of enzymes that play a distinct role in histone modifications has grown rapidly, for review see 
Peterson et al251.  
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However, the first enzyme that was identified to carry out histone modification at H3 lysine 9 came 
from studies of suppressor of position effect variegation (PEV) in Drosophila270. Characterization 
of the PEV suppressors, such as Su(var)3-9, the trithorax-group protein Trithorax (TRX), and 
the Polycomb-group protein   Enhancer of zeste E(Z) revealed a common motif designated the 
SET (Suppressor of Variegation, Enhancer of Zeste and Trithorax) domain271-273.  The human and 
mouse ortholog was identified by Rea and colleagues and shown to specifically methylate H3-
K9 and to associate with repression of transcription274.  The catalytic domain responsible for the 
modification was mapped in mutagenesis studies.  This showed that not only the evolutionary 
conserved SET motif is required but that in addition two small cysteine-rich flanking regions 
which enclos the SET domain, named pre- and post-SET, play an important functional role.  
In addition to SuV39H1 several other methyltransferases were identified which showed specificity 
for H3K9 methylation.  SuV39H2 was isolated by O’Carroll and colleagues and showed high 
homology to SuV39H1 with the exception of a presence of highly basic N-terminus275.  Analysis 
of proteins with motifs comparable to SuV39H1 and SuV39H2 resulted in the isolation of a gene 
encoding for the G9a protein, with methylation specificity for H3-K9 in addition to methylation 
specificity towards lysine 27 (K27) at histone 3 (H3-K27)276.  Generation of null mice for either 
SuV39H1 or SuV39H2 did not show any phenotype.  SuV39H1/SuV39H2 double null mice 
develop normally until embryonic day 12.5, but at later stage of development the embryos 
show growth retardation, high reabsorption rates, and prenatal lethality, due to chromosomal 
segregation defects as the majority of cells exhibit increased numbers of chromosomes 
(tetraploid and octaploid)256.  On the contrary, G9a null mice do not survive beyond day 8.5 
due to profound levels of apoptosis in combination with developmental defects277.  The global 
pattern of H3-K9 methylation also differs between these two models.  Although there is lack of 
methylation observed at the pericentric heterochromatic regions in the SuV39H1/2 double null 
mice the broad pattern of H3-K9 methylation is still retained as compare to G9a null mice where 
chromatin wide methylation is abolished completely256,277.
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5. Scope of the thesis
The Ecotropic integration site 1 (EVI1) gene is implicated as a factor in development and 
progression of acute myeloid leukemia (AML).  The EVI1 locus rearrangement at chromosome 
3 in patients causes inappropriate expression of EVI1 and development of myelodysplastic 
syndrome (MDS) and AML.  However, the molecular mechanisms behind EVI1 oncogenic role 
are still poorly understood up to date.  
Chapter 1 gives an overview of the role of transcriptional factors in erythropoiesis and 
myelopoiesis, regulation of transcription and what is known about the role and mechanism of 
Evi1 in leukemia progression. 
To mimic the aberrant expression of EVI1 as observed in AML patients we generated a novel 
transgenic mouse model for the Evi1 gene. In Chapter 2 and Chapter 3 we describe the 
analysis and phenotype of inappropriate activation and expression of Evi1 during fetal erythroid 
development. 
To gain more insight into the possible role of EVI1 in leukemogenesis we performed a protein-
binding screen to determine which factor(s) may cooperate with EVI1 in leukemia.   In Chapter 
4 we identified a novel binding partner of Evi1, methyl binding domain 3b (Mbd3b) that is 
a member of the histone deacetylase complex NuRD.  Chapter 5 describes another group of 
proteins that were found to interact with Evi1, and belongs to the histone methyltransferase 
family.    Chapter 4 and 5 provide evidence that Evi1 may have a role in epigenetic control of 
the gene expression.
Chapter 6 will summarize the results presented in this thesis, draw a conclusion and discuss the 
possible mechanism of Evi1 in leukemogenesis. 
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Abstract
Patients with myelodysplastic syndrome (MDS) carrying 3q26 aberrations are characterized 
by refractory anemia and high expression of the proto-oncogene EVI1, suggesting direct 
interference of EVI1 with erythropoiesis. Although forced expression of Evi1 in non-committed 
murine hematopoietic stem cells has been shown to induce multi-lineage cytopenia, the specific 
in vivo effects of Evi1 overexpression within the erythroid lineage have not been determined. 
We established novel Vav-loxp-stop-loxp-Evi1 transgenic mouse lines that conditionally express 
Evi1 in the hematopoietic system, and crossed these with the erythroid-lineage specific pEV-Cre 
line to specifically induce Evi1 expression in erythroid cells in vivo. Erythroid-specific Evi1 
overexpression induced fetal anemia, with major defects in definitive erythropoiesis. E12.5 fetal 
livers showed an arrest in erythroid differentiation, a high percentage of apoptotic and dysplastic 
cells, and a reduced number of erythroid progenitors. Molecular analysis of Evi1 expressing 
erythroid cells revealed a significant upregulation of Pu.1 and c-myb expression. Our data 
demonstrate that the specific enforcement of Evi1 expression in the erythroid lineage interferes 
with fetal erythropoiesis. 
Introduction
Evi1 (ecotropic virus integration site 1) is a myeloid transforming gene that was originally 
identified as a common retroviral target in virally induced murine leukemia.1,2 Evi1 encodes for a 
nuclear DNA binding protein with two zinc finger domains, i.e. an N-terminal domain containing 
zinc fingers 1-7 and a more C-terminal domain containing zinc fingers 8-10. Zinc fingers 1-7 
recognize the sequence GA(C/T)AAGA(T/C)AAGATAA that shows overlap with the consensus 
sequence bound by GATA family transcription factors.3-5
In humans, EVI1 that is located at chromosome 3q26 is expressed at very low levels in normal 
blood or BM.6,7 Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome 
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(MDS), harboring 3q26 translocations, frequently show aberrant expression of EVI1 (reviewed 
by Buonamici et al.8). Moreover, EVI1 overexpression is observed in 10% of AML patients 
and 30% of MDS patients without abnormalities in 3q26,7,9 as a result of currently unknown 
mechanisms. Applying gene expression profiling, we recently found that EVI1 expressing 
cases constitute a specific subset of AML samples that are severely resistant to anti-leukemic 
therapy.9,10 
Various in vitro studies have provided support for a direct involvement of Evi1 in the development 
of MDS and AML. Evi1 blocked G-CSF induced differentiation of 32Dcl3 cells,11 interfered 
with proliferation of the erythropoietin (Epo-) responsive cell line 32D-Epo and decreased Epo-
induced colony formation from BM progenitors.12 
The available in vivo studies have mainly addressed the effects of Evi1 on non-committed 
progenitors. We previously used the Sca1 promoter to drive pan-hematopoietic expression of 
Evi1 in transgenic mice.13 Mice of two Sca1-Evi1 transgenic lines developed normally, but virally 
induced leukemia development was greatly enhanced in these mice compared to non-transgenic 
littermates, providing evidence for a cooperative potential of Evi1 in tumor progression. Severely 
impaired hematopoiesis with major defects in BM, spleen and peripheral blood was observed 
specifically in males of a third line in which the transgene had integrated on the X-chromosome. 
However, it remains unclear whether these defects were due to a position effect of the transgene 
or to overexpression of Evi1.13 Recently, Nucifora and her colleagues14 expressed Evi1 in mouse 
BM progenitors using a retroviral expression vector. Following transplantation of the transduced 
BM, the recipient mice developed an MDS-like syndrome, characterized by an early phase of 
BM hyperproliferation and delayed differentiation with no peripheral abnormalities, eventually 
culminating in BM apoptosis, peripheral pancytopenia and death.14 
Together, the in vitro and in vivo data indicate that the effects of Evi1 on hematopoiesis may 
be diverse and dependent on the developmental stage of the hematopoietic cells. The fact that 
we did not obtain high Evi1 expression in the Sca-Evi1 model, and the observation that Evi1 
coupled to strong promoters yielded no transgenic lines at all or lines in which Evi1 expression 
could not be detected (D.S and R.D, unpublished data), suggest that high Evi1 expression in the 
hematopoietic system is embryonic lethal. 
We have generated Evi1 transgenic mouse lines with Cre recombinase-inducible Evi1 expression 
in the hematopoietic system. These novel lines allow us to study the effects of Evi1 in separate 
hematopoietic lineages. We examined in this study the effects of Evi1 activation on survival, 
proliferation and differentiation of erythroid progenitors, by breeding the Evi1 transgenic lines 
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with the erythroid lineage specific pEV-Cre transgenic line. We show that erythroid specific Evi1 
overexpression interferes with fetal erythroid development. 
Results
Generation of transgenic mouse lines with conditional Evi1 expression
To establish an Evi1 transgenic mouse model that allows strict control over the spatio-temporal 
expression of Evi1, we made use of a loxP-flanked transcriptional stop box (LSL) that represses 
Evi1 transcription unless the stop box is deleted by the Cre enzyme. Upon transfection of Phoenix 
cells with a PLNCX2-LSL-GFPEvi1 construct in the absence or presence of a Cre expression 
construct, we exclusively observed nuclear GFP-tagged Evi1 expression in presence of Cre, 
demonstrating that this approach results in low background expression and efficient induction of 
Evi1 expression after Cre-mediated recombination in vitro (Figure 1A). 
Figure 1 Cre induced recombination and 
transgenic constructs (A) Principle of Cre 
recombinase mediated excision of a loxP-
flanked transcriptional stop box (LSL) and 
induction of Evi1 expression. In Phoenix cells 
transfected with the PLNCX2-LSL-GFPEvi1 
construct, the LSL cassette prevents the CMV 
promoter driven transcription of GFPEvi1 
(upper panel). Upon co-transfection of the 
Cre expression plasmid pMC-Cre, recombination takes place between the loxP sites, leading to excision of the stop 
sequence, transcription and nuclear expression of GFP-tagged Evi1 protein that is visible in the nucleus (lower panel). 
(B) Maps of the Vav-LSL-GFPEvi1 and the Vav-LSL-FlagEvi1 transgenic constructs. Upstream and downstream Vav 
regulatory sequences are indicated.
Arrowheads indicate the position of PCR primers used for the detection of recombination. (C) Recombination PCR. 
In Vav-LSL-GFPEvi1+/- livers (Evi1+) a 2.1 kb PCR product is detected representing the non-recombined transgene. In 
Vav-LSLEvi1+/-/pEV-Cre+/- transgenic livers (Evi1+/Cre+) a 0.75 kb PCR product is amplified, that corresponds to the 
recombined transgene. 
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To generate the transgenic mice we used constructs that contain regulatory sequences of the Vav 
gene, the LSL cassette and either GFP-tagged or Flag-tagged versions of the Evi1 gene (Fig 1B). 
The Vav regulatory sequences drive transgene expression in all fetal and adult hematopoietic cell 
lineages, irrespective of the stage of development, and in few non-hematopoietic tissues.16,20-22 
We generated four Vav-LSL-GFPEvi1 transgenic lines (GFPEvi1 lines A, B, C and D) and three 
Vav-LSL-FlagEvi1 transgenic lines (FlagEvi1 lines A, B and C). In the absence of Cre protein, 
we could not detect background recombination or any obvious phenotypic defects in any of these 
lines (data not shown). 
Specific induction of Evi1 expression in the erythroid lineage 
The transgenic lines were used to investigate whether erythroid lineage-specific Evi1 
overexpression would directly affect erythropoiesis. Crossings were initiated between 
heterozygous mice from all Vav-LSL-GFPEvi1 and Vav-LSL-FlagEvi1 transgenic lines and 
pEV-Cre+/- transgenic mice. In the pEV-Cre line, Cre expression starts at the pro-erythroblast 
stage and recapitulates the expression pattern of β-like globin genes, thereby efficiently driving 
recombination of floxed loci within the erythroid lineage with very low recombination activity 
in other lineages.18 
PCR confirmed recombination between loxP sites and deletion of the stop box in the genomic 
DNA of fetal livers isolated from E12.5 Vav-LSL-GFPEvi1+/-/pEV-Cre+/- (Figure 1C) and 
Vav-LSL-FlagEvi1+/-/pEV-Cre+/- (not shown) double transgenic embryos as opposed to single 
transgenic littermates. Depending on the number of copies, deletion of the stop sequence could 
have taken place in two ways; between loxP sites flanking the same stop sequence(s) or between 
loxP sites flanking separate stop sequences in case of a multi-copy transgene. 
By consequence, in Vav-LSL-GFPEvi1 lines A and B and Vav-LSL-FlagEvi1 line C (Figure 
2A) deletion of the stop sequence was accompanied by a significant induction of Evi1 mRNA 
expression in the fetal liver as shown by real-time quantitative (RQ)-PCR. Although FlagEvi1 
or GFPEvi1 protein were undetectable by western blotting, we could demonstrate a low but 
consistent induction of GFPEvi1 protein by flowcytometry in double transgenics of lines Vav-
LSL-GFPEvi1 A, B (data not shown) and C (Figure 2B) compared to controls. 
Embryos double transgenic for pEV-Cre and Vav-LSL-GFPEvi1 lines A, B and C or Vav-LSL-
FlagEvi1 line C displayed a clear and very similar phenotype (see below), therefore data of 
these four lines were combined and from this point on will be referred to as Vav-LSL-Evi1. In 
Vav-LSL-GFPEvi1 line D and Vav-LSL-Flag lines A and B expression of Evi1 was very low 
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or undetectable by RQ-PCR or flow cytometry, and accordingly, these lines did not show any 
phenotypic defects (data not shown). 
Enforced expression of Evi1 in the erythroid lineage induces fetal anemia 
We determined the genotype distribution of offspring from crossings between Vav-LSL-Evi1+/- 
and pEV-Cre+/- mice at E12.5 and in neonates. Whereas the genotype distribution followed a 
Mendelian ratio at E12.5, the percentage of Vav-LSL-Evi1+/-/pEV-Cre+/- offspring was reduced 
to 15% in neonates (Table 1). Surviving Vav-LSL-Evi1+/-/pEV-Cre+/- neonates had normal blood 
counts (unpublished data). This suggested that part of the double transgenic animals died 
between E12.5 and birth, and indeed we observed presence of dead double transgenic embryos 
in E13.5 litters (data not shown).
Figure 2 Evi1 transgene expression in E12.5 fetal livers (A) RQ-PCR showing Evi1 transgene mRNA expression 
in double transgenic and control livers of Vav-LSL-GFPEvi1 line A and B and Vav-LSL-FlagEvi1 line C. Data are 
expressed as the mean relative Evi1 expression of littermates with the same genotype. (B) Flowcytometric analysis 
of a Vav-LSL-GFPEvi1+/-/pEV-Cre+/- liver (green) and WT (red), pEV-Cre+/- (pink) and Vav-LSL-GFPEvi1+/- (blue) 
controls showing increased GFP fluorescence in the double transgenic liver. Dead cells were excluded from the analysis.
Table 1 Genotype 
distribution of 
offspring from Vav-
LSL-Evi+/- x pEV-
Cre+/- crossings 
at E12.5 and in 
neonates
E12.5 neonate
genotype n % (expected %) n % (expected %)
Wt
Cre+
Evi1+
Evi1+/Cre+
45
40
34
34
29.4
26.1
22.2
22.2
(25)
(25)
(25)
(25)
39
26
17
33
33.9
22.6
14.8
28.7
Total 153 115
(25)
(25)
(25)
(25)
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We focused on the analysis of the E12.5 embryos. Double heterozygous embryos from the 
four Vav-LSL-Evi1 lines could be readily distinguished from littermates at this stage because 
of the pale appearance of their visceral yolk sacs (Figure 3A). Moreover, Vav-LSL-Evi1+/-/pEV-
Cre+/- embryos were paler than their littermates and showed a clear reduction in the size of the 
fetal liver (Figure 3A) that contained significantly less cells compared to controls (Figure 3B). 
Although these embryos were clearly anemic they were alive as assessed by heart beating.  
While the blood of control embryos mainly consisted of a uniform population of primitive 
erythrocytes at E12.5 (Figure 4A), fetal blood from Vav-LSL-Evi1+/-/pEV-Cre+/- embryos 
contained abnormal immature cells, and mature primitive erythroid cells of which many were 
larger than normal and showed signs of dysplasia (Figure 4A). Flowcytometric analysis of fetal 
Figure 3 Evi1 induces fetal 
anemia (A) Photographs 
showing E12.5 embryos within 
their yolk sacs (upper panels), the 
same embryos without yolk sac 
(middle panels) and fetal livers 
isolated from these embryos 
(lower panels). Vav-LSL-Evi1+/-
/pEV-Cre+/- embryos show 
compared to control littermates 
a clear pallor of the yolk sac (far 
right, upper panel). The embryo 
itself is also paler than the 
controls (far right, middle panel) 
and has a very pale liver that is 
reduced in size (far right, lower 
panel). (B) Vav-LSLEvi1+/-/pEV-
Cre+/- E12.5 transgenic livers 
contain significantly less cells 
than control livers by Bonferroni 
statistic (*p<0.001, n≥28). Data 
are expressed as mean ± SD.
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blood also demonstrated the increased average size of Vav-LSL-Evi1+/-/pEV-Cre+/- fetal blood 
cells compared to controls (Fig 4B) and confirmed the expression of GFPEvi1 protein in double 
transgenic blood in Vav-LSL-GFPEvi1 lines A, B (not shown) and C (Figure 4B).
The reduced fetal liver cellularity clearly indicated that definitive erythropoiesis was disturbed 
in Vav-LSL-Evi1+/-/pEV-Cre+/ embryos. Cytological analysis showed an overrepresentation of 
immature erythroid cells in Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers compared to controls (Figure 
5A-B). Flowcytometric analysis demonstrated a clear reduction of the TER119+/CD71- cell 
population in double transgenic fetal livers confirming the maturation arrest within the erythroid 
lineage (Figure 5C). This arrest was accompanied by an increased percentage of dysplastic cells 
that were characterized by asynchronous maturation of the nucleus and cytoplasm (Figure 5D-E). 
Moreover, a clear increase in fetal liver apoptosis was observed since the percentage of Annexin 
V+, propidium iodide- (PI-) cells had doubled in Vav-LSL-Evi1+/-/pEV-Cre+/- compared to control 
livers (Figure 5F). As a result of increased apoptosis, the percentage of dead cells (Annexin V+, 
PI+) was also increased in Vav-LSL-Evi1+/-/ pEV-Cre+/- compared to control livers (Figure 5F).
E12.5 Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers contain a reduced number of CFU-E
To determine the number of BFU-E (burst forming unit-erythroid) and CFU-E (colony forming 
unit-erythroid) progenitors in E12.5 double transgenic livers, we performed colony assays. Fetal 
liver cells were grown in semi-solid medium in presence of Epo, or Epo and SCF, to determine 
the number of CFU-E and BFU-E, respectively, per liver. E12.5 Vav-LSL-Evi1+/-/pEV-Cre+/- fetal 
livers consistently contained less CFU-E than single transgenic and WT littermates. In contrast, 
Figure 4 E12.5 fetal blood in Vav-LSLEvi1+/-
/pEV-Cre+/- embryos and controls (A). Control 
blood (left) contains a uniform population of 
mostly nucleated primitive erythrocytes with 
few enucleated definitive erythrocytes. In Vav-
LSLEvi1+/-/pEV-Cre+/- fetal blood a less uniform 
population of cells is observed with presence 
of immature cells, and cells that shown signs 
of dysplasia (large size, abnormal ratio between 
cytoplasm and nucleus). (B). Flowcytometric 
analysis of Vav-LSL-GFPEvi1+/-/pEV-Cre+/- fetal 
blood (green) and WT (red), pEV-Cre+/- (pink) and 
Vav-LSL-GFPEvi1+/- (blue) control fetal blood. 
Dead cells were excluded from the analysis. The 
Vav-LSL-GFPEvi1+/-/pEV-Cre+/- sample displays 
increased GFP fluorescence (left panel) and has 
a higher forward scatter (FSC) compared to the 
controls indicating larger cell size (right panel). 
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no difference in the number of BFU-E was observed (Figure 6A). 
Figure 5 Evi1 induces differentiation arrest, 
dysplasia and apoptosis of erythroid cells in the 
E12.5 fetal liver (A) Cytospins of E12.5 fetal liver 
cells and (B) differential counts of a representative 
litter. Compared to WT, pEV-Cre+/- and Vav-
LSL-Evi1+/- controls, the Vav-LSL-Evi1+/-/pEV-
Cre+/- livers contain relatively more basophilic 
erythroblasts (baso) and less polychromatophilic 
(poly) and orthochromatophilic (ortho) 
erythroblasts indicating a partial block in erythroid 
differentiation. proery=pro-erythroblasts. (C) 
Flowcytometric analysis of E12.5 fetal liver cells 
labeled with anti-TER119-PE and anti-CD71-FITC. Dead cells (7AAD+) were excluded from the analysis. The ratio 
of cells in each quadrant is shown. The TER119+/CD71- population that contains the more mature erythroid cells is 
decreased in Vav-LSL-Evi1+/-/pEV-Cre+/- livers, while more immature populations are increased. (D) Vav-LSL-Evi1+/-
/pEV-Cre+/- fetal livers contain significantly more dysplastic cells than all control groups by Tamhane’s T2 statistic 
(*p≤0.031, n≥18). (E) Normal cells in a control and dysplastic cells in a Vav-LSL-Evi1+/-/pEV-Cre+/- liver. The dysplastic 
cells are larger than normal, have an abnormal ratio between cytoplasm/nucleus, and show asynchronous maturation 
of cytoplasm and nucleus, i.e. an immature non-condensated nucleus in combination with a more mature acidophilic 
cytoplasm. (F) Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers (n=4) contain significantly more apoptotic and dead cells 
(*p=0.006, Mann Whitney U Test) than controls (n=7). E12.5 fetal liver cells were labeled with AnnexinV and PI and 
analyzed by flowcytometry to determine the percentage of apoptotic (Annexin V+/PI-) and dead cells (Annexin V+/PI-) 
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Expansion of Vav-LSL-Evi1+/-/pEV-Cre+/- fetal liver progenitors in liquid culture
Fetal liver progenitors can be expanded in a liquid culture system that exploits the vigorous 
self-renewal capacity of erythroid progenitors.23,24 When we cultured fetal liver cells of double 
transgenic and controls in the presence of Epo, SCF and glucocorticoids to stimulate the self-
renewal of erythroid progenitors, only in the most severely affected double transgenic fetal livers 
(containing less than 106 cells per liver), cells failed to expand normally. 
per fetal liver.  For the analysis of this experiment, WT, Vav-LSL-Evi1+/- and pEV-Cre+/- livers were joined in one control 
group. Data are expressed as mean ± SD.
Figure 6 In vitro culture of Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers (A) Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers contain a 
reduced number of CFU-E.  Fetal liver cells from Vav-LSL-Evi1+/-/pEV-Cre+/- and control livers were seeded in duplicate 
in methylcellulose and counted as described in Methods. Values are expressed as the total number of BFU-E and CFU-E 
colonies per liver relative (in %) to the average number of colonies of fetal livers from wild type littermates. This was 
done to correct for differences between experiments with respect to assay conditions and the stage of the used embryos. 
Grey bars indicate the mean of all livers for each genotype. While no significant difference in the number of BFU-E was 
found (upper panel), the number of CFU-E (lower panel) was significantly lower in Vav-LSL-Evi1+/-/pEV-Cre+/- compared 
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For most Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers, expansion of double transgenic fetal liver 
cells was comparable to control littermates, showing that erythroid progenitors in these livers 
were still responsive to growth factors (Figure 6B). Moreover, progenitors from these cultures 
differentiated normally upon transfer to medium containing Epo and transferrin (data not 
shown). 
Pu.1 and c-myb expression is up regulated in Vav-LSL-Evi1+/-/pEV-Cre+/- livers
RQ-PCR was applied to compare the expression of a number of important regulators and 
markers of erythroid development between double transgenic and control livers (Figure 7). 
Pu.1 is a transcription factor that promotes the self-renewal of erythroid progenitors, thereby 
preventing differentiation.25 In mouse erythroleukemia (MEL) cells, virally induced Pu.1 blocks 
differentiation by acting as a functional antagonist of Gata1.26,27 Interestingly, expression of Pu.1 
was upregulated in Vav-LSL-Evi1+/-/pEV-Cre+/- livers compared to controls, and this was also the 
case for c-myb that acts downstream of Pu.1 in MEL cells.28 
The transcription factor Gata1 plays a critical role in erythroid development, since both loss and 
gain of Gata1 function severely affect growth and survival of erythroid cells, and binding sites 
for Gata1 are found in the regulatory sequences of many erythroid specific genes (reviewed by 
Ferreira et al.29). Gata1 expression levels were comparable between Vav-LSL-Evi1+/-/pEV-Cre+/- 
to control livers (*p≤0.001, Mann Whitney U Test). (B) Expansion of fetal liver progenitors in liquid medium containing 
Epo, SCF and dexamethasone. Three independent experiments are shown representing three different litters. Vav-LSL-
Evi1+/-/pEV-Cre+/- cultures are shown in black, all control livers are in grey. Dashed black lines indicate the growth curves 
of cultures obtained from double transgenic livers that were severely reduced in size (containing less than 106 cells per 
liver). These cultures show reduced expansion compared to control livers and less affected double transgenic livers.
Figure 7 Upregulation of Pu.1 and c-myb expression in Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers Fold change in RNA 
expression of genes involved in erythroid development in compared to controls from the same litter as determined by 
RQ-PCR. Mean and SD of three independent experiments are shown.  
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and control livers (Figure 7). Epo is the major growth factor for erythroid cells. Although it was 
previously reported that expression of the Epo Receptor (EpoR) was down regulated in Evi1 
overexpressing BM cells14, EpoR expression was unchanged in Vav-LSL-Evi1+/-/pEV-Cre+/- livers 
compared to controls (Figure 7). In contrast, transcription of the genes encoding for the major 
β-globin chain (a subunit of hemoglobin) and aminolevulinic acid synthase 2 (Alas2, a heme 
biosynthesis enzyme) was lower in Vav-LSL-Evi1+/-/pEV-Cre+/- livers compared to controls. 
This confirmed the observed maturation arrest since these Gata1 target genes are normally up 
regulated during terminal erythroid differentiation.30 
Discussion
We established novel Evi1 transgenic mouse lines with conditional expression in the 
hematopoietic system. In this report we have demonstrated the use of these Vav-LSL-Evi1 lines 
to study the specific in vivo effects of Evi1 in the erythroid lineage. Although aberrant Evi1 
expression is associated with MDS/AML with severe anemia, previous in vivo studies did not 
resolve whether Evi1 interferes with erythroid development directly, by affecting committed 
erythroid progenitors, or indirectly by deregulating non-committed stem cells. The experiments 
presented here show that Evi1 directly interferes with erythroid development in vivo. Enforced 
erythroid lineage specific Evi1 overexpression induced fetal anemia that was characterized by 
arrested erythroid maturation, increased apoptosis and dysplasia. 
Fetal anemia induced by erythroid lineage specific Evi1 overexpression is transient 
Our data show that the Evi1-induced fetal anemia causes embryonic lethality in 40% of cases. 
In the other cases the anemia appears to be transient since surviving Vav-LSL-Evi1+/-/pEV-Cre+/- 
mice have normal blood counts showing that steady-state erythropoiesis is unaffected in these 
adults. The restriction of the anemic phenotype in embryonic stages is not unique to our model. 
For instance, ATF4 and Stat5a/5b null mutants,31,32 and mutant mice expressing a truncated Gata1 
protein33 display a similar transient embryonic erythroid phenotype. In the first two studies31,32 
this phenomenon was explained by the considerably lower erythropoietic reserve capacity of 
early embryos compared to adults; this capacity is thought to be lower because the rapid growth 
of the embryo must be matched by a rapid concomitant increase in the amount of red cells. Since 
erythropoiesis during early development is in many aspects similar to stress erythropoiesis in the 
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adult, mild erythroid defects in the adult Vav-LSL-Evi1+/-/pEV-Cre+/- mice may be revealed under 
stress conditions, like in the Stat5a/5b null mutants.31 
An alternative explanation for the transient fetal anemia may be that Evi1 specifically affects 
the development of erythroid cells in response to interactions with fetal liver supportive cells, 
since it is striking that erythroid progenitors from most Vav-LSL-Evi1+/-/pEV-Cre+/- fetal livers 
proliferated and differentiated normally in a liquid culture system containing saturating amounts 
of growth factors. There is evidence that during early stages of fetal liver erythropoiesis higher 
levels of Epo are necessary to sustain survival and differentiation than at later stages.34 It is 
possible that during this critical period the survival factor levels in Evi1 overexpressing livers are 
insufficient to compensate for the effects of Evi1. When sufficient Epo is present, like in liquid 
culture or in Vav-LSL-Evi1+/-/pEV-Cre+/- embryos at a later stage, stimulation of Epo-dependent 
survival pathways may rescue the remaining progenitors. The fact that EpoR expression in 
E12.5 Vav-LSL-Evi1+/-/pEV-Cre+/- livers did not differ from controls, and the observation that 
in surviving E13.5 Vav-LSL-Evi1+/-/pEV-Cre+/- embryos fetal liver cellularity had returned to 
normal (unpublished data) support this notion. Only in the most severely affected E12.5 Vav-
LSL-Evi1+/-/pEV-Cre+/- livers, that contain the lowest total amount of cells and the highest 
percentage of apoptotic and dead cells, and that show decreased proliferation in vitro, the rescue 
may come too late, leading to embryonic lethality. 
We observed a reduction in the number of CFU-E erythroid progenitors in Vav-LSL-Evi1+/-
/pEV-Cre+/- fetal livers. Although this suggests a direct interference of Evi1 with commitment 
of progenitors to the CFU-E stage, a more plausible explanation may be that the reduction is 
secondary to the observed maturation arrest, since pEV-Cre driven recombination in the erythroid 
lineage is temporally restricted, recapitulating the expression pattern of β-like globin genes.18 To 
determine the effect of Evi1 at the more immature stages of erythroid development it would be 
applicable to use transgenic mouse lines that express Cre at earlier stages of erythropoiesis.
Possible mechanisms involved in Evi1 induced anemia
The mRNA expression levels of a number of key factors involved in erythroid development were 
examined to learn more about targets and pathways that could be affected by Evi1 overexpression. 
Epo is the main growth factor for erythroid cells. Interaction with its receptor, EpoR, stimulates 
signaling cascades involved in survival, proliferation and differentiation of erythroid progenitors 
(reviewed by Lacombe and Mayeux35). The transcription factor Gata1 is part of a large and 
highly dynamic protein complex that changes in abundance during hematopoietic development 
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and that is involved in development of the erythroid and megakaryocytic lineages (reviewed 
by Cantor and Orkin36 and by Ferreira et al.29). Previous studies in BM and 32D-Epo cells have 
provided evidence for interference of Evi1 with Gata1 function and/or Epo signaling, possibly 
by downregulation of EpoR expression.12,14 We however did not detect any difference in either 
EpoR or Gata1 expression between Vav-LSL-Evi1+/-/pEV-Cre+/- and control fetal livers.  
Strikingly, we did observe increased expression of the transcription factors Pu.1 and c-myb. 
In MEL cells, virally induced Pu.1 causes a block in terminal differentiation by functionally 
interacting with Gata1 and thereby repressing Gata1 target genes.26,27 C-myb has been shown 
to act downstream of Pu.1 in MEL cells.28 Although we cannot exclude that the changes in 
Pu.1 and c-myb expression are (partly) due to the observed arrest in maturation, the direct or 
indirect induction of Pu.1 expression by Evi1 is an interesting option that deserves further 
investigation. 
Materials and Methods
Generation of expression constructs
A loxP-flanked transcriptional stop (LSL) cassette15 was inserted into XhoI / NotI digested 
PLNCX2 to generate PLNCX2-LSL. Blunt-ended GFPEvi1 and FlagEvi1 fusions, containing 
the full length 4.5 kb Evi1 cDNA, were inserted into the StuI site of PLNCX2-LSL resulting 
in PLNCX2-LSL-GFPEvi1 and PLNCX2-LSL-FlagEvi1. The Vav-LSL-GFPEvi1 and Vav-LSL-
FlagEvi1 transgenic constructs were generated by digestion of a Vav-hCD4 construct16 with SfiI 
and NotI (resulting in removal of hCD4 sequences), blunting of the overhangs, and insertion 
of blunt-ended LSL-GFPEvi1 and LSL-FlagEvi1 fragments after excision from the PLNCX2-
LSL-GFPEvi1 and PLNCX2-LSL-FlagEvi1 constructs by EcoRI and partial ClaI digestion, 
respectively. The integrity of the constructs was confirmed by restriction enzyme analysis.  
Transfection and immunofluorescence
Phoenix cells were transfected using the calcium phosphate transfection method with 10µg of 
the PLNCX2-LSL-GFPEvi1 plasmid in presence or absence of 0.5 µg of the pMC-Cre plasmid17. 
Two days after transfection expression was visualized using a Leica DMIRB fluorescence 
microscope (Leica, Rijswijk, The Netherlands).
54
Chapter 2
55
Evi1 induces fetal anemia
Generation of transgenic mice
Fragments for microinjection were prepared by linearization of the Vav-LSL-GFPEvi1 and Vav-
LSL-FlagEvi1 transgenic constructs with PvuI (which partially removes the vector backbone), 
gel-purification of the desired fragments with the Jetsorb kit (Genomed, Löhne, Germany), 
and an additional purification step using Elutip-d columns (Schleicher and Schuell, Dassel, 
Germany). Fragments were microinjected into the pronucleus of fertilized FVB mouse eggs 
and transferred into pseudo-pregnant mothers. Transgenic founders were bred with FVB mice 
to establish transgenic lines. Vav-LSL-GFPEvi1 and Vav-LSL-FlagEvi1 transgenic mice were 
crossed with the pEV-Cre transgenic line18 to induce specific excision of the transcriptional stop 
sequence in the erythroid lineage of double transgenic offspring. All mice were maintained under 
standard conditions and treated according to institutional animal health care and use guidelines. 
Collection of embryos and fetal livers
Vav-LSL-FlagEvi1+/- or Vav-LSL-GFPEvi1+/- mice were crossed with pEV-Cre+/- mice and 
embryos were dissected at E12.5. Fetal blood was collected in tubes containing PBS / 5mM 
EDTA.  Single cell suspensions of fetal livers were made by pipetting in PBS / 0.5% BSA. 
Genotype analysis
DNA isolated from embryonic heads or livers and adult tails was used for genotype analysis. 
Genotyping was done by PCR using the following primer sets: Vav-LSL-GFPEvi1: 5’-
GATCACATGGTCCTGCT-3’ and 5’-CAGTTTTCACACTCATAGTGC-3’, Vav-LSL-FlagEvi1: 
5’-GGACGACGATGACAAAGAT-3’ and 5’-CAGTTTTCACACTCATAGTGC-3’, pEV-Cre: 
5’-GCACGTTCACCGGCATCAAC-3’ and 5’-CGATGCAACGAGTGATGAGGTTC-3’. PCR 
conditions for all reactions were 1’ 94°, 1’ 55°, 1’ 72°C (36 cycles). 
Detection of in vivo recombination
PCR on genomic DNA isolated from fetal livers was applied to detect the deletion of 
the transcriptional stop sequence. The following primer sets were used for this PCR: 
5’-GGAAGTGGTGTTGTAGTTGTC-3’ and 5’-CCTTGAAGAAGATGGTGCG-
3’ for Vav-LSL-GFPEvi1 mice, 5’- GGAAGTGGTGTTGTAGTTGTC-3’ and 5’-
CAGTTTTCACACTCATAGTGC-3’ for Vav-LSL-FlagEvi1 mice. PCR was performed under 
the following conditions:  1’ 94°, 1’ 55°, 3’ 72°C (38 cycles).
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RQ-PCR
Total RNA was extracted from single cell suspensions of fetal livers with guanidium thiocyanate 
and purified by centrifugation in cesium chloride solution. RNA was transcribed into cDNA 
using Superscript (Invitrogen, Breda, The Netherlands) and random hexamers according to the 
recommendations of the manufacturer. RQ-PCR amplification was performed in an ABI PRISM 
7900 HT Sequence Detector (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands), 
using 12.5 µl SYBR Green PCR Master Mix (Applied Biosystems), 2 µl (1/4 diluted or 
undiluted) cDNA, 0.5 μl of each primer (10 pmol/μl) and 9.5 µl water. Sequences of primer pairs 
used for RQ-PCR are available on request. The PCR conditions were 2’ 50°C (1 cycle), 10’ 95°C 
(1 cycle), 15’’ 95°C followed by 1’ 60°C (45 cycles). Average Ct (threshold cycle) values from 
duplicate readings were normalized using the endogenous reference (∆Ct = Ct target RNA - Ct 
Hprt). To quantify the relative expression of GFPEvi1 and FlagEvi1 RNAs, the ∆Ct values of 
transgenic fetal livers were compared with the mean ∆Ct value of samples from WT littermates 
as a calibrator, using the “deltadelta Ct” method (ΔΔCt=ΔCt sample - ΔCt WT). To quantify the 
relative expression of erythroid RNAs the mean ΔCt of all (WT and single transgenic) samples 
from control littermates was used as the calibrator. Relative expression was calculated by the 
formula 2 −ΔΔCt.
Liquid culture of fetal liver cells
Following disaggregation of the fetal liver, the total amount of cells was determined by counting 
cell suspensions with a CASY1 electronic cell counter (Schärfe-System, Reutlingen, Germany). 
Fetal liver cells were expanded in StemPro-34TM medium (Invitrogen) supplemented with 
0.36 units/ml human recombinant erythropoietin (Epo; Eprex, Janssen-Cilag, Tilburg, The 
Netherlands), 100 ng/ml murine recombinant SCF (R&D Systems, Minneapolis, MN, USA) and 
10-6 M dexamethasone (Sigma-Aldrich, Zwijndrecht, The Netherlands) with daily adjustment of 
the cell density to 1x106 cells/ml. To measure differentiation, fetal liver cultures were washed 
twice with 50 ml PBS and spun at 700 rpm for 7’ to enrich for erythroid progenitors that were 
subsequently cultured for 48h in StemPro-34TM medium supplemented with 5 units/ml Epo and 
1 mg/ml iron saturated human transferrin (Intergene, Purchase, NY, USA).
Colony assays
Fetal liver cells were assayed for their content of CFU-E and BFU-E by in vitro colony 
formation in semisolid methylcellulose culture medium. Cells were plated in duplicate in 35-
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mm Petri dishes (BD, Aalst, Belgium) at a concentration of 60,000 to 100,000 cells per dish. The 
components included in the methylcellulose cultures are described in de Jong et al.19 Cultures 
were maintained in a humidified atmosphere of 5% CO
2
 in air. Colonies were counted at day 2 
(CFU-E) and day 8 (BFU-E). 
Flow cytometry
Single cell suspensions of fetal liver cells were incubated with PE-conjugated anti-mouse 
TER119 and FITC-conjugated CD71 (BD) to determine the differentiation status. Dead cells 
were excluded from analysis by staining with 7-aminoactinomycin-D (7AAD; Invitrogen). 
To identify apoptotic cells, single cell suspensions were stained with AnnexinV-FITC and 
Propidium iodide (PI, BD). A total of 5x104 events were counted per sample. 
Cytology and differential counting
Cytospins of freshly isolated fetal liver, bone marrow or spleen cells were stained with May-
Grünwald Giemsa and double-blindly analyzed. A differential count was performed on 200 or 300 
nucleated cells per slide and the percentage of dysplastic erythroblasts was obtained. Dysplasia 
was characterized as deformation of the nucleus, megaloblastic changes or asynchronous 
maturation of the cytoplasm and the nucleus. 
Statistics
Data sets were analyzed using SPSS statistical analysis software (SPSS, Chicago, IL). Small 
datasets (with group sizes smaller than n=10) were analyzed by pair wise comparisons between 
groups using the Mann Whitney U test. For larger data sets, first the normal distribution was 
confirmed by determining the Kolmogorov-Smirnov statistic. Significant differences among 
groups were subsequently determined using ANOVA. When significance was detected, pair wise 
comparisons were made between groups using either Tamhane’s T2 or Bonferroni post hoc tests 
in case of respectively unequal and equal variation of the dependent variable across the groups. 
Statistical significance was defined as p<0.05. 
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Early expression of Evi1 in fetal erythroid development causes 
considerable increase of cell death in a conditional transgenic mouse 
model.
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Philipsen2, Eric van den Akker1 and Ruud Delwel1
1Department of Hematology, 2Department of Cell Biology, Erasmus University Medical Center, 
Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
Abstract
Aberrant expression of EVI1 has been observed in patients with myelodysplastic syndrome 
(MDS) or acute myeloid leukemia (AML) carrying 3q26 aberrations. In MDS patients expressing 
this aberration, refractory anemia is frequently observed suggesting direct interference of EVI1 
with erythropoiesis. We recently established novel Vav-loxp-stop-loxp-Evi1 transgenic mouse 
lines that conditionally express Evi1 in the hematopoietic system. 
Here we crossed these animals with mice expressing the Cre-enzyme in early erythroid-
progenitors under the control of the Epo-receptor promoter (ErGFPCr).  The effects of Evi1 
expression on early erythroid progenitors differentiation revealed a strong correlation between 
inappropriate expression of Evi1 and cell death.  The fetal liver from E12.5 embryos showed 
significant decrease in size and cell number.  Furthermore, a significant decrease of early 
progenitors (CFU-e and BFU-e) was found and forced in vitro differentiation of these cells 
showed inability of progression towards mature erythrocytes.  In addition, fetal blood cells 
showed anisocytosis, which is a characteristic feature of anemia.  
These findings support the notion that inappropriate expression of EVI1 plays a role in 
development and progression of MDS or AML in humans.  Moreover, we have found that earlier 
expression of Evi1 during erythroid differentiation has a more severe outcome as compared with 
previously analysed β-globin specific erythroid Cre lines.  
Introduction
Evi1 (ecotropic virus integration site 1), which was originally identified as a myeloid transforming 
gene by means of retroviral insertional mutagenesis in mouse leukemias, encodes a nuclear DNA 
binding zinc finger protein.1,2 Patients with acute myeloid leukemia (AML) or myelodysplastic 
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syndrome (MDS) harboring 3q26 translocations, the region where EVI1 is located, frequently 
show aberrant expression of EVI1.3-5  Moreover, in 10% of AML patients and 30% of MDS 
patients without abnormalities in 3q26,4,6  EVI1 overexpression has been observed as a result of 
unknown mechanisms. Evi1 protein contains two zinc finger domains, i.e. an N-terminal domain 
of seven zinc fingers and a more C-terminal domain containing three zinc fingers. Although the 
exact mechanism of transformation by Evi1 is unknown, the fact that EVI1 is capable of binding 
DNA through the two zinc finger domains, each recognizing a specific and unique nucleotide 
sequence, suggests that it is involved in transcriptional control .7-9 
Several in vivo and in vitro studies have provided support for an involvement of Evi1 in 
hematopoietic differentiation and consequently in the development of MDS and AML. Evi1 
has been shown to interfere with cytokine induced neutrophilic or erythroid differentiation 
using 32D cell line models or bone marrow progenitor cells in vitro. 10,11 Moreover, evidence for 
interference with differentiation by Evi1 in vivo has been obtained from studies using Sca-Evi1 
transgenic lines showing mild erythroid defects. 12 Severe erythroid defects were reported from 
studies in which Evi1 transduced BM progenitors were transplantated into sublethally irradiated 
mice.13 Our previous observation that only low or undetectable levels of Evi1 expression could be 
achieved in the Sca-Evi1 model and the findings showing that Evi1 coupled to strong promoters 
(e.g. H-2k) yielded no transgenic lines at all (D.S and R.D, unpublished data), prompted us to 
generate Evi1 transgenic mouse lines with Cre recombinase-inducible Evi1 expression in the 
hematopoietic system. 14 We examined the effects of Evi1 activation on survival, proliferation 
and differentiation of erythroid progenitors, by crossing the Evi1 transgenic lines with the 
erythroid lineage specific pEV-Cre (Cre under the control of the beta-globin locus control region) 
transgenic line. Although this combination of mice allowed expression of Evi1 at a relatively late 
stage of erythroid development, significant interference by Evi1 with fetal erythroid development 
was observed. To investigate the effects of Evi1 in more immature erythroid precursors we bred 
the Cre recombinase-inducible Evi1 lines with mice expressing the Cre enzyme under control of 
the Epo-receptor promoter, ErGFPCre. We show that Evi1 expression in the double transgenic 
animals results in a more severe phenotype that observed in Evi-1 mice crossed with pEV-Cre. 
We observed substantial cell death of fetal liver cells, suggesting that inappropriate expression 
of Evi1 is detrimental for erythroid precursors and may reflect the erythroid malformations 
frequently observed in MDS patients showing high EVI1 expression as the result of 3q26 
aberrations. 
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Results
Vav-LSL-Evi1 and ErGFPCre double transgenic animals: macroscopic defects of fetal 
erythroid development.
The transgenic lines Vav-LSL-Evi1 previously demonstrated to express Evi1 following pEV-Cre 
breeding were used for this study and crossed with ErGFPCre transgenic mice.  In the ErGFPCre 
line, Cre expression is under the control of the Epo-receptor gene, allowing expression of the 
enzyme in the erythroid lineage starting at early stage, thereby efficiently driving recombination 
of floxed loci within the entire erythroid lineage (Figure 1A)17.  Although only one litter of 
neonates has been analyzed, no double transgenic Vav-LSL-Evi1+/-/ErGFPCr+/- offspring was 
observed (Table 1). However, Southern blotting (Figure 1B) revealed that 9/50 (19%) E12.5 
embryos were double heterozygous for ErGFPCre and Evi1 (Table 1). 
Figure 1 Expression pattern of 
ErGFPCr+/- and Vav-LSL-Evi1+/- 
mice (A) Evi1 driven by the Vav 
promoter targets all hematopoietic 
lineages.  The short LSL sequence 
is flanked by two LoxP sites (grey 
arrows), which upon deletion by the 
Cre enzyme removes the LoxP sites 
and allows transcription of Evi1.  The 
ErGFPCr+/-mouse expresses the Cre 
recombinase enzyme under the control 
of the Epo-Receptor gene and allows 
expression starting from the BFU-e 
stage.  (B) Southern blot using genomic 
DNA of E12.5 littermates.  DNA was 
digested with EcoRV and probed with 
EGFP probe.  Heterozygous embryos 
showed presence of both constructs, 
wild type embryo has absence of 
both constructs, and in homozygous 
embryos single product was detected. 
(C) Recombination PCR on genomic 
DNA obtained from fetal liver cells. 
Vav-LSL-Evi1 band indicates non-
recombined product, whereas Vav-
Evi1 shows recombination upon Cre 
presence. 
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Table 1  Genotypic distribution of E12.5 and newborn animals from 
ErGFPCr+/-/Vav-LSL-Evi1+/- crossings
ErGFPCr+/-/Vav-LSL-Evi1+/- double heterozygous animals follow normal 
Mendelian distribution.  Analysis of neonates did not reveal presence of 
ErGFPCr+/-/Vav-LSL-Evi1+/- animals.
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PCR confirmed recombination between loxP sites and deletion of the stop box in the genomic 
DNA of fetal livers isolated from E12.5 Vav-LSL-Evi1+/-/ErGFPCr+/- double transgenic embryos 
as opposed to single transgenic littermates (Figure 1C).  
Double heterozygous embryos could be readily distinguished from littermates at this stage 
because of the exceptionally pale appearance of the visceral yolk sacs (Figure 2A). In addition, 
Vav-LSL-Evi1+/-/ErGFPCre+/- embryos were paler than their littermates and showed a clear 
reduction in the size of the fetal liver (Figure 2A).  Moreover, double transgenic fetal livers 
contained significantly less cells compared to control livers (Figure 2B).
Figure 2  Macroscopic analysis of day 
12.5 embryos
(A) Photographs showing E12.5 embryos 
within their yolk sacs (upper panels), 
without yolk sac (middle panels) and fetal 
livers only (lower panels). ErGFPCr+/-/Vav-
LSL-Evi1+/- embryos are characterized by 
clear pallor of the yolk sac (upper panel, 
far left), paler embryo (middle panel, far 
left) and significantly reduced in size pale 
Evi1+/Cre+ WT Evi1+ Cre+
A
Evi1+/Cre+ Evi1+/Cre+ WT Figure 3 Cellular morphology of 
fetal blood cells at E12.5
Cytospins of fetal blood samples of 
two independent ErGFPCr+/-/Vav-
LSL-Evi1+/- shows heterogeneous 
populations of cells.  The 
composition of blood cells range 
from immature cells (white 
arrows), dissimilar size of cells 
(anisocytosis) (black arrows) and 
dead cells (arrow heads).  Control 
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liver (lower panel, far left). (B) ErGFPCr+/-/Vav-LSL-Evi1+/- E12.5 transgenic livers showed greatly reduced number of 
cells as compared to control livers.   
blood of wild type (WT) littermate showed a uniform population of mature erythroblasts.     
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Severe hypocellularity and anisocytosis of fetal red blood cells in double heterozygous 
embryos
Since macroscopic analysis of the visceral yolk sacs suggested inappropriate fetal erythropoiesis 
we analysed blood samples by May-Grunwald Giemsa staining (Figure 3). We observed 
hypocellularity of fetal blood samples from Vav-LSL-Evi1+/-/ErGFPCr+/- embryos as compared 
to control fetal blood samples. In fact, a significant number of dead cells were observed in 
samples from double heterozygous blood samples. Moreover, we also observed immature 
erythroblasts in the latter samples and not in control samples (White arrows in Figure 3). In 
contrast to blood samples from wt or single transgenic embryos, yolk sac blood samples from 
Vav-LSL-Evi1+/-/ErGFPCr+/- animals did not show a uniform population of mature erythroblasts, 
but demonstrated severe forms of anisocytosis (dark arrows in Figure 3), characteristically 
associated with severe anemia.  
Dysplasia, block of differentiation, and increased cell death of fetal liver erythropoiesis in 
double heterozygous embryos
Dysplasia is characterized by asynchronous maturation of the nucleus and cytoplasm and 
has previously also been described for Vav-LSL-Evi1+/-/ pEV-Cre+/- animals. 14 Analysis of the 
preparations revealed a significant increase of the percentage of dysplastic cells in double 
heterozygous fetal livers (data not shown). However, immunostaining of the fetal liver cells 
using c-kit/CD71 did not revealed a significant increase of immature c-kit+/CD71- or c-kit+/
CD71+ cells (Figure 4). These data suggest that there is not a severe block and accumulation of 
very immature erythroid precursor cells. 
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Figure 4  Percentage of immature cell 
population in E12.5 fetal liver
Flow cytometric analysis of CD71+/c-kit+ 
and CD71+/c-kit- cells from fetal liver
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Since morphological and immunological analysis did not reveal a severe block or accumulation 
of earlier precursors, whereas macroscopic analysis showed clear interference of erythroid 
development (Figure 2), we decided to study survival of fetal liver cells. Fetal liver cells in one 
experiment were stained Ter119 and exposed to 7AAD. We observed extremely high percentages 
of dead cells within Vav-LSL-Evi1+/-/ErGFPCr+/- fetal livers as compared to any of the control 
samples (Figure 5A). This increase was independent of the presence of TER119, suggesting 
that cell death was not only observed in the mature fraction. In a separate experiment we also 
analyzed whether cell death was due to apoptosis, by performing Annexin V and 7AAD staining 
(Figure 5B). Again a significant increase of 7AAD stained cells was observed. However, no 
increase in Anexin V+/7AAD- cells was found, suggesting that cells might not die as result of 
apoptosis.   
Evi1 interferes and blocks terminal differentiation of erythrocytes
To analyze in more detail the ability of fetal liver cells to differentiate in vitro, we induced 
terminal erythroid differentiation in hanging drop cultures. Cells were analyzed by flow 
cytrometry, using the CD71 and Ter119 markers, prior and after two days of culture. In control 
cultures at day 0 the majority of the cells (approximately 80%) express both CD71 and TER119 
markers and very few CD71- TER119+ cells are present. After two days in culture about 30-40% 
of the control cells were CD71- TER119+ , indicating that terminal erythroid differentiation has 
occurred (Figure 6). It is clear already by day 0 that double transgenic erythroid progenitors 
Figure 5  Significant increase of dead cells in ErGFPCr+/-/Vav-LSL-Evi1+/- embryos
(A) Flowcytometric analysis of TER119+ or TER119- cell population stained with 7Amino-Actinomycin D (7AAD). (B) 
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showed an increased block in differentiation since the CD71+ Ter119+ cell population is 
reduced. 
Thus the normal down regulation of CD71 expression, reflecting normal differentiation, is not 
evident.  After two days of differentiation the vast majority of these cells in double transgenic 
animals were dead and the remaining ones that survived were most likely not erythroid since 
they did not express CD71 or Ter119 (Figure 6). Taken together these results suggest that cells 
expressing Evi1 at early stages of erythroid differentiation can survive but expression in later 
stages is lethal. 
Figure 6  Decrease of 
mature erythroid cells 
in ErGFPCr+/-/Vav-LSL-
Evi1+/- fetal livers
Fetal liver cells were 
double stained with CD71+ 
and TER119+ at day 0 and 
after two days in hanging 
drop culture.  Cells were 
analyzed by flow cytometry 
and the numbers depict 
the percentage of each 
population.  
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E12.5 Vav-LSL-Evi1+/-/ErGFPCr fetal livers contain reduced number of BFU-E and CFU-E
To determine the number of BFU-E (burst forming unit-erythroid) and CFU-E (colony forming 
unit-erythroid) progenitors in E12.5 double transgenic livers, we performed colony assays. Fetal 
liver cells were grown in semi-solid medium in presence of Epo, or Epo and SCF, to determine 
the number of CFU-E and BFU-E, respectively, per liver. E12.5 Vav-LSL-Evi1+/-/ErGFPCr+/- 
fetal livers contained significantly lower numbers of BFU-E and CFU-E than livers obtained 
from single transgenic or WT littermates (Figure 7).  
Discussion
We previously established novel Evi1 transgenic mouse lines with conditional expression in 
the hematopoietic system and showed that Evi1 interfered with fetal erythroid development 
when the mice were bred with pEV-Cre animals, in which the Cre gene was under the 
control of the β-globin–LCR. Here we demonstrate that Vav-LSL-Evi1 mice when crossed 
with animals expressing Cre under the control of the Epo-R promoter display a more severe 
erythroid dysplasia in E12.5 embryos, which is most likely explained by an earlier onset of 
the Evi1 gene in those double transgenic embryos. We observed a reduction in the number 
of CFU-E as well as BFU-E erythroid progenitors in Vav-LSL-Evi1+/-/ErGFPCr+/- fetal livers. 
This suggests a direct interference of Evi1 with more primitive erythroid progenitors than we 
previously reported in Vav-LSL-Evi1+/-/pEV-Cre+/- embryos, in which an effect on CFU-E but 
Figure 7  BFU-E and CFU-E colony assay on E12.5 fetal liver cells
5x104 single cell suspension cells isolated from fetal livers were plated in BFU-e or CFU-e methylcellulose medium. 
Colonies were counted on day 2 for CFU-e and day 8 for BFU-e.  All experiments were performed in duplicate.
0
1
2
3
4
5
6
7
8
9
10
Evi1+/Cre+ Evi1+/Cre+ Evi1+ Cre+ WT
N
um
be
r
of
B
FU
-e
/f
et
al
liv
er
(x
10
)3
0
1
2
3
4
5
6
7
8
N
um
be
r
of
C
FU
-e
/f
et
al
liv
er
(x
10
)4
Evi1+/Cre+ Evi1+/Cre+ Evi1+ Cre+ WT
70
Chapter 3
71
Evi1 enforced expression in early erythroid precursors
not BFU-E progenitors was observed. These data together with the severe effects observed on 
primitive hematopoieisis in the yolk sac (Figures 3), which appeared to be less pronounced in 
Vav-LSL-Evi1+/-/pEV-Cre+/-, suggest that the animals reported here have a much more severe 
phenotype. Since only few neonates have been analyzed so far, it is currently unclear whether 
Vav-LSL-Evi1+/-/ErGFPCr+/mice will be born alive.  Given the fact that the phenotype of the 
Vav-LSL-Evi1+/-/ErGFPCr+/-embryos appears more severe than those of Vav-LSL-Evi1+/-/pEV-
Cre+/- embryos, double transgenic animals may not be born. In case newborn double transgenic 
animals will be born, they would provide an interesting model to study the effects of Evi1 on 
adult erythropoieisis in the context of dysplasia, which is frequently found in AML or MDS with 
high EVI1 expression. 
Our studies suggest that the effects of Evi1 are not simply explained by interference of a 
differentiation program. In fact it appears that high Evi1 expression is detrimental for the 
erythroid cells, independent of the stage of differentiation. In a way this effect is very similar 
to what Buonamici et al.13 have described following transduction of Evi1 into bone marrow 
precursors and subsequent transplantation. These data have been interpreted as an erythroid 
defect corresponding to the erythroid defects observed in myelodysplastic syndrome. Here we 
show, based on the Annexin V/7AAD staining, that the massive death of erythroid cells may not 
be explained by apoptosis. Although this might be true, we assume that it is still possible that the 
timing of the analysis may affect this conclusion and that in case we analyze the data at an earlier 
time, e.g. E11.5 or E12, we may find that apoptosis is the major cause of cell death.  
Most data available from in vivo studies have revealed that aberrant expression of Evi1 
has unfavorable effects on the cells it is expressed in. This would mean that to become a 
transforming gene for hematopoietic cells additional transforming events are required, which 
prohibit the “death promoting” effects of Evi1.  The development of strategies to directly target 
oncoproteins has been one of the most attractive and promising approaches of cancer research 
in the last decade. The fact that EVI1, which may be highly expressed in certain AML patients, 
can be so damaging to cells suggests that to eradicate EVI1 expressing tumor cells, one should 
not target the function of Evi1, but rather interfere with pathways that allow Evi1 to be present in 
those cells. Targeting genes or products thereof that cooperate with Evi1 in transformation, may 
release the “suicidal” effects of Evi1 and thereby lead to destruction of tumor cells by aberrant 
expression of EVI1. 
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Materials and Methods
Collection of embryos and fetal livers from mutant mice
The generation of Vav-LSL-FlagEvi1+/- or Vav-LSL-GFPEvi1+/- mice has previously been 
described 14. Both transgenic line showed similar phenotype and have been used in this study 
and will further be designated Vav-LSL-Evi1.  The animals were crossed with ErGFPCre knock 
in mice 15 (kindly donated by Dr. Klingmuller, Freiburg, Germany) and embryos were dissected 
at E12.5. Fetal blood was collected with PBS / 5mM EDTA.  Single cell suspensions of fetal 
livers were made by pipetting in PBS / 0.5% BSA. Following disaggregation of the fetal liver, 
the total amount of cells was determined by counting cell suspensions with a CASY1 electronic 
cell counter (Schärfe-System, Reutlingen, Germany).
Genotype analysis
DNA isolated from embryonic heads or livers and adult tails was used for genotype analysis. 
Genotyping was done by PCR using the following primer sets: Vav-LSL-GFPEvi1: 5’-
GATCACATGGTCCTGCT-3’ and 5’-CAGTTTTCACACTCATAGTGC-3’, ErGFPCre: 5’-
CAGCACCTGGGCCAGCTCAAC-3’ and 5’- TGGCAGAAGGGGCAGCCACAC-3’. PCR 
conditions for all reactions were 1’ 94°, 1’ 55°, 1’ 72°C (36 cycles). 
Southern blot was performed by digesting genomic DNA with EcoRV and hybridizing with 
EGFP fragment derived from C
3
EGFP (Clontech, Palo Alto, CA) using Eco47III and XhoI 
restriction enzymes.
Detection of in vivo recombination
PCR on genomic DNA isolated from fetal livers was applied to detect the deletion of 
the transcriptional stop sequence. The following primer sets were used for this PCR: 5’-
GGAAGTGGTGTTGTAGTTGTC-3’ and 5’-CCTTGAAGAAGATGGTGCG-3’ for Vav-LSL-
GFPEvi1 mice. PCR was performed under the following conditions:  1’ 94°, 1’ 55°, 3’ 72°C (38 
cycles).
Colony assays
Fetal liver cells were assayed for their content of CFU-E and BFU-E by in vitro colony formation 
in semisolid methylcellulose culture medium. Cells were plated in duplicate in 35-mm Petri 
dishes (BD, Aalst, Belgium) at a concentration of 5x104cells per dish. The components included 
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in the methylcellulose cultures are described in de Jong et al.16 Cultures were maintained in a 
humidified atmosphere of 5% CO
2
 in air. Colonies were counted at day 2 (CFU-E) and day 8 
(BFU-E). 
Hanging drop cultures.
Hanging drop cultures were performed as described previously. 17  In short, cells were spun 
down and resuspended in HD medium (DMEM supplemented with 20% FCS, 0.1% β-
mercaptoethanol, 2x10-4 M Hemin, 1% penicillin/streptomycin, 2U/ml Epo, 5μg/mL insulin). 20 
μL drops containing approximately 2.5x104 cells each were pipetted on the inner side of the lid of 
a tissue culture Petri dish. After distribution of the drops, the lid was inverted and placed on the 
Petri dish, which contained PBS to humidify the culture chamber. Cultures were harvested after 
2 days by washing the drops with PBS supplemented with 0.5% heat inactivated FCS.  
Flow cytometry
Single cell suspensions of fetal liver cells were incubated with PE-conjugated anti-mouse 
TER119, FITC-conjugated CD71 or PE conjugated c-kit (BD) to determine the differentiation 
status. Dead cells were excluded from analysis by staining with 7-aminoactinomycin-D (7AAD; 
Invitrogen). Identification of apoptotic cells was performed using single cell suspensions and 
stained with AnnexinV-FITC and Propidium iodide (PI, BD). 
Cytology and differential counting
Cytospins of freshly isolated fetal blood or fetal liver cells were stained with May-Grünwald 
Giemsa and double-blindly analyzed. A differential count was performed on 200 or 300 
nucleated cells per slide and the percentage of dysplastic erythroblasts was obtained. Dysplasia 
was characterized as deformation of the nucleus, megaloblastic changes or asynchronous 
maturation of the cytoplasm and the nucleus. 
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Abstract
Ecotropic virus integration site 1 (EVI1) gene is expressed in acute myeloid leukemias (AML) 
or myelodysplastic syndrome (MDS) patients with chromosomal abnormalities involving 3q26 
locus, where the gene resides.  In this study we investigated by means of protein interaction 
screens, which proteins interact with Evi1 and are critical for transcriptional repression by Evi1. 
Using yeast two-hybrid screen we have identified a novel binding partner of Evi1, the methyl 
binding domain 3b (Mbd3b) protein, a member of the histone deacetylase complex NuRD. 
Mbd3b binds Evi1 through the methyl binding domain (MBD) and the adjacent downstream 
40 amino acids. Biochemical analysis demonstrated that both proteins interact in vitro and in 
vivo.  Evi1 and Mbd3b co-localized in subcellular speckles in the nucleus. Immunoprecipitation 
experiments and GST pull down assays showed that the first three zinc fingers of Evi1 are 
required for interaction with Mbd3b. Moreover, we demonstrate that Evi1 was capable of 
interacting with endogenously expressed Mbd3b. Using a reporter assay we demonstrated 
that Evi1 enhances the transcriptional repression of Mbd3b, in a dose dependent manner.  The 
interaction between Evi1 with Mbd3b may be important for epigenetic chromatin modification 
and leukemic transformation. 
Introduction
The ecotropic integration site 1 (EVI1) oncogene has been well recognized to be associated 
with human and murine myeloid tumors.  In humans, EVI1 is found to be overexpressed in 
AML patients with translocations or inversions involving chromosome 3, e.g. t(3;3)(q21;26) or 
inv(3)(q21;q26), the locus where the gene resides 1,2.  Recently, it has been shown that aberrant 
EVI1 mRNA expression also occurs in patients without chromosome 3 karyotypic abnormalities 3. 
The mechanism of transformation as a result of high EVI1 expression in both cases is currently 
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unknown.  Evi1 was initially identied in the mouse as a common proviral integration site in 
virus-induced leukemias, 4 and overexpression of Evi1 in mouse bone marrow revealed a block 
of differentiation in myeloid precursors cells 5.  Enforced expression of Evi1 in the red blood cell 
lineage impairs erythroid differentiation 6, whereas in megakaryocytic cells the gene appears to 
enhance differentiation 7. An in vivo model of Evi1 expressed from the murine Sca-1 promoter 
showed a reduced number of colony forming units in the erythroid lineage (CFU-E) in the bone 
marrow 8.  More recently, bone marrow cells transduced with EVI1 and transplanted into recipient 
mice showed development of fatal myelodysplastic syndromes after a latency of 10 months 9. 
Although these in vitro and in vivo findings are in agreement with the clinical manifestations 
of malignant disease with high EVI1 expression, the mechanisms by which EVI1 evokes these 
distinct effects are largely unknown. 
Evi1 encodes a nuclear protein of 145kDa with domains characteristic of transcriptional 
regulatory proteins.  It has 10 Cys
2
His
2
 type zinc fingers of which 7 are at the N-terminal and 3 
at the C-terminal part of the protein.  A proline rich region separates the two zinc finger domains 
and a small acidic domain is located C-terminal of the second zinc finger domain 10.  Both zinc 
finger domains are able to bind specific DNA sequences in vitro: the N-terminal zinc finger 
domain recognizes the nucleotide sequence (GACAA) GACAAGATAA 11-13 and the C-terminal 
domain is capable of binding to GAAGATGAG 14.  Although the recognition sequence of the 
N-terminal zinc finger domain exhibits similarity to GATA1 binding sequences and it has been 
proposed that Evi1 may interfere with GATA1 binding sites to deregulate its targets 6, binding of 
Evi1 to GATA1 specific promoter sequences has not been demonstrated.  
In recent years it has been demonstrated that Evi1 can bind to other proteins, and may thereby 
execute its capacity to transform cells.  For instance, Smad3 interaction with the first zinc finger 
domain of Evi1 disturbs the TGFβ pathway, which is known to be a negative regulator for cellular 
growth and differentiation 15.  Others reported that the repression activity of Evi1 may be due to 
interaction with the co-repressor carboxyl-terminal binding protein (CtBP) 16,17, and with histone 
deacetylases, HDAC1 and HDAC2 18.  These latter data suggest that the transformation by Evi1 
is associated with transcriptional repression of crucial target genes, for which interaction with 
transcriptional repression complexes is essential.  We identified a novel Evi1 interacting protein, 
methyl-CpG-binding domain protein Mbd3b, a member of the Mi2/NuRD transcriptional 
repressor complex. We investigated the interaction of Evi1 and Mbd3b and the role of Evi1 
within this complex. Evi1 interaction appears highly specific for Mbd3b, as other members of 
MBD motif containing family do not interact with Evi1. We show that the interaction recruits 
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Mi2/NuRD into the transcriptional repression complex, via Mbd3b, by which Evi1 may exert, its 
function in transcriptional repression. 
Results
Evi1 frequently interacts with Methyl-CpG Binding Domain Protein 3b (Mbd3b) in a 
yeast-two-hybrid protein interaction assay  
To identify potential novel binding partner(s) of Evi1, we carried out a Gal4 based yeast-two 
hybrid protein interaction screen.  PJ69-4A yeast cells containing the Gal4-BD-Evi1 fusion-gene 
were transformed with a mouse 17-day embryo cDNA library, in which the cDNA transcripts 
were cloned in frame with the GAL-4 transactivation domain.  Of the approximately 1x107 
transformed cells, 124 clones survived selection on medium lacking Trp, Leu, His, and Ade, 
which were further analyzed for β-galactosidase activity using the X-gal plate assay. This 
analysis revealed 25 positive clones, which were further confirmed in the β-galactosidase 
liquid culture assay (data not shown).  These positive clones were sequenced and 6 encoded 
for a Methyl-CpG Binding Domain Protein 3 isoform b (Mbd3b), a member of the Mi-2/NuRD 
transcriptional repressor complex.  Interaction between Evi1 and Mbd3b was confirmed on 
plates lacking Trp, Leu, His, and Ade (Fig. 1A). β-galactosidase reporter gene activation by 
Mbd3b in the presence of Evi1 appeared more than 5 fold higher as compared to what observed 
with Mbd3b alone (Fig. 1B). 
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Figure 1 Identification of a novel Evi1 binding partner 
Mbd3b, in a yeast two-hybrid screen
(A) Analysis of the interaction between Evi1 and Mbd3b in a 
yeast two-hybrid screen.  Evi1 containing plasmid (pGBT9-Gal4-
BD-Evi1) alone is not able to support growth on medium lacking 
the adenine (-Ade) amino acid, whereas in the absence of histidine 
(-His) no inhibition of growth was observed.  Introduction of an 
Mbd3b containing plasmid (pGBT9-Gal4-AD-Mbd3b) caused 
Ade transactivation due to the interaction between Evi1 and Mbd3b and allows yeast to grow.  (B) pGBT9-Gal4-AD-
Mbd3b was assayed in liquid culture to examine β-galactosidase activity either in the presence of pGBT9-Gal4-BD-
Evi1 or an empty vector pGBT9-Gal4-BD.  Increased β-galactosidase activity demonstrates the interaction between 
Mbd3b and Evi1.
78
Chapter 4
79
Evi1 interacts with NuRD via Mbd3b
A 40 amino acid region adjacent to the methyl CpG binding domain of Mbd3b is required 
for Evi1 interaction 
Mbd3b has a methyl CpG binding domain (MBD) at the N-terminus, and a coiled-coil (C-C) 
as well as a glutamic acid repeat (EE) domain at the C-terminal part of the protein (Fig. 2A). 
To determine the critical regions for Evi1 interaction, we performed yeast-two-hybrid analysis 
using Mbd3b mutants and full length Evi1.  
The EE domain was neither required nor sufficient to bind Evi1.  In contrast, deletion of the 
MBD+40 amino acids domain abolishes Evi1 association (∆MBD+40), while the MBD+40 
domain alone is able to associate with Evi1.  Notably, the 40 amino acids adjacent to the MBD 
domain are required to bind Evi1 (Fig. 2B).
Evi1 and Mbd3b colocalize and interact in mammalian cells
To study whether Evi1 and Mbd3b colocalize, Phoenix cells (ϕΕ) were transiently transfected 
with Flag-Evi1 and HA-Mbd3b. Cells were stained with specific anti-Flag and anti-HA 
antibodies followed by secondary FITC and TRITC staining respectively. By means of confocal 
microscopy we observed that Evi1 was expressed in a speckled pattern in the nucleus, as 
described previously 26. Moreover, HA-Mbd3b showed a similar staining pattern and merging of 
both images revealed 
Figure 2  Mapping the regions in Mbd3b that 
interact with Evi1 in a yeast two-hybrid analysis
(A) Full length Mbd3b and Mbd3b mutants that were 
used in the yeast-two hybrid interaction assay.  The 
dark grey area indicates the MBD domain at the N-
terminus. Other areas are the 12 glutamate repeat 
domain (EE), and the coiled-coil domain (CC). 
Full length Evi1 was transformed together with full 
∆ Μbd -40 -
Mbd +40 +
∆ EE +
EE -
Mbd -
A
Interaction
Mbd3b MBD +CC
E
E
Evi1
MbdMbd +40∆ Μ −40bdMbd3b
B
length Mbd3b or its mutants. (B) Yeast growth on selective plates lacking tryptophan (Trp), leucine (Leu), histidine (His), 
and adenine (Ade) shows selective growth of Mbd3b and MBD+40.
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the presence of Evi1 within several of the Mbd3b containing subnuclear speckles (Fig. 3).    
Immunoprecipitation of HA-Mbd3b using anti-HA in lysates from HA-Mbd3b/Flag-Evi1 co-
infected ϕE cells revealed the co-precipitation of Flag-Evi1 as determined by Western blot 
analysis using an anti-Flag antibody (Fig. 4A). In addition, HA-Mbd3b could be co-precipitated 
from the same lysates when an anti-Flag antibody was used to immuno-precipitate Flag-Evi1 
(Fig. 4A). These results demonstrate the interaction between Mbd3b and Evi1 in mammalian 
cells.
10µm 10µm 10µm
Evi1 Mbd3b Overlay
Figure 3  Evi1 and Mbd3b colocalize in the nucleus
Confocal microscopy of ϕE cells transiently transfected with Flag-Evi and HA-Mbd3b.  Flag-Evi was stained with anti-
Flag antibody followed by secondary TRITC staining (Red). HA-Mbd3 was stained with anti-HA antibody followed 
by secondary FITC staining (Green).  Both proteins form nuclear speckles and the merged slide shows co-localization 
between the two proteins (Yellow).              
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Figure 4  Evi1 physically interacts 
with Mbd3b in mammalian cells
(A) Co-expressed Flag-Evi1 and 
HA-Mbd3b in ϕE cells were 
immunoprecipitated with either 
anti-Flag or anti-HA antibody. 
Following PAGE and Western 
blotting, the immunoprecipitate with 
HA antibody was stained 
with anti-Flag antibody 
to analyze the presence 
of Evi1 (left blot). In the 
parallel experiment anti-
HA antibody was used 
to study the presence of 
Mbd3b following anti-
Flag immunoprecipitation 
(right blot). As a 
control (lane 2 in both 
experiments) lysates were 
exposed to unspecific 
antibody and beads. (B) 
Mbd3b binding region 
alignment with Mbd2 
amino acid sequence.  The 
interacting 40 amino acids 
of Mbd3b (position 69 
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Evi1 does not interact with other MBD family members or with Mbd3a 
The high homology within the MBD family members provoked us to investigate the possibility 
of Evi1 interaction with other members. Whereas, the homology between Mbd3b and Mbd1, 
Mbd4 or MeCP2 is restricted to the MBD domains only, Mbd2 shows homology with Mbd3b 
outside this region as well 27. 
Particularly, the 40 amino acids region required for interaction between Mbd3b and Evi1 shows 
high homology (65%) with a comparable region in Mbd2 (Fig. 4B).  Although co-precipitated 
with HA-Mbd3b using an anti-HA antibody, no Evi1 was observed in a co-immunoprecipitation 
experiment in Flag-Evi1/HA-Mbd2 transfected cells (Fig. 4C). Moreover, no interaction has 
been observed between Evi1 and Mbd1, Mbd4 or MeCP2 using transfected ϕE cells (data not 
shown). Two splice forms of Mbd3 have been identified, i.e. Mbd3a and Mbd3b. The Mbd3a 
splice variant contains an additional 30 amino acids within the MBD domain. Interestingly, no 
interaction was observed between Mbd3a and Evi1 in a immunoprecipitation experiment using 
co-transfected ϕE cells (data not shown), indicating that the Mbd3b-specific MBD domain is 
required for Evi1 interaction.
The first three zinc fingers of the N-terminal zinc finger domain of Evi1 are required for 
Mbd3b interaction 
We next investigated which domains of Evi1 are required for interaction with Mbd3b. HA-
Mbd3b was co-transfected with Flag-Evi1 or Flag-Evi1 mutants lacking either zinc finger 
domain 1 (∆ZF1-7) or the second zinc finger domain (∆ZF8-10) (Fig. 5A).  Immunoprecipitation 
was performed with an anti-HA antibody against HA-Mbd3b and the Western blot analysis was 
carried out with anti-Flag epitope antibody to detect Evi1.  Full length Evi1 and the Evi1 
to 109) show 65% identity with Mbd2 sequence (position 
216 to 256) and 82% similarity (underlined region).  (C) 
Immunoprecipitation of Evi1 from ϕE cells that were 
transiently co-transfected with Flag-Evi1 and either HA-
Mbd2 or HA-Mbd3.  Proteins were immunoprecipitated with 
anti-HA antibody or unspecific antibody (U). Western blot 
detection was performed using anti-Flag antibody.  Bottom 
figure shows Western blot to demostrate Evi1 expression in 
all samples.
IgG
Evi1
Evi1
WB: Flag
C
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+
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+
-
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82
Chapter 4
83
Evi1 interacts with NuRD via Mbd3b
mutant lacking the second zinc finger domain did bind to HA-Mbd3b, however, the Evi1 mutant 
lacking the first seven zinc fingers (∆ZF1-7) did not interact with HA-Mbd3b (Fig. 5B).  These 
results were confirmed using GST-Mbd3b pull-down experiments. Flag-Evi1 mutants (Fig. 5A) 
were expressed in mammalian ϕE cells and lysates were exposed to purified GST-Mbd3b protein 
bound to glutathion-beads. Western blot analysis of captured proteins from the lysates revealed 
that Flag-Evi1 mutants lacking the first 7 zinc fingers (mutants ∆ZF1-7 and ∆ZF1-10) did 
not bind to Mbd3b.  Mutants of Flag-Evi1 containing the ZF1-7 domain were all capable of 
binding to Mbd3b. A mutant that lacked four zinc fingers in the first domain (∆ZF4-7) showed 
strong Mbd3b interaction, indicating that the first three zinc fingers are sufficient for protein 
interaction. 
Interaction between Evi1 and endogenous Mbd3b
Next, we studied whether transiently overexpressed HA-Evi1 in ϕE cells could interact with 
endogenous Mbd3b.  HA-Evi1 immunoprecipitation with anti-HA antibody and subsequent 
staining with a specific antibody against Mbd3 showed a specific band of Mbd3b (Fig. 6A).  
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Figure 5 N-terminal zinc finger domain of Evi1 interacts with 
Mbd3b
(A) Diagram of Evi1 full coding sequence and its mutants. All Evi1 
constructs were fused in frame with single Flag epitope. Interaction 
with Mbd3b is indicated (+). (B) ϕE cells were transiently 
transfected with HA-Mbd3b and constructs of full length or mutant 
Evi (Flag-tagged).  Total cell lysates were immunoprecipitated (IP) 
with anti-HA antibody and the proteins were analyzed by Western 
blot with anti-Flag antibody to detect Flag-Evi1.  (C) Mapping of 
the interaction domain of Evi1 using GST-Mbd3 in a pull-down assay.  The Evi1 or mutants were transiently expressed 
in ϕE cells.  Cells were lysed and whole protein extracts were incubated with purified GST-Mbd3b or GST only coupled 
to sepharose beads.  Protein complexes were separated by electrophoresis, and stained with Flag antibody to detect Flag-
Evi1. Input levels of wt or mutants of Flag-Evi1 are shown in the lower panel of Figure 5C.
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No Mbd3b band was detected when the same sample was incubated with protein G-sepharose 
beads only. To study Evi1/Mbd3b binding under more physiological conditions, we decided to 
study this interaction in the retrovirally-induced myeloid leukemia cell line (NFS 56) 28, which 
harbours an Evi1 proviral integration. Due to this proviral integration within the Evi1 locus the 
gene is overexpressed and the protein is detectable using Evi1-specific antibodies (Fig. 6B). 
Immunoprecipitation using specific Evi1 antibody and subsequent Western blot analysis using 
Mbd3-specific antibodies revealed the presence of low but significant levels of a protein with a 
size corresponding to that of Mbd3b (Fig. 6B).
Evi1 interacts with the Mi2/NuRD complex  
Mbd3b is present in Mi2/NuRD, a transcriptional repressor complex with chromatin remodelling 
and histone deacetylase activity.  The complex contains several components, of which RbAp46/
p48, HDAC1 and HDAC2 form the core complex that is mutual between Mi-2/NuRD and the 
Sin3-histone deacetylase complex.  Factors that are restricted to Mi-2/NuRD only are: MTA2, 
Mi-2, Mbd3a and Mbd3b 29.  To gain more insight in the involvement of Evi1 in the Mi-2/
NuRD complex, we introduced Evi1 in 293T cells expressing stably TAP-tagged-Mbd3a.  It has 
been demonstrated that the entire Mi-2/NuRD complex can be isolated from these cells using 
purification steps to isolate the TAP-tagged Mbd3a protein. We wondered whether Evi1, when 
coexpressed in TAP-tagged Mbd3a-expressing 293T cells, could be co-purified with the Mi-2/
NuRD complex using the TAP-Mbd3a purification procedure. The cells were transiently 
HA-Evi1++
B
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ds
H
a
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Mbd3b
A IP
Figure 6  Evi1 interacts with endogenous Mbd3b
(A) ϕE cells transiently transfected with HA-Evi1 were lysed and incubated with anti-HA antibody (HA) or sepharose 
G-protein beads (Control sample).  Immunoprecipitates (IP) were separated by electrophoresis and stained with anti-
MBD3 antibody.  Endogenous MBD3b band was specifically detected in the presence of HA-Evi1 but not in the control 
sample.  Western blot (WB) stained with anti-Mbd3 confirms the presence of Mbd3b protein in both lysates.  (B) 
Immunoprecipitation of Evi1 in lysates from the myeloid leukemia cell line NFS 56, with Evi1 specific antibody. Upper 
panel: Protein extract from NFS 56 cell line was incubated with Evi1 antiserum (+) or sepharose G-protein beads (-) 
and stained with anti-MBD3 antibody.  Omission of Evi1 antiserum results in absence of Mbd3b band.  Presence of 
endogenous Mbd3b in both lysates is confirmed by a Western blot (WB) analysis.  Lower panel: The same Western blot 
was stained with Evi1 antiserum.  Presence of Evi1 protein was confirmed in the sample with Evi1 antiserum.  Total cell 
lysate was used to detect the presence of endogenous Evi1 in NFS 56 cell line. 
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transfected with HA-Evi1 or with a mock expressing vector.  As a control, wild type 293T cells 
were used using the same procedures.  After purification we observed presence of Evi1 in TAP-
Mbd3a samples but not in the control samples (Fig. 7a).  The positive staining using antibodies 
directed against HDAC2, MTA-2 and Rbp-46 confirmed that we indeed purified the Mi-2/NuRD 
complex using this procedure (Fig. 7b). Since Evi1 does not directly associate with Mbd3a but 
with Mbd3b, we conclude that Evi1 physically interacts with Mbd3b in the context of Mi-2/
NuRD complex.  
Evi1 enhances transcriptional repression by Mbd3b in luciferase assay 
To investigate whether Evi1 is involved in transcriptional repression through Mbd3b interaction, 
we performed a luciferase reporter assays.  The DNA binding domain of Gal4 was fused in 
frame to full length Mbd3b (Fig. 8A) and co-expressed with either full length Evi1 or mutants of 
Evi1 in ϕE cells.  Expression of full length Evi1 decreases the luciferase activity in the presence 
of Gal4-Mbd3b in a dose dependent manner but not in the control experiments without Gal4-
Mbd3b (Fig. 8B).  Similar results were obtained using a deletion mutant lacking zinc finger 4 to 
7 (∆ZF4-7).  However, this repression was lost when all first seven zinc fingers of Evi1 (∆ZF1-
7) were deleted. Interestingly, mutant Evi1 partially lacking the C-terminal binding protein 1 
(CtBP1) interacting proline rich region (∆pro) lost its ability to repress luciferase activity. This is 
in agreement with previous reports showing that the interaction with the transcriptional repressor 
CtBP1 is also critical for transcriptional repression by Evi1.  The observed effects were not due 
to squelching, since comparable levels of protein were detected in all samples by a Western blot 
(Fig. 8B).
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HA-EVI1 + +- -
293MBD3 293
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Figure 7  In vivo association of Mi2/
NuRD complex with Evi1 in 293T cell 
line
(A) 293T cells with or without stably 
expressed TAP-MBD3a were transfected 
with HA-Evi1 or an empty vector.  TAP-
MBD3a was immunoprecipitated from 
the total cell lysate using sepharose IgG 
beads.  Imunopreciptation complexes were 
stained for the presence of Evi1 (anti HA 
staining, upper blot).  The arrow indicates 
HA-Evi1.  For Western blot (WB) 5% 
from the total cell lysate was used as 
input.  (B) Presence of Mi-2/NuRD 
proteins in IgG immunoprecipitation 
experiment was confirmed using specific 
antibodies against different components 
of the complex.  The original blot was 
re-stained with anti-HDAC2, anti-MTA-2, 
and anti-RbAp-46 antibody.
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Discussion
Evi1 is a nuclear zinc finger protein involved in myeloid leukemia development, and acts 
as a transcriptional repressor 30-33.  Here we demonstrates a direct interaction between Evi1 
and the methyl-binding domain 3 protein-b (Mbd3b), a member of the histone deacethylase 
transcriptional repressor complex Mi-2/NuRD 34,35.  Six independent Mbd3b expressing clones 
were identified as Evi1 binding partner in a yeast-two hybrid protein interaction screen. These 
observations and the fact that the interaction also occurred in mammalian cells suggest that 
our findings are relevant and that the Mi-2/NuRD repressor complex may be involved in the 
transcriptional repression frequently observed with Evi1. The specificity of the interaction 
between Evi1 and Mbd3b is demonstrated by the fact that Evi1 did not interact with Mbd3a or 
any of the other Mbd family members. The experiments showing that Mbd3b and Evi1 repress 
transcription in a luciferase reporter assay indicate that this interaction may occur in vivo. This 
conclusion is substantiated by the fact that transcriptional repression is dependent on domains 
that are also required for the interaction with Mbd3b. Since Evi1 interacts with endogenous 
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Figure 8  Evi1 enhances transcriptional 
repression via Mbd3b
(A) Schematic representation of the 
reporter construct that was used in the 
luciferase assay containing four repeats 
of the Gal4 activating domain (GalAD) 
upstream of a thymidine kinase promoter 
driven luciferase marker gene.  In the 
expression vector a full length Mbd3b 
cDNA was fused in frame with the 
Gal4 DNA binding domain (Gal4DBD). 
(B) Luciferase assay showing repression of Gal4-Mbd3b mediated 
luciferase activity in a dose dependent manner by Evi1.  Phoenix cells 
were transfected with 0.1µg 4xGal4-TK-Luc construct as a reporter. 
Increasing amounts (0.025, 0.050, 0.1, 0.15µg) of Evi1, Evi1∆4-7, 
Evi1∆pro, and Evi1∆1-7 mutant expression vectors (closed bars) were 
cotransfected with 20 ng of Gal4-Mbd3b.  An open bar represents 
cells transfected with 0.15µg of the different Evi1 constructs alone. 
The expression level of the luciferase vector 4xGal4-TK-Luc alone 
was normalized to 1.0. (C) Western blot on protein samples isolated 
from cells used for the luciferase assay.  Lower blot shows actin 
staining for equal loading.      
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Mbd3b in ϕE cells and Evi1 transformed NFS56 cells, and is found to be associated with the 
Mi-2/NuRD complex via Mbd3b, we conclude that this complex may be of importance in Evi1 
mediated leukemic transformation. 
Mbd3 is a member of a larger family of proteins, which possesses a conserved methyl binding 
domain (MBD) 27.  This motif has been shown to recognize methylated CpG islands, however, 
Mbd3 appears to have lost this function during evolution 36,37.  Mbd3b is required for early 
development since Mbd3 null mice are embryonically lethal 38. In contrast to Mbd3, other family 
members such as Mbd1, Mbd2 and MeCP2 repress transcription through direct interaction with 
methylated cytosines in CpG islands 39.  These proteins recruit repressor complexes towards 
particular sites in the genome and subsequently interfere with transcription. Since Mbd3 does not 
interact with methylated DNA through its MBD domain, it is currently unclear how Mbd3 may 
be involved in the transcriptional repression 36.  We demonstrate by confocal microscopy that 
Mbd3b colocalized with Evi1 within certain subnuclear foci. Although the exact nature of these 
speckles is not clear yet, it is possible that they represent loci where Evi1 interacts with DNA, as 
Evi1 recognizes and binds to specific nucleotide sequences via the zinc fingers 4-7 of domain 1 
or the zinc fingers 8-10 of domain 2 12,40,41 . The first three zinc fingers do not interact with DNA. 
Since we show here that particularly these fingers are critical for the interaction with Mbd3b, we 
may have identified a specific function of zinc fingers 1-3, which are highly conserved between 
mouse and man. 
It is also possible that Mbd3b recruits Evi1 and thereby allows it to act as transcriptional 
repressor, possibly via the Mi-2/NuRD repression complex. In fact, the luciferase reporter 
experiments demonstrate recruitment of Evi1 to a site where Gal4-Mbd3b interacts with 
DNA, causing causes repression of transcription of the Tk-promoter driven luciferase gene. 
The repression activity was achieved in a dose-dependent manner as the Evi1 deletion mutant 
(∆ZF1-7) lost this activity, due to the inability to form a complex with Mbd3b.  Although these 
experiments may be explained by a synergistic effect between Evi1 and Mbd3b, it is also possible 
that in this experiment Mbd3b mainly recruits Evi1 to the promoter sites and allows it to repress 
transcription.  The repression potency of Evi1 was mapped earlier in the region between the 
two zinc finger domains, containing a specific sequence which interacts with CtBP, a repressor 
of transcription 31,32,42,43. CtBP was shown to be a part of a multisubunit repressor complex that 
contains all the necessary proteins required for histone modifications 44.  Clearly, the repression 
by Evi1 was lost with the mutant ∆pro (Figure 8), lacking this CtBP interacting region. Thus, 
recruitment of Evi1 to the Mi-2/NuRD complex through Mbd3b does not necessarily mean 
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that Evi1 should interact with DNA.  It is of interest to note that MTA2 and RbAp46/48, 
other members of the Mi2/NuRD complex, contain DNA binding zinc fingers (GATA-like), 
presumably capable of interacting with specific nucleotide sequences or histones 34.   Moreover, 
several transcription factors with well-defined nucleotide recognition sites, such as Ikaros, Rorγ, 
and SATB1 have been demonstrated to interact with the Mi-2/NuRD 45-47.  Recently, it has been 
demonstrated that Gata1 interacts in erythroid cells via Fog1 with the NuRD complex 48,49.  Since 
aberrant Evi1 expression has been demonstrated to cause erythroid abnormalities 9,50, it will be of 
great interest to investigate whether the Evi1/NuRD interaction affects Gata1 or Fog1 function in 
erythroid precursors.  Thus, although it is possible that Evi1 binds DNA and recruits repressors 
such as CtBP, HDACs or Mi-2/NuRD, it is also possible that Evi1 acts as an adaptor that attracts 
repressors such as CtBP or HDAC.  
The role of Evi1 in malignant transformation and leukemia progression is well recognized and 
different in vitro and in vivo models have indicated a dominant role of Evi1 in leukemogenesis. 
One of the indisputable functions of Evi1 is its capability to repress transcription, by interaction 
with distinct factors 51.  In recent years it has become evident that transcriptional repressors are 
able to associate with multi-protein complexes that contain repressor subunits 52.  The interaction 
is not always direct, but frequently requires adaptor proteins 53 .  Although the exact mechanism 
is not clear yet, our results add more evidence to the notion that Evi1 plays an important role 
in transcription inhibition by interacting with transcription repression complexes. For instance, 
it has been demonstrated that Evi1 may bind to Smad3 and block transcription initiated by this 
transcription factor 54 .  Additional evidence showing a major function of Evi1 in repression of 
transcription comes from recent experiments demonstrating that Evi1 also interacts with several 
histone methyltransferases (unpublished observation D.S and R.D.).  This would suggest, that 
Evi1 also interacts with proteins involved in modifications at the histone level, i.e. either histone 
deacetylation or histone methylation, thereby causing the creation of a repressive chromatin 
environment. We are currently analyzing the modifications that may take place at the histone 
level in the presence of Evi1.  Insight into the exact interactions between Evi1 and these distinct 
repression complexes as well as the effects thereof will provide invaluable information required 
for the development of molecules that may interfere with these complexes. 
88
Chapter 4
89
Evi1 interacts with NuRD via Mbd3b
Materials and Methods
Yeast Two-Hybrid protein interaction screen
Mouse Evi1 cDNA was subcloned into the pGBT9 (Clontech, Palo Alto, CA) expression vector 
in frame with the Gal4-DNA binding domain (BD) to produce a fusion transcript. The construct 
was introduced by a standard polyethylene glycol/lithium acetate (PEG/LiAc) transformation 
method 19 into the yeast PJ69-4A strain (Kind gift from Dr. P.James, University of Wisconsin, 
Madison, WI).  An expression library from mouse 17-day total embryo cDNA (Clontech, Palo 
Alto, CA) was then introduced into yeast and screened by selection on plates lacking tryptophan 
(Trp), leucine (Leu), histidine (His), and adenine (Ade), but containing 4mM of 3-aminotriazole 
20.  Selected clones were further analyzed in liquid culture assay for β-galactosidase expression 
according to the manufacture’s protocol (Clontech, Palo Alto, CA).  Isolation of plasmid DNA 
from PJ69-4A strain was performed using DNA mini columns (Qiagen, Westburg B.V, NL). 
Positive clones were analyzed by restriction enzyme analysis and nucleotide sequencing (Applied 
Biosystems, Nieuwekerk aan den IJsel, NL) to determine the correct open reading frame with 
regard to the Gal4-activating domain (AD).  The identity of the candidate Evi1 binding partners 
was determined by using public databases (NCBI).    
Expression construct 
 Evi1 cDNA was fused in frame with FLAG (FLAG-Evi1) or HA (HA-Evi1) nucleotide sequences, 
inserted into the pCMV mammalian expression vector (Clontech, Palo Alto, CA) under the early 
cytomegalovirus promoter (CMV). All deletion mutants were generated from the original cDNA 
of FLAG-Evi1 using available restriction sites (available upon request).  Full length Mbd3b was 
subcloned from the pACT2 vector using BglII restriction sites and inserted into the BamHI site 
of the pCMV vector.  Mbd2 was amplified from mouse day 17 total embryonic cDNA library 
using Pfu polymerase (Promega, Madison, WI) and primers containing specific restriction sites. 
All inserts were cloned in frame with the HA epitope using pBluescript (Stratagene, Amsterdam, 
NL) followed by subcloning into the pCMV vector.  All constructs were sequenced for correct in 
frame fusion and the expression of all proteins was confirmed by Western blot analysis.    
Yeast two-hybrid plasmid  
The Mbd3b mutant constructs were generated using available restriction sites within the pACT2 
cloning vector. Deletion constructs of Mbd3b were generated using AgeI and XhoI to generate a 
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Mbd3b mutant lacking the MBD domain and adjacent 40 amino acids (∆MBD+40), BglII and 
AgeI to generate a construct expressing the Mbd3b MBD domain and adjacent 40 amino acids 
(MBD+40), NheI and XhoI to generate a construct expressing the Mbd3b EE domain (EE) and 
BglII and NheI for a Mbd3b mutant lacking the EE domain (∆EE).  The Mbd3b MBD domain 
only was amplified using Pfu polymerase (Promega, Madison, WI) and cloned using EcoRI and 
XhoI sites.
The entire open reading frame of Mbd2 was amplified using Pfu polymerase (Promega, Madison, 
WI) with primers containing either an EcoRI or an XhoI restriction site.  Amplified fragments 
were cloned in frame with GAL4 AD (pACT2 vector) and fully sequenced.
GST fusion protein - For the preparation of a Mbd3b glutathione S-transferase (GST) fusion 
protein, Mbd3b was subcloned into the EcoRI site of pGEX-2Tk  (Amersham Pharmacia 
Biotech).
Luciferase assay plasmids: For the luciferase assay experiment, we cloned full length Mbd3b 
into the pcDNA3.1 GAL4 vector (kindly donated by Dr. R. Deplus, Free University of Brussels, 
Belgium).  In this vector the expression of the Gal4 DNA-binding domain (DBD) is driven by 
the CMV promoter.  The reporter construct 4xGal4-TK-Luc (kindly donated by Dr. R.Deplus, 
Free University of Brussels, Belgium) contains four GAL4 duplicate binding sites upstream of 
the thymidine kinase promoter driving expression of the luciferase gene21,22.  
Immunoprecipitation and Western Blot analysis  
Phoenix (ϕE) cells were maintained in Dubelco’s modified Eagle medium (DMEM, Life 
Technologies, Paisley, UK) supplemented with 10% FCS.   2x106 cells were seeded in 100mm2 
dishes (Becton Dickinson, Franklin Lakes, NJ) and transfected with 20µg DNA using calcium 
phosphate co-precipitation 23. 
Cells were harvested 48 hours post transfection, washed once with cold PBS and lyzed in Carin 
lysis buffer (20mM Tris pH 8.0, 137mM NaCl, 10mM EDTA, 100mM NaF, 1% NP-40, 10% 
Glycerol) on ice for 10min containing complete protease inhibitor mix and Pefablock (Roche, 
Zwijndrecht, NL).  Cell debris was removed by centrifugation for 15 minutes at 13000rpm at 
40C.  The supernatant was incubated at 40C with an appropriate antibody (1µg) for 2hr, followed 
by overnight incubation with sepharose G-protein beads (Sigma-Aldrich, St.Louis, MO). 
Beads containing the bound proteins were collected, washed 4 times with cold lysis buffer and 
resuspended in 1X SDS Laemmli buffer 24.  Purified complexes were denatured, and separated 
on 8-10% sodium dodecyl sulfate-polyacrylamide electrophoresis gel (SDS-PAGE), transferred 
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to nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany), blocked in 4% blocking 
milk (Bio-Rad, Hercules, CA) and incubated with the appropriate antibodies.  Detection was 
performed using a secondary horseradish peroxidase-conjugated antibody (Dako Diagnostic 
BV, Denmark) and visualize by enhanced chemiluminescence according to the manufacturers 
protocol (ECL, Boston, MA).  The following antibodies were used in this study: anti-HA 
and anti-actin (I-19)(Santa Cruz Biotechnology, Santa Cruz, CA), anti-Flag (Sigma-Aldrich, 
Zwijndrecht, NL), anti-EVI1 (a kind gift of Dr. J.N. Ihle, Memphis, USA), and anti-MBD3 
(IBL, Naka, Japan).
GST pull down - Mbd3b was fused in frame with GST recombinant protein in pGEX-2TK vector 
and expressed in DH12 Escherichia coli.  Cells were grown overnight at 370C, diluted to OD
600
 
0.2 and grown to OD
600 
0.6 before induction with 1mM of IPTG for 3 hours at 370C.  They were 
harvested at 40C.  Cells were resuspended in TEND lysis buffer (1X TBS, 0.5% NP-40, 1mM 
EDTA, 1mM DTT) containing complete protease inhibitor mix and Pefablock, sonicated and 
centrifuged for 10 minutes at 13000rpm.  Supernatant was incubated at 40C with Glutathione 
beads (Amersham Pharmacia Biotech), for 2hr at 40C, and washed extensively with TEND 
buffer.  Purified GST-Mbd3 recombinant protein was incubated overnight at 40C with total cell 
lysates from different FLAG-EVI1 mutants expressed in ϕE cells.  Glutathione beads were 
pelleted, washed 4 times in cold Carin lysis buffer and resupended in 1X SDS Laemmli buffer. 
Bound proteins were analyzed by SDS-PAGE.
Immunofluorescence microscopy  
ϕE cells grown on glass cover slips were transfected with FLAG-Evi1 and HA-Mbd3b using 
calcium phosphate coprecipitation method (Graham FL et al) and harvested 48 hours post 
transfection. The cells were washed once with ice cold PBS, and subjected to immunofluorescence 
staining as described previously 25.  In brief, cells were fixed for 15 min in 4% paraformaldehyde 
in PBS, and permeabilized with 0.2%Triton X-100 in PBS for 60 min at room temperature.  Cells 
were washed once with 0.05% Tween-20 and blocked o/n at 40C in 1% BSA with 0.05% Tween-
20 in PBS and stained with anti-FLAG and anti-HA MAbs for 2 hours at room temperature, 
washed extensively with 0.05% Tween-20 in PBS and detected with tetramethylrhodamine 
isothiocyanate (TRITC) and isothiocyanate (FITC) conjugated secondary antibodies (Dako 
Diagnostic BV, Denmark) for 1 hour at room temperature.  After washing with 0.05% Tween-20 
in PBS, cells were embedded in Vectashield (Vector Laboratories, Burlingame, CA).  Stained 
cells were analyzed using a Zeiss confocal laser scanning microscope (LSM510).  
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Luciferase reporter assays  
ϕE cells were plated on 24-well plates at 0.1x106 cells/well in 1ml DMEM+10%FCS and 
cultured overnight, followed by transfection with 300ng 4xGAL-TK-Luc, 20ng pcDNA3-DBD-
Mbd3b, 300ng pRSVLacZ and various concentration of the indicated expression plasmid.  Final 
concentrations of 1µg plasmid were normalized using an empty pCMV expression vector.  A 
volume of 100µl precipitate was added to each well.  48 hours post transfection cells were 
washed in PBS and lysed in 100µl lysis buffer (25mM Tris phosphate pH 7.8, 15% glycerol, 
1% Triton X-100, 1mM DTT, 8mM MgCl
2
).  25µl of cell lysates were transferred to 96-well flat 
bottom plates (Costar, Corning Inc, Corning, NY) and 25µl of a 16mg/ml luciferase substrate-
containing buffer (Steady-Glo luciferase assay System, Promega) was added to each well.  Light 
emission intensity was measured using a TopCount luminometer (Packard, Meriden, CT).  In 
parallel, 25µl of cell lysate were incubated with 75µl β-galactosidase buffer containing 0.56mg/
ml o-Nitrophenyl β-D-galacto pyranoside (ONPG, Sigma) for 5 minutes at 370C.  Absorption 
was measured at 450nm in a microplate reader (BioRad 450, Veenendaal, NL).  All assays were 
carried out in triplicates.
Purification of the NuRD complex using TAP-MBD3a 
293T cell line stably expressing TAP (Tandem Affinity Purification)-tagged MBD3a.  The cells 
were transiently transfected with HA-Evi1 in pCMV mammalian expression vector.  Cells were 
lysed in cold lysis buffer (20mM Tris pH 8.0, 137mM NaCl, 10mM EDTA, 100mM NaF, 1% NP-
40, 10% Glycerol) and incubated with sepharose IgG beads for 2 hours at 40C.  Sepharose beads 
were collected by short centrifugation and washed extensively in lysis buffer with increased salt 
concentration (20mM Tris pH 8.0, 400mM NaCl, 10mM EDTA, 100mM NaF, 1% NP-40, 10% 
Glycerol).  Members of the complex were visualized using HDAC2 (Santa Cruz Biotechnology, 
Santa Cruz, CA), RbAp46 and MTA2 (Abcam, Cambridge, UK) antibodies.
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Abstract
Deregulated expression of the zinc finger transcription factor ecotropic viral integration site 
1 (EVI1) is associated with acute myeloid leukemia (AML) and myelodysplastic syndrome 
(MDS) in patients due to chromosomal aberration of chromosome 3.  However, its role in 
transcriptional regulation has remained elusive. Here, we show that Evi1 interacts with the 
histone methyltransferase SUV39H1.  The direct interaction requires the N-terminal part of Evi1 
and the H3-specific histone methyltransferase domain, SET, of SUV39H1. Although Evi1 does 
not affect SUV39H1 activity it may direct its activity to specific targets, as we show that the 
Evi1-SUV39H1 complex exhibits methyltransferase activity.  Presence of SUV39H1 enhances 
Evi1 transcriptional repression in a dose dependent manner and ablation of the interacting SET 
domain of SUV39H1 abrogates this effect.  Furthermore, we show histone H3/SUV39H1/Evi1 
complex formation.  In addition, we demonstrate that Evi1 also interacts with another histone 
methyltransferase G9a but not with SET9.  These results establish Evi1 as a transcriptional 
regulator that is able to form higher order complexes with histone methyltransferases and may 
cause transcriptional repression of putative target genes during tumorgenesis.       
Introduction
Ecotropic viral integration site 1 (Evi1) encodes for a zinc finger transcriptional regulator which 
has been identified as a common virus integration site in murine leukemia 1. Moreover, aberrant 
expression of EVI1 has been shown in myeloproliferative disorders including myelodysplatic 
syndrome (MDS) and acute myeloid leukemia (AML), particularly in patients with 
translocations or inversions involving chromosome 3q26 2.  AML patients with inappropriate 
expression of EVI1 belong to the high-risk group of AML patients, and current therapies are not 
adequate to treat the disease in those cases.  In addition, in vitro and in vivo studies support the 
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notion that inappropriate expression of EVI1 plays a critical role in development of MDS and 
AML. Enforced overexpression of EVI1 blocks differentiation of myeloid progenitor (32Dcl3) 
cells towards mature neutrophils 3.  Furthermore, in the early erythroid lineage (32DEpo1) 
overepression of EVI1 diminishes erythropoietin sensitivity 4.  However, how EVI1 is involved 
in the process of transformation at the molecular level remains unclear.  
EVI1 contains two DNA binding motifs. The N-terminal part of the protein possesses a domain 
containing 7 zinc fingers, which recognizes GACAAGATAA nucleotide sequences, whereas a 
region of 3 zinc fingers at C-terminus binds GAAGATGAG sequence 5-7.   One of the possible 
mechanisms to explain the oncogenic effect of Evi1 is the direct binding and interaction with 
putative target genes.  However, up to date no EVI1 specific target genes have been identified. 
Another possible mechanism by which transcriptional regulators may affect target genes is 
through complex formation with other proteins, critical for transcriptional regulation.  In fact, 
EVI1 has been shown to interact with several transcriptional regulators, e.g. Smad3, HDAC’s, 
and CtBP and exhibits transcriptional repression activity 8-12. 
In recent years the analysis of post-translational modifications of histone tails such as methylation, 
acetylation, phosphorylation, and ubiquitination has unveiled the important role of chromatin 
remodeling in transcriptional regulation 13-17.  Modifications at specific histone residues represent 
important biological effects on transcription. The so-called “histone code” affects the regulatory 
status of a gene, as it causes specific proteins to recognize modified histones and translate the 
code into either hetero- or euchromatin 18-20.  Methylation has been one of the first modifications 
shown to play an important role in chromatin regulation.   Histone H3 methylation at different 
lysine residues by specific methyltransferases has been shown to either activate or silence 
transcription 21-23.  The first protein that showed methyltransferase specificity towards histone H3 
lysine 9 (H3-K9) was the mammalian SUV39H1 enzyme, a homologous of S.pombe Clr4 and 
Drosophila Su(Var)3.9 24. This preferential methylation of H3 depends on its SET domain, a 130 
amino-acid domain that is conserved among different species.  In addition to SUV39H1 several 
other methyltransferases were identified, e.g. SET9 or G9a, with specific methylation activities 
with respect to histone H3-lysine 4, lysine 9 and lysine 27 21-23. 
Evi1 belongs to the PRDM family of genes. The features of the PRDM3 (MDS-Evi1) gene 
showed high analogue to the PRDM2 (RIZ) and PRDM1 (Blimp-1) genes, as each express 
a shortened protein missing the PR domain. Recently it has been demonstrated that another 
member of this family of proteins PRDM1-BF1 (BLIMP-1) interacts with the methyltransferase 
G9a, suggesting that PRDM proteins may have a function in histone methylation 25.  
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Here we investigated whether Evi1 may form a complex with histone methyltransferases and 
show that it physically interacts with SUV39H1.  This interaction involves the SET domain of 
SUV39H1 and the N-terminus of Evi1.  Our data establish an epigenetic role of Evi1 in cell 
transformation by recruiting higher order chromatin remodeling complexes.      
Results
Evi1 and SUV39H1 interact in vivo 
To establish whether Evi1 is able to interact with SUV39H1, ϕE cells were transiently transfected 
with Myc-SUV39H1 and HA-Evi1.  SUV39H1 and Evi1 complexes were immunoprecipitated 
using anti-Myc or anti-HA antibodies. Analysis of these complexes on Western blot showed that 
Myc-SUV39H1 is present in HA-Evi1 immunoprecipitates, while, in the reverse experiments, 
HA-Evi1 could be detected in Myc-SUV39H1 immunoprecipitates (Figure 1A).  The interaction 
is specific, as only very low background levels of HA-EVI1 or Myc-SUV39H1 was observed 
using anti-Myc or anti-HA respectively in cells that were singly transfected. 
Applying immunofluorescence analysis and confocal microscopy we observed partial co-
localization between Evi1 and SUV39H1 in small-punctuated speckle like structures in Cos 
cells transiently transfected with both constructs (Figure 1B). These findings confirm the 
immunoprecipitation experiments showing that the two proteins may be present in a complex 
in vivo.
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Figure 1  Evi1 
and SUV39H1 
interact in vivo
( A ) P r o t e i n 
e x t r a c t s f r o m 
P h o e n i x ( ϕ E ) 
cells transiently 
transfected with 
Myc-SUV39H1 
and HA-Evi1 
were immunoprecipitated with anti-Myc antibody (left panel) 
or anti-HA (right panel) followed by Western blot analyses 
using anti-HA (left panel) or anti-Myc antibody (right panel)). 
In control experiments, immunoprecipitations were performed 
with lysates that were only transfected with HA-Evi1 (left 
panel) or only Myc-SUV39H1 (right panel). WB indicates 
Western blot analysis using 10% input from the cell lysate used 
in the immunoprecipitation analysis.  (B) Confocal microscopy 
analysis of COS cells co-transfected with Myc-SUV39H1 
and HA-Evi1.  Cells were stained with anti-Myc and anti-HA 
antibody followed by secondary TRITC (Red) and FITC (Green) 
staining.  Merged analysis revealed association of both proteins 
in punctuate structures of the nucleus.
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The SET domain of SUV39H1 and the N-terminal zinc finger domain of Evi1 are required 
for interaction. 
To identify which domain of SUV39H1 is responsible for the interaction with Evi1 we carried 
out co-immunoprecipitation experiments with full length HA-Evi1 and various Myc-SUV39H1 
mutants (Figure 2A).  SUV39H1 possesses several functional domains that have all been shown 
to play an important role in the function of the protein.  We used for this analysis Myc-SUV39H1 
constructs (1) lacking the chromatin organization modifier domain (Myc-SUV39H -∆chromo) 
shown to be important for chromatin targeting, (2) containing only the small chromo domain 
(Myc-SUV39H1-chromo), and (3) mutant lacking the SET (Su(var)3-9, Enhancer-of-zeste, 
Trithorax) domain and post-SET domain (Myc-SUV39H1-∆SET) required for methylation of 
H3-K9.  The mutants were co-transfected with full length FLAG-Evi1 into ϕE cells and lysates 
were immunoprecipitated using anti-Myc antibody.   The results showed that absence of the SET 
domain abolishes the interaction (Figure 2B).  In contrast, expression of constructs possessing 
the SET domain, Myc-SUV39H1-∆chromo or Myc-SUV39H1, preserves the interaction, as a 
specific product was obtained after staining with anti-FLAG antibody.
To identify the region of Evi1 required for interaction with SUV39H1 we constructed a panel of 
FLAG-Evi1 mutants (Figure 3A).  We used deletion mutants within zinc finger domains, FLAG-
Evi1∆1-7, FLAG-Evi1∆4-7, FLAG-Evi1∆1-10, and a mutant that only possesses the zinc fingers 
8 to 10 plus the remaining C-terminal part of the protein, FLAG-Evi1-8-10+AD.  Full length 
Myc-SUV39H1 showed interaction only with FLAG-Evi1 mutants that contained an intact N-
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Figure 2  The SET domain of SUV39H1 is required for interaction with Evi1
(A) SUV39H1 domains: Chromo (CHRomatin Organization MOdifier), SET (Su(var), Enhancer of zeste, Trithorax) 
and Pre-SET.   SUV39H1 and its mutants used for the analysis.  ∆SET: mutant lacking the SET domain; ∆Chromo: 
mutant with deletion of the chromo domain; Chromo Core: Chromo domain only. (B) Full length Myc-SUV39H1 and 
corresponding mutants were transfected with full length of FLAG-Evi1.  Following anti-Myc immunoprecipitation on 
cell lysates, Western blot analysis was performed using anti-FLAG antibody to detect FLAG-Evi1.  Input of 10% from 
total proteins was used for Western Blot (WB) analysis and is depicted in lower panel.  
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terminal zinc finger domain or that only missed zinc finger 4-7.  This indicates that the region 
required for interaction is located within the first zinc finger domain (Figure 3B).
Evi1 binds histone H3 N-terminus in the presence of SUV39H1
H3-K9 is a specific target for the SUV39H1 enzyme. To investigate if SUV39H1 and Evi1 
can form a complex at the H3 tail we performed GST-pull down experiments using a GST-H3 
histone tail fusion protein. ϕE cells transfected with HA-Evi1 alone or in combination with Myc-
SUV39H1 were lysed and incubated with an equal concentration of GST-H3 (Figure 4).  The 
complex bound to H3 was analyzed using either anti-Myc or anti-HA antibodies.  Staining with 
anti-HA antibody revealed the presence of Evi1 in the samples that also contained SUV39H1, 
whereas no HA-Evi1 signal was observed in the control samples with HA-Evi1 and GST-H3 
alone.  Using purified GST only we did not observe any binding of SUV39H1 or Evi1 (Figure 
4).
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Figure 3  The N-terminal zinc finger domain of Evi1 is 
required to associate with SUV39H1
(A) Diagram representing the full length of Evi1 and Evi1 
mutants used in mapping analysis with full length SUV39H1. 
Evi1 domains: ZF 1-7 (N-terminal domain containing 7 zinc fingers), RD (repression domain), ZF 8-10 (C-terminal 
domain containing 3 zinc fingers), AD (acidic domain).  (B) Myc tagged full length SUV39H1 was transiently 
transfected with full length FLAG-Evi1 or with one of its mutants into ϕE cells.  Immunoprecipitation was performed 
using anti-Myc antibody. Proteins were detected by Western blot analysis using anti-FLAG antibody.  Input of 10% from 
total proteins was used for Western Blot (WB) analysis and is depicted in lower panel.  
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Figure 4  Evi1 forms a complex with SUV39H1 
on histone H3 amino termini
Pull down assays using GST recombinant protein 
fused to histone H3 N-terminal tail (amino acids 
1-57) (GST-H3) (left panel) or GST only (right 
panel) on total cell extracts from ϕE cells transiently 
transfected with HA-Evi1 plus Myc-SUV39H1 
or HA-Evi1 only.  Presence of HA-Evi1 was 
determined by Western blot analysis using anti-HA 
antibody, and Myc-SUV39H1 was detected by anti-
Myc antibody (top panel).  The expression level of 
proteins in each sample is shown by Western blot 
(WB) (middle panel).  Presence of purified GST-
H3 or GST was determined by Ponceau S staining 
(bottom panel).
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The Evi1/SUV39H1 complex displays methyltransferase activity
SUV39H1 possesses histone methyltransferases activity specific for H3-K9 24.  To investigate 
whether the Evi1-SUV39H1 complex possesses methyltransferases activity, we transfected 
ϕE cells with FLAG-Evi1, Myc-SUV39H1 or with both constructs. Evi1, SUV39H1 or the 
Evi1-SUV39H1 complex were immunoprecipitated and tested for in vitro H3 methylation in 
a histone methyltransferase assay (HMT). Immunoprecipitation of SUV39H1 clearly showed 
methylation of histone 3 as expected (Figure 5, lane 1), while immunoprecipitated Evi1 did not 
show any activity (Figure 5, lane 2). Notably, Evi1 immunoprecipitated by anti-FLAG from 
cells transfected with both constructs showed weak but significant signal indicating that Evi1-
SUV39H1 complex displays methyltransferases activity (Figure 5, lane 3). 
Evi1 does not interfere with SUV39H1 activity
Our in vitro binding analysis suggests that the interaction between Evi1 and SUV39H1 requires 
a specific region within the SET domain of SUV39H1.  As this domain is also required for 
the enzymatic activity of SUV39H1, we asked the question if interaction between Evi1 and 
SUV39H1 might influence histone methyltransferase activity.  ϕE cells were co-transfected 
with Myc-SUV39H1 and FLAG-Evi1 and the proteins were subsequently immunoprecipitated 
with anti-Myc and anti-FLAG antibodies.  The methyltransferase activities of the complexes 
were analyzed in a HMT assay (Figure 6).  The results showed that even in the presence of high 
concentrations of FLAG-Evi1 the activity of Myc-SUV39H1 was unchanged (Figure 6, lane 
2) as compared to a sample without FLAG-Evi1 (Figure 6, lane 3).  Single purification of each 
of the proteins and subsequently combining the two samples in a HMT assay did not change 
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Figure 5  Evi1 shows methylation activity of histone H3 when in a 
complex with SUV39H1 
Immunoprecipitates obtained from FLAG-Evi1/Myc-SUV39H1 or 
FLAG-Evi1 alone using anti-FLAG antibody were analyzed in HMTase 
assays with 1µg purified H3 peptide in presence of S-Adenosyl-L-
[methyl-14C] methionine as a methyl donor.  Myc-SUV39H1 was 
purified with anti-Myc antibody and used as a positive control (left 
lane). Closed arrows indicate purified FLAG-Evi1; open arrows indicate 
Myc-SUV39H1 and purified histone H3 is depicted by an arrow on 
Coomassie Brilliant Blue R-250 staining (upper panel).   The presence 
of Histone H3 is demonstrated in each lane. Histone H3 methylation is 
demonstrated by autoradiography in the lower panel. 
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the outcome of the SUV39H1 methylation activity (data not shown).  Western blot analysis 
revealed equal amounts of SUV39H1 in samples with or without Evi1 (Figure 6, lower panel). 
The results indicate that HA-Evi1 binding to Myc-SUV39H1 does not interfere with histone 
methyltransferase activity.   
SUV39H1 binding enhances transcriptional repression of Evi1
To determine if interaction between SUV39H1 and Evi1 may influence Evi1 transcriptional 
repression properties we performed transcription reporter assays.  A GAL4-DBD-Evi1 construct 
in combination with Myc-SUV39H1 plasmid and luciferase reporter gene (GAL4-AD-Luc) 
were transiently transfected into ϕE cells.  Expression of low concentration of Evi1 did not 
significantly repress luciferase expression (Figure 7A).  ϕE cells transfected with GAL4-
DBD-Evi1 plus increasing concentrations of Myc-SUV39H1 showed significant repression of 
luciferase activity (Figure 7A).  On the contrary, in an experiment in which the SET domain of 
SUV39H1 was deleted we did not observe significant changes in repression of the luciferase 
activity (Figure 7B).  These results showed that SUV39H1 may cooperate with Evi1 and enhance 
its transcriptional repression activity in a dose dependent manner and requires the SET domain 
of SUV39H1 for this functional interaction.
Evi1 interacts with selected SET domain containing proteins
SET domains are found in many proteins and consist of a 130 amino-acid motif first identified 
in members of the polycomb group (PcG) and Trithorax group (TrG) of genes 26.  To date 
several mammalian SET domain proteins have been identified, and have been shown to directly 
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Figure 6  Evi1 does not interfere with SUV39H1 histone 
methyltransferase activity
FLAG-Evi1 and Myc-SUV39H1 were transfected alone or 
together into ϕE cells. Purified complexes using corresponding 
antibodies were analyzed in HMTase assay.  Arrows indicate 
presence of purified proteins or histone H3. Specific H3 
methylation was demonstrated by autoradiography (lower 
panel).  
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or indirectly associate with chromatin 27,28.  To address the possibility that Evi1 interacts with 
other SET containing proteins we performed immunoprecipitation assays with two other known 
methyltransferase proteins, i.e., SET9 and G9a.  
HA-Evi1 was co-transfected either with FLAG-SET9, FLAG-G9a, or Myc-SUV39H1 into ϕE 
cells.  Complexes were precipitated with anti-FLAG antibodies and analyzed by Western blotting 
using anti-HA antibodies to determine the interaction between HA-EVI1 with FLAG-SET9, 
FLAG-G9a or Myc-SUV39H1. The experiments in Figure 8A demonstrate that FLAG-G9a (lane 
2) as well as SUV39H1 (lane 3) form a complex with Evi1, whereas FLAG-SET9 and HA-Evi1 
(lane 1) did not show any interaction. No HA-EVI1 was identified in the immunoprecipitation 
experiments in the absence of anti-FLAG/anti-Myc antibody (beads only; lane 4).  Vice versa, 
when anti-HA was used for the immunoprecipitation experiments, only G9a and SUV39H1 
could be detected by anti-FLAG Western blot analysis (data not shown).
To specifically demonstrate that the enzymatic activity of G9a could be precipitated in a complex 
with EVI1 we performed an HMT assay on H3-histones using HA-Evi1/FLAG-G9a transfected 
ϕE cells. H3 peptide methylation was demonstrated using purified FLAG-G9a methyltransferase 
(Figure 8B, lane 3), whereas this activity was not detectable when the same lysate was exposed 
to beads without anti-FLAG antibody in the immunoprecipitation experiment (Figure 8B, lane 
5).  Using anti-HA antibody we immunoprecipitated HA-Evi1 with G9a and observed weak but 
significant methylation of purified H3 in an HMT assay (Figure 8B, lane 1).  Autoradiography 
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Figure 7  SUV39H1 enhances transcriptional repression activity of Evi1
(A) ϕE cells were cotransfected with a luciferase reporter plasmid containing four GAL4 binding sites upstream of 
the thymidine kinase promoter (4XGAL4-TK-Luc) with Evi1 fused to GAL4 DNA binding domain (GAL4-Evi1) and 
different concentration of SUV39H1 expression plasmid.  The concentration of GAL4-Evi1 was kept constant at 0.1µg 
of DNA.  The amount of SUV39H1 DNA for each plasmid increase as follow: 0.1µg, 0.2µg, and 0.3µg. 4XGAL4-TK-
Luc expressions were normalized to 1.0.  Transfection efficiencies were normalized using LacZ assay.  All luciferase 
assays were performed in two independent duplicated experiments.  Error bars indicate variations of all experiments.
(B) Luciferase experiment using SUV39H1∆SET instead of SUV39H1.  The experimental settings were identical as 
described for SUV39H1.
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revealed no signal in the precipitate obtained in the absence of anti-HA or anti-FLAG (Figure 
8B, lanes 4 and 5) or when no G9a (lane 2) or EVI1 (lane 4) was introduced into ϕE cells. We 
conclude that Evi1 might physically interact with G9a and causes methylation of histone-H3.      
Discussion
Evi1 encodes for a nuclear zinc finger containing protein, which is required for early development 
29. Inappropriate activation of the gene in hematopoietic precursor cells disturbs normal cellular 
proliferation and differentiation pathways as observed in patients with MDS or AML harboring 
translocation or inversion of chromosome 3 involving band q26 2.  Although the mechanism 
of transformation by this nuclear zinc finger protein is still unknown, it has been shown that 
Evi1 may act as a transcriptional repressor 9-11,30.  Evi1 protein has been shown to physically 
and functionally interact with different classes of nuclear proteins involved in transcriptional 
control 9,10,12,31. Here we demonstrate association between Evi1 and SUV39H1, a member of 
the histone methyltransferase family of genes, and show that this interaction enhances Evi1 
mediated transcriptional repression in a dose dependent manner. Moreover we also show that 
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Figure 8  Evi1 binds to methyltransferase protein G9a but not to SET9
(A) ϕE cells were transiently transfected with Myc-SET9, FLAG-G9a, Myc-SUV39H1, HA-Evi1 or control (φ).  Pre-
cleared cell lysates were immunoprecipitated with anti-Myc or anti-FLAG antibodies to immunoprecipitate the histone 
methyltransferases. The immunoprecipitates were analyzed with anti-HA antibody for the presence of Evi1.  Cell 
lysates were analyzed by Western blotting for the presence of input proteins (lower three panels).  (B) HMTase assay 
with FLAG-G9a and HA-Evi1.  Lysates from ϕE cells transiently transfected with FLAG-G9a and HA-Evi1 were 
immunoprecipitated with anti-HA antibody and analysed for specific histone H3 activity (top panel).  FLAG-G9a was 
purified with anti-FLAG antibody and used as a positive control.  Presence of G9a and Evi1 proteins in samples was 
detected using Western blot analysis.   
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Evi1 may interact with another repressor belonging to the family of histone methyltransferase, 
i.e. G9a. The ability of Evi1 protein to directly bind DNA and its capability to interact with 
these strong repressors of transcription further substantiates the idea that deregulation of gene 
expression consequently leading to abnormal homeostasis may be one of the effects of Evi1 in 
transformation.
Methylation of histones within promoter regions is thought to be the main cause of transcriptional 
silencing of target genes by SUV39H1, resulting in changes in chromatin structure 32,33.  In 
accordance to the “histone code”, modification of the histone H3 terminus influences the 
chromatin state, resulting in either silenced heterochromatin due to specific lysine methylation 
or active euchromatin due to acetylation.  Recently, it has been shown, that SUV39H1 is 
capable of interacting with transcription factors involved in development.  Interaction between 
SUV39H1 and AML1 interferes with DNA binding of AML1, whereas TAL1/SCL association 
with SUV39H1 facilitates specific histone methylation within the DNA target regions of 
TAL1/SCL 34,35.  Retinoblastoma protein (Rb) interacts with SUV39H1 resulting in repression 
of cyclin E and E2F promoter activity 36,37.  Interaction with Smad family members by histone 
methyltransferases enhances silencing of the muscle creatine kinase (MCK) promoter 38.   Thus 
SUV39H1 appears to be a transcriptional repressor 39 that methylates histone residues, but 
requires specific DNA binding proteins to be recruited to particular promoter regions.  This could 
provide a model in which Evi1 targets methyltransferases to specific promoter regions, leading 
to transcriptional silencing. The hypothesis that Evi1 may recruit histone methyltransferases 
towards target genes is in line with a recently reported finding, showing that the Evi1 family 
member BLIMP-1 interacts with G9a and this complex is recruited to the BLIMP target gene 
IFBN1 25 Promoter binding by this complex resulted in silencing of IFBN1 through histone H3-
K9 methylation. 
Evi1 recognizes and binds to specific nucleotide sequences via fingers 4-7 of zinc finger 
domain 1 or fingers 8-10 of zinc finger domain 2, whereas the first three zinc fingers have been 
demonstrated not to interact with DNA.  Therefore, we may have identified a specific function 
of zinc fingers 1-3 of the N-terminal zinc finger domain of Evi1, which are highly conserved 
between mouse and human.  It is also possible that Evi1 does not directly target DNA itself, 
but mainly acts as an adaptor that may attract multiple repressor complexes.  Recently, it has 
been demonstrated that zinc finger containing protein friend of Gata1 (Fog1) modulates Gata1 
activity via interaction with multiprotein complexes 40,41.  In any case, it appears that Evi1 is able 
to interact with repressor complexes and bring them to particular sets of genes either through 
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DNA binding of Evi1 itself or via other DNA-binding transcription regulators. It suggests that 
Evi1 may play a key role in the different steps in the process of gene silencing, i.e. it may affect 
histone deacetylation, histone methylation and possibly even DNA methylation.  Unveiling all 
these possibilities requires the application state-of-the-art proteomic approaches such as mass 
spectrometric analysis of purified Evi1 containing protein complexes. Such studies combined 
with gene array analysis in patient samples and well-defined in vitro and in vivo animal models 
are indispensable to unravel the mechanisms of transformation by Evi1. 
Domain mapping studies revealed that the SET domain of SUV39H1 is involved Evi1 
interaction. The SET domain and surrounding pre-SET domains are required for specific 
enzymatic activity towards histone H3 lysine 9 methylation 24.  The luciferase reporter assays 
revealed that enhancement of transcriptional repression by Evi1 required the SET domain as 
well. These data are in agreement with reports showing that SUV39H1 transcriptional repression 
is impaired in mutants lacking the SET domain 38. Thus the absence of repression enhancement 
by SUV39H1-∆SET can be explained by the lack of Evi1 interaction and by a defect in its 
function. The interaction, between Evi1 and SUV39H1 through the SET domain, appeared 
not to influence the histone methyl transferase acitivity. In addition to our findings showing 
that Evi1 interacts specifically with SUV39H1 we also showed an interaction between another 
methytransferase G9a.  G9a methylates histone H3 at lysine 9 and lysine 27 (H3-K9 and H3-
K27) 42 also leading to transcriptional repression. On the contrary, we did not observe interaction 
with SET9 methyltransferases, which methylates histone H3 at lysine 4 (H3-K4) 22. In contrast 
to SUV39H1 and G9a, SET9 is involved in transcriptional activation rather than repression 22. 
The reason for Evi1 binding selectively to SUV39H1 and G9a remains unclear, but it again 
emphasizes that transcriptional repression may be the major function of Evi1.  The fact that Evi1 
is frequently involved in myelodysplastic disorders and AML may indicate a function in the 
repression of genes required for normal myeloid proliferation and differentiation.  
Materials and Methods
Expression constructs
Evi1 cDNA was fused in frame with FLAG (FLAG-Evi1) or HA (HA-Evi1) nucleotide sequences 
and inserted into the pCMV mammalian expression vector (Clontech, Palo Alto, CA) under the 
early cytomegalovirus promoter. All deletion mutants were generated from the original cDNA of 
FLAG-Evi1 using available restriction sites (available upon request).  
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Full length SUV39H1 and its mutants; SUV39H1-∆SET, SUV39H1-∆chromo, and SUV39H1-
chromo core, all cloned into a mammalian expression vector under the CMV promoter were 
kind gifts from Dr. A.H. Peters (IMP, Vienna, Austria).  All constructs were Myc tagged at the 
N-terminus.
pCMV-FLAG-G9a expression vector was a kind gift from Dr. I Talianidis (Institute of Molecular 
Biology & Biotechnology, Crete, Greece) and has been described previously 43. 
The cDNA of SET9 was amplified from HL-60 human cell line using Pfu polymerase.  The 
amplified fragment was cloned into a pCMV-FLAG expression vector to generate pCMV-
FLAG-SET9 construct.  The insert was sequenced and the expression was confirmed using 
Western blot analysis.
Immunoprecipitation and Western Blot analysis    
2x106 Phoenix (ϕE) cells were seeded in 100mm2 dishes (Becton Dickinson, Franklin Lakes, 
NJ) and cultured in Dubelco’s modified Eagle medium (DMEM, Life Technologies, Paisley, 
UK) supplemented with 10% FCS and transfected with 20µg DNA using calcium phosphate 
co-precipitation 44.  Cells were harvested, washed with cold PBS and lysed in Carin lysis 
buffer (20mM Tris pH 8.0, 137mM NaCl, 10mM EDTA, 100mM NaF, 1% NP-40, 10% 
Glycerol) containing complete protease inhibitor mix and Pefablock (Roche, Zwijndrecht, NL). 
Supernatants were incubated at 40C with an appropriate antibody (1mg) for 2hr, followed by 
2hr incubation with sepharose G-protein beads (Sigma-Aldrich, St.Louis, MO).  Bound proteins 
were collected, washed extensively with cold lysis buffer and resuspended in 1X SDS Laemmli 
buffer 45.  Complexes were denatured, separated on 8-10% SDS-PAGE gel and transferred to 
nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany).  The membrane was blocked 
in 4% milk (Bio-Rad, Hercules,CA) and incubated with the appropriate antibodies.  Detection 
was performed using a secondary horseradish peroxidase-conjugated antibody (Dako Diagnostic 
BV, Denmark) and visualize by enhanced chemiluminescence according to the manufacturers 
protocol (ECL, Boston, MA).  The following antibodies were used in this study: anti-HA (Santa 
Cruz Biotechnology, Santa Cruz, CA), anti-FLAG, and anti-Myc (Sigma-Aldrich, Zwijndrecht, 
NL).
Immunofluorescence microscopy
COS-7 cells were grown on cover slips and transfected with equal concentrations (4µg) of Myc-
SUV39H1 and HA-Evi1 using FuGENE transfection reagent according to the manufacturer’s 
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(Roche, Zwijndrecht, NL) specification.  48 hours post transfection cells were washed with cold 
PBS and processed as described previously 46.  Cells were stained with anti-HA and anti-Myc 
primary antibodies.  Detection of primary antibodies was performed using tetramethylrhodamine 
isothiocyanate (TRITC) and fluorescein isothiocyanate (FITC) conjugated secondary antibodies 
(Dako Diagnostics BV, Denmark).  Cells were analyzed using Zeiss confocal laser scanning 
microscopy (LSM510).  
Protein purification and in vitro histone methyltransferase assay (HTMase)
ϕE cells were grown in DMEM supplemented with 10% FCS and transfected with corresponding 
plasmid by calcium phosphate co-precipitation.  Cells were grown for 48 hours, collected, 
washed once with cold PBS and lysed as described above.  Purified sepharose G-protein beads 
with bound proteins were washed extensively in Carin lysis buffer, and used directly for the 
methyl transferase assay.  HTMase was performed as described previously 42.  Briefly, purified 
sepharose bound proteins were incubated in HMTase buffer (50 mM Tris, pH 8.5, 20 mM KCl, 
10 mM MgCl
2
, 10 mM β-mercaptoethanol, 250 mM sucrose) containing 250nCi S-Adenosyl-
L - [methyl-14C] methionine (MP Biomedicals, Amsterdam, NL) as a methyl donor and 1µg 
purified native histone H3 as substrate (Roche Molecular Biochemicals).  Reactions were 
incubated at 300C for 1 hour under constant rotation.  Tubes were centrifugated and the reaction 
was terminated by addition of 3X SDS-Laemmeli sample buffer 45.  Samples were heated at 950C 
for 2 minutes and separated on 12.5% SDS-polyacrylamide gel.  Proteins were visualized by 
staining SDS-polyacrylamide gel with Comassie Brilliant Blue R-250 (N.V Life Technologies 
S.A. Merelbeke, NL).  
Histone H3 pull down assay  
Mouse histone H3 cDNA cloned into pGEX-4T-3 (Amersham Pharmacia Biotech) bacterial 
expression vector was a kind gift of Dr. Y. Shinkai (Department of Cell Biology, Kyoto 
University, Japan).  The isolation and purification of the fusion was performed as described 
previously 42.  In short, transfected DH12 or JM110 Escherichia coli were grown to OD
600
 0.6 
and induced with 1mM IPTG for 3 hours at 370C.  Cells were collected by centrifugation at 40C 
and lysed in TEND buffer (1X TBS, 0.5% NP-40, 1mM EDTA, 1mM DTT) containing protease 
inhibitor mix and Pefablock (Roche, Zwijndrecht, NL).  Clear lysates were incubated with 
Glutathione beads (Amersham Pharmacia Biotech) for 2 hours at 40C.  Recombinant proteins 
were washed extensively and the concentration was verified using Coomassie Brilliant Blue R-
108
Chapter 5
109
Evi1 interacts with methyltransferase SUV39H1
250 staining. Equal concentrations of the GST-H3 recombinant protein were incubated with ϕE 
purified cell extract transfected previously with Myc-SUV39H1 with or without HA-Evi1.  The 
complexes were incubated overnight at 40C, washed with cold Carin lysis buffer, and separated 
by 8% SDS-polyacrylamide gel.  Detection with antibodies was performed as described above.
Luciferase reporter assays
The luciferase assay was performed as described previously 47.  In short, ϕE cells at 1x105 cells 
per well were transfected with 300ng 4xGAL-TK-Luc, 100ng pcDNA3-DBD-Evi1, 300ng 
pRSVLacZ and various concentration of pCMV-SUV39H1.  Total amount of plasmid was 
normalized using empty pCMV expression vector.  48 hours post transfection cells were lysed in 
100µl lysis buffer (25mM Tris phosphate pH 7.8, 15% glycerol, 1% Triton X-100, 1mM DTT, 
8mM MgCl
2
).  25µl of cell lysate was transferred to 96-well flat bottom plates (Costar, Corning 
Inc, Corning, NY) and 25µl of a 16mg/ml luciferase substrate-containing buffer (Steady-Glo 
luciferase assay system, Promega, Madison, WI) was added to each well.  Light emission 
intensity was measured using a TopCount luminometer (Packard, Meriden, CT).  In parallel, 
25µl of cell lysate was incubated with 75µl β-galactosidase buffer containing 0.56mg/ml o-
Nitrophenyl β-D-galactopyranoside (ONPG, Sigma).  Absorption was measured at 450nm in a 
microplate reader (BioRad 450, Veenendaal, NL).  All assays were carried out in triplicate.
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General Discussion
The application of retroviral insertion mutagenesis in mouse models to identify potential proto-
oncogenes, has led to identification of a substantial number of genes that may be involved in 
human pathogenesis.  One of the genes that was identified as a common integration site in murine 
leukemia was the ecotropic viral integration 1 (Evi1) gene1.  This finding suggested a possible 
role for the aberrantly expressed gene in myeloproliferative disorders such as myelodysplastic 
syndrome (MDS) and human acute myeloid leukemia (AML).  Analysis of chromosome 3, the 
locus where the gene resides, in AML patients revealed a group of cases that were harboring 
translocations or inversions involving chromosome 3, e.g. t(3;3)(q21;26) or inv(3)(q21;q26)2. 
Inappropriate expression of EVI1 as a result of these chromosomal aberrations has been shown 
to be directly or indirectly involved in dysregulation of cellular homeostasis and induction 
of tumorigenesis.  To elucidate the role of Evi1 in cellular transformation we generated and 
analyzed a mouse model for Evi1.  Furthermore, we extended the analysis of Evi1 in the context 
of complex formation with novel binding partners of Evi1. 
Evi1 in vivo model
AML is a cancer due to uncontrolled cell proliferation of hematopoietic cells that can result 
from dysregulation of the balance between cellular proliferation, differentiation and apoptosis. 
The traditional paradigm of cancer is that it is the result of a multi-step process involving an 
accumulation of mutations in multiple genes that contribute in the control of cell proliferation 
(gain-of-function or overexpression) or growth inhibition (mutational inactivation).  
Louz et al, using the murine stem cell antigen 1 promoter Sca-1 (Ly-6E.1), for the first time 
presented experiments that suggested the consequences of aberrant expression of Evi1 in vivo. 
Overexpression of Evi1 in multipotent hematopoietic stem cells (HSC) negatively affected the 
number of erythroid colony forming units (CFU-E).  Additional genetic alteration delivered by 
retroviral induction increased the incidence of tumor development as proposed by the multi-hit 
theory of cancer development3.  
Another approach to deliver Evi1 into progenitors cells, using retroviral transduction of 
lineage negative bone marrow cells followed by transplantation, was undertaken.  The animals 
showed abnormalities 10 months post-transplantation, characterized by a phenotype similar 
to that observed in patients with MDS i.e., pancytopenia, hypercellular bone marrow and 
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dyserythropoiesis4.
In Chapter 2 and Chapter 3 of this thesis we describe the generation of a novel mouse model 
for Evi1, targeting exclusively the hematopoietic system.  In addition, the expression of Evi1 
gene is conditionally expressed using specific transcriptional control DNA sequences enclosed 
by LoxP sites.  Using this model we analyzed the expression and effect of Evi1 during fetal 
erythropoiesis.  Using specific lines in which Cre was under the β-globin regulatory elements 
the expression pattern of the Cre gene was predominantly active in the erythroid lineage (Figure 
1).  Analysis of E12.5 fetal liver from double positive littermates revealed interference of Evi1 
with normal erythroid development.  Morphologically the fetal livers showed a distinguished 
paleness and significant decrease in size, that correlated with a decrease of late, differentiated 
cells and lower cell counts.  The expression of TER119/CD71 cell markers validates our findings 
that the differentiation program within the erythroid lineage was impaired.  In agreement with 
the block in differentiation, fetal livers obtained from double positive embryos showed reduced 
numbers of colony forming units-erythroid (CFU-E).  
Our results support the notion that inappropriate expression of Evi1 interferes with cellular 
homeostasis and contributes to neoplastic development.  However, the mechanism behind 
cellular transformation remains elusive.  Observations in the transplantation model described by 
Buonamici et al, suggested interference of Evi1 with factors that are indispensable for normal 
erythroid development.  For instance, expression of the erythropoietin receptor (EpoR) was 
affected4.  Although a direct link between Evi1 and down regulation of EpoR expression in 
vivo has not been shown, it suggested more an indirect effect in combination with other specific 
erythroid factors.  In contrast, our findings demonstrate that both genes are unaltered in the 
presence of Evi1.  The observed effects could be partly due to the methods that were used to 
deliver Evi1.  In both models, using the bone marrow or an established cell line the Evi1 gene 
was introduced using the retroviral transduction method.  The random proviral insertion of the 
enhancers within the genome could affect the overall outcome of these experiments.    
We showed that the expression of transcription factors Pu.1 and c-Myb was altered in presence 
of Evi1 in double heterozygous fetal erythroid cells. This could provide some explanation for 
the block in differentiation.  The Pu.1 gene plays a key role in granulocytic development5,6. 
Alteration in Pu.1 expression due to proviral insertion as shown in Friend virus induced murine 
erythroleukemia (MEL) leads to cellular transformation7.  Several groups have demonstrated 
that Gata1 and Pu.1 mutually antagonize the transactivation activity of each other8-10.  This 
cross-antagonizing effect is achieved as a result of direct physical interaction between Gata1 and 
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Pu.111.  Pu.1 binds to the DNA binding domain of Gata1, thereby blocking Gata1 ability to bind 
DNA.  Gata1 can bind Pu.1 and displaces the c-Jun protein, an important coactivator of Pu.1 for 
proper transactivation of myeloid target genes.  As the fine-tuning balance between those two 
factors is necessary for maturation of erythroid cells in vivo, fluctuation of levels due to ectopic 
expression of Evi1 may perturb the equilibrium.  Our findings that c-myb expression levels 
had also changed are not unexpected.  The hierarchical transcription factor model proposed for 
MEL cells in which Pu.1 is able to block differentiation of proerythroblasts is in part achieved 
by inducing the c-myb gene, which in turn is able to deregulate the expression of c-myc gene, 
and possibly other genes.  Interestingly, downregulation of c-myb is necessary for the terminal 
differentiation of erythroid cells, as ecotopically expressed c-myb block differentiation of MEL 
cells, even though PU.1 is downregulated12. 
The next important step to understand the impediment of Evi1 in erythropoiesis will be to 
elucidate how Evi1 interferes with other essential factors.  In addition, experiments with 
X
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Figure 1 Lineage specific expression of Evi1 in novel mouse model
The expression of Evi1 is under the control of Vav hematopoietic promoter (chess box).  The Evi1 gene is silent, due to 
transcriptional stop box flanked with Cre sites (arrows) inserted between the gene and the promoter.   Cross-breeding 
between Evi1 mouse with specific Cre recombinase mouse (PEV-Cre) removes the transcriptional box and allows for 
Evi1 expression in a lineage specific manner.  The expression pattern of the Vav promoter as well as the β-LCR promoter 
within the erythroid lineage is depicted.  Stages during erythroid differentiation are as follow: HSC, hematopoietic stem 
cell; CMP, common myeloid progenitor; EMP, erythroid myeloid progenitor; BFU-e, burst forming units-erythroid; 
CFU-e, colony forming units-erythroid, Pro, proerythroblasts; Baso, basophilic erythroblast; Poly, polychromatic 
erythroblast; Ortho, orthochromatic erythroblast; Ret, reticulocyte; and Ery, erythrocyte.  
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transgenic animal models bearing expression of the Cre gene at different stages during erythroid 
development, such as EpoR-Cre, may help to understand additional genetic changes resulting in 
the outgrowth of malignant clones.
Evi1 possesses DNA binding motifs, which have been shown in vitro to bind artificial 
AGATA sequences and repress transcription of synthetic promoters13,14.  While it remains to 
be established whether this mechanism is also operational in vivo, other mechanism could 
be the cross-antagonistic activity of Evi1.  This phenomenon is observed during normal cell 
development where genes are shutdown to allow lineage commitment15,16.  On the other hand, 
in leukemia development inappropriate gene expression due to chromosomal translocation, 
viral insertion, or epigenetic changes can cause adverse effects in an uncontrolled manner by 
interference with normal transcription factors.  In such a hypothetical scenario, Evi1 can directly 
cross-react and antagonize a specific, until now unidentified, gene thereby producing an arrest 
in cell maturation.      
Although analysis of fetal erythropoiesis in the Evi1 transgenic mouse model is important 
to understand the role and function of Evi1 in cellular transformation, the ultimate goal is to 
comprehend its role in myeloid lineage in view of its role in AML.  For this purpose, our animal 
model can be crossed with specific Cre model(s) to induce the expression within the granulocytic 
lineage.  Finally, as Evi1 belongs to a transcription factor family, that possess affinity for specific 
recognition sites within the genome, it seems logical to perform a large scale screen using 
genomic approaches to bring closer the molecular changes within the cell in the presence of 
Evi1.               
In the sea of interactions
Transcription factors function is not solely restricted to interactions with DNA.  In addition they 
form protein-protein interactions with other proteins, which can transform their functions in 
different ways.  The interaction between Evi1 and several different proteins has been described 
in Chapter 1.  The question for each and all of those interactions is to sort out which ones 
are functionally significant and play a role in Evi1 transformation, and what their functional 
relationship is.  
It has been shown for many different transcription factors that physical interaction with other 
proteins or protein complexes modulates their activity.  The changes in activity can be achieved 
through different levels of direct protein modifications, such as phosphorylation, methylation, 
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acetylation, or ubiquitination17,18.  It can also be accomplished by interaction with multiprotein 
complexes, such as Sin3/HDAC, nucleosome remodeling and histone deacetylation (Mi-2/
NuRD), N-CoR/SMRT, Sin-associated proteins (Sin3-SAP), and SWI/SNF19-21.  Since in general 
multiprotein complexes do not have intrinsic DNA-binding activity, they can, directly or via an 
adaptor protein, recruit transcription factor, which can then target the complex to specific gene 
promoters.  The activity of a transcription factor bound complex can be modulated to carry out 
a positive or negative effect on transcription.  This depends on the relation between different 
complexes to each other, as the composition might change during cell development in both the 
spatial and temporal context.  Furthermore, the regulation can be achieved by additional, as yet 
unidentified, factors, which may participate and contribute further functions.  Finally, the activity 
associated with different complex points toward specialization.          
The modulation characteristics of large complexes are achieved via functionally different 
members of a given complex.  Most complexes combine and exhibit multiple enzymatic 
activities such as histone acetylation, histone methylation, and nucleosome modulation.  The 
most common subunits of several complexes are histone deacetylases (HDAC1 and HDAC2). 
HDACs are found in complexes such as Sin3-SAP, NuRD, CoREST-HDAC, and N-Cor/SMRT22-
26.  In addition some complexes contain more common subunits, such as retinoblastoma protein 
(Rb) associated proteins RbAp-46 and RbAp-48 found in Sin3-SAP and NuRD complex27.  This 
indicates that the core HDAC complex recruits additional proteins that impart distinct functional 
roles for each complex.  Furthermore, the close relationship between DNA methylation and 
gene silencing via methylated CpG dinucleotides can be achieved via direct interaction between 
methyl-CpG-binding protein MeCP2 and HDACs.  This transient physical interaction occurs 
without MeCP2 being a subunit of the N-CoR/SMRT complex28.             
In Chapter 4 we have identified a novel interacting partner of Evi1, the methyl binding domain 
3b protein, a member of the nucleosome remodeling complex (NuRD)29,30.  The analysis was 
extended to show that the complex between those two proteins does exist in vivo, and therefore 
Evi1 is found to interact directly with the NuRD complex.  
The characterization of the NuRD complex and its components have been described in details 
previously29.  The complex exerts two major functions, chromatin remodeling via the Mi2 
subunit, and histone deacetylase activity through HDAC-1 and HDAC-2.  Those two functions 
seem to be of importance in altering chromatin structure and control of gene transcription.
In general, eukaryotic repressors can exhibit this function in many different ways: 1) By 
competitive DNA binding, when the repressor occupies the binding site, and thus does not allow 
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binding of an activator, 2) By interaction between repressor and activator at the binding sites, 
masking the activation surface of the activator, 3) By direct interference of the repressor with the 
general transcription factors and thereby inhibit transcription, 4) By recruitment of repressive 
chromatin remodeling complexes and 5) By recruitment of histone deacetylase complexes, 
which might change the pattern of acetylation at the histone level.      
As Evi1 contains several interesting motifs, it is tempting to propose several different option 
how Evi1 can exhibit its dominant repressive function.  Many transcription factors contain 
repressor motifs that are generally highly charged and mediate direct interactions with basal 
transcription factors.  They also interact with activators or co-activators or with co-repressors, 
which physically modulate binding to the ultimate target.  In Chapter 5 we investigated the 
interaction between Evi-1 and a histone methyltransferases enzyme SUV39H1.
Covalent post-translational modifications of core histone amino (N) terminal tails (H2A, H2B, 
H3, and H4) at specific amino acid residues is achieved by diverse enzymes.  The array of 
different modifications includes acetylation, methylation, phosphorylation, ubiquitylation, 
sumoylation, and ADP-ribosylation31,32.  This combinatorial pattern of modifications, “histone 
code”, is a main determinant of chromatin structure and gene activity.  In general, acetylation of 
histones correlates with transcriptional activity, whereas histone methylation was shown to be 
involved in both activation and repression.  These modifications are reversible, and the level of 
specific modifications is associated with transcriptional activity.     
SUV39H1 belongs to a family of enzymes that possess specific methyltransferase activity on 
histone H3 lysine 9 (H3-K9)33.  This is achieved through a conserved domain, SET, found 
amongst many different proteins.  The specificity of methylation is highly selective for each 
enzyme, as different modifications of histone tails dictate different states of chromatin.  We 
have found a direct interaction between Evi1 and SUV39H1 and shown found that Evi1 can 
selectively interact with other methyltransferases, namely G9a, but not with SET9.  Interestingly, 
SUV39H1 and G9a were shown to modify the active chromatin into an inactive state via histone 
methylation34,35.  On the contrary, SET9 modifications modified chromatin into an active state36. 
This indicates that Evi1 may predominantly co-operate with methyltransferases that are involved 
in transcriptional repression rather than activation.  Both proteins (SUV39H1 and G9a) require 
specific DNA binding proteins to be recruited to particular promoter regions.  As Evi1 can 
interact with specific DNA sequences it may target methyltransferases to specific promoter 
regions, leading to transcriptional silencing (Figure 2).
The question that arises is who recruits whom?  Is the multiprotein complex recruited to a specific 
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DNA motif by a DNA-binding transcription factor, or does the transcription factor bind to the 
DNA upon already established access by the remodeling complex? Experiments with different 
transcription factors point to a possibility where both scenarios may be true.  Some factors are 
able to bind compact chromatin DNA, whereas others can not.  Thus, the model proposes is that 
transcription factors that can bind the recognition sites of chromatin DNA recruit a remodeling 
complexes alleviates chromatin structure, and thus allow other factors to bind DNA.
In our studies we have found that Evi-1 interferes with factors that are involved in chromatin 
remodeling (Mbd3b) and histone modification by methylation (SUV39H1 and G9a).  Direct 
interaction with those factors showed an inhibitory effect at the transcriptional level.  However, 
EVI-1 has also been shown to interact with group of molecules, C-binding protein (CBP) and 
p300/CBP-associated factor (P/CAF), that are involved in transcriptional activation rather then 
repression37. 
So, how can one trans-acting protein be both an activator and a repressor?  To answer this question 
the best example that can be referred to is the tumor suppressor p53 protein.  As mentioned 
earlier proteins may undergo different post-translational modifications.  Each of the specific 
protein modifications may play a role and dictates the state either to be an activator or repressor. 
The C-terminal part of p53 contains regulatory domain that undergoes multiple modifications at 
different residues.  It has been shown that acetylation of several lysine residues (K372, K373, 
K381, K382, and K320) can be achieved by histone acetyltransferase (HAT) enzyme, which 
increases the DNA-binding activity, and transactivation of p5338,39.  However, DNA bound p53 
is in an unmodified form and after DNA damage several lysine residues are acetylated, which in 
turn recruits HDAC complexes that release the HAT enzymes from the promoter site and induce 
rapid promoter repression.  Such highly selective changes regulate the p53 status from being an 
activator towards a repressor during specific phases of the cell cycle40.
 
Future directions
Although our knowledge about the role of aberrantly expressed transcription factors in AML 
improved largely over the years, we still lack the insight into the pathways that could be disrupted 
in AML by those transcription factors.  Animal model studies are crucial to comprehend the 
pathogenesis of human diseases.  Analysis of our animal model generated to specifically 
expressed Evi1 in a control manner in all hematopoietic lineages may be a useful tool to dissect 
and reveal the full significance of Evi1 interference with lineage specific differentiation.  
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Our working hypothesis that Evi1 interferes with erythroid lineage differentiation was 
recapitulated by showing a direct link between Evi1 expression and erythroid lineage 
impediment during the development of fetal erythropoiesis.  Although the interference of Evi1 
with fetal erythropoiesis is an important observation, it still does not fully explain in details the 
genetic abnormalities behind the transformation.  Therefore, to further study the changes at the 
molecular level on a genome wide scene, analysis of selective population of fetal hematopoietic 
cells could be analyzed by means of genomic approaches like microarray analysis.  
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Figure 2 Proposed model 
for Evi1 transcriptional 
repression
Schematic representation 
of nucleosomes and histone 
tails.  The DNA strands 
are wrapped around the 
nucleosome and extrude 
the histone N-terminus 
tails.  The tails undergo 
specific modifications 
at different amino acids. 
The acetylated status 
of histone tails dictates 
transcriptional activation 
as the nucleosomes are in 
a relaxed form.  Interaction 
between Evi1 and Mbd3b 
(Chapter 3) brings in the 
histone deacetylation 
complex (NuRD), which 
is able to deacetylase, the 
histones.  As Evi1 also 
interacts with SUV39H1 
(Chapter 4) this interaction 
can exhibit specific 
methylation at histone 
H3 lysine 9 (H3-K9). 
Methylation of H3-K9 
is found to be associated 
with histone condensation 
and thus transcriptional 
repression.      
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In addition, of great interest is to study inappropriate expression of Evi1 in myeloid lineage. 
Analysis of blast cells from AML patients with aberrant expression of Evi1 clearly shows a 
lineage- and stage-specific block of differentiation, supporting the idea that the stem cells 
compartment is also involved.  To elucidate fully on the involvement of Evi1 in myeloid 
leukemia development, it might be worthwhile to intercross the Evi1 transgenic mice with 
various transgenic mice lines that specifically express Cre enzyme at a stage specific time point 
during myelopoiesis.  Furthermore, this will also help to understand if Evi1 is solely responsible 
for AML development or additional genetic abnormalities are needed to recapitulate human 
AML.  In situation when Evi1 is not able to induce AML on its own, cooperating mutations can 
be introduced by crossing Evi1 mice with transgenic mice expressing other genes frequently 
found to be involved in AML development and progression. 
Equally interested are more detailed studies of Evi1 protein-protein interactions and contribution 
to the block of differentiation found in AML.  In particular, Evi1 interactions with factors 
implicated in epigenetic gene control and/or with multi subunit complex involved in chromatin 
remodeling can provide further knowledge of aberrantly disrupted transcription factors in critical 
cellular processes such as cell growth, proliferation, differentiation, and apoptosis.
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Ecotropic viral integration site 1 (Evi1) is a zinc finger containing nuclear protein, which 
is involved in transcriptional control.  Although Evi1 expression during normal embryonic 
development is essential for survival, the level of expression appears less necessary in the later 
stages of development.  
Inappropriate “re-expression” of Evi1 in patient’s hematopoietic precursor cells due to 
chromosomal abnormalities has been found to be a contributing factor in the development 
and progression of malignancies such as myelodysplastic syndrome (MDS) or acute myeloid 
leukemia (AML).  Patients with high levels of Evi1 transcript have a poor survival rate and 
current therapy is not suitable to treat the disease. 
Chapter 1 gives an overview of current knowledge in development of two hematopoietic 
lineages, i.e. erythroid and myeloid.  The role and function of the most important transcription 
factors in these specific lineages will be described.  Furthermore, the Evi1 gene is introduced in 
the context of 1) leukemia development, 2) interaction with known proteins and 3) formation of 
fusion proteins in human disease.  Finally, regulation of transcription by histone modification is 
briefly described.       
The involvement of Evi1 in cellular transformation has been shown in vitro using several 
different models.  However, its role in vivo was not addressed as extensively.  To elucidate on 
the effects of Evi1 in vivo we generated and analyzed a novel Evi1 transgenic mouse model as 
described in Chapter 2.  Using conditionally expressed Evi1 in a restricted manner, i.e. within 
the erythroid lineage we have found a lethality rate of almost 40% in double heterozygous 
embryos.  Analysis of E12.5 fetal livers from double transgenic animals revealed profound 
anemia, characterized by abnormal maturation of erythroid cells, with the presence of large 
dysplastic cells.  The differentiation capacity of cells was also affected as significant reduction in 
the numbers of colony forming units-erythroid (CFU-E) was obtained upon culture of fetal liver 
progenitors.  Moreover, several different erythroid markers genes were affected: We observed an 
increase in expression of Pu.1 and c-Myb, but a decrease in beta-major and Alas2.  No changes 
were observed in Gata1 and EpoR mRNA expression levels.  The results indicate and support the 
notion that erythroid specific overexpression of Evi1 interferes with erythroid development in 
the mouse.  In Chapter 3 we described analysis of Evi1 expression in early erythroid progenitors 
using Cre mouse under the erythropoietin receptor promoter.  The analysis revealed severe 
126
Summary
127
Summary
phenotype characterized by profound cell death, decrease number of progenitor cells, inability 
of erythroid precursors to terminally differentiate, and dysplasia.        
Chapter 4 of this thesis describes identification and analysis of a novel Evi1 binding partner 
found in yeast two-hybrid screen.    Methyl binding domain 3b (Mbd3b) was found to interact 
with Evi1, a component of histone deacetylase complex (NuRD). The association between 
several other transcriptional factors and NuRD indicate its role in transcriptional repression. 
The interaction requires zinc finger domain of Evi1 and the MBD domain plus a short stretch 
of amino acids close to the MBD domain of Mbd3b.  Biochemical analysis revealed that both 
proteins interact in vivo, and are found in subcellular speckles in the nucleus.  Although the nature 
of the nuclear speckles has been not identified up to date, it may represent specific loci where 
Evi1 interacts with DNA.  Interaction of Evi1 with Mbd3b may recruit the NuRD complex to 
those specific areas.  In luciferase reporter assay the direct interaction between those two proteins 
was able to repress transcriptional activity.  The binding between Evi1 and Mbd3b showed that it 
might be involved in epigenetic chromatin modification and leukemic transformation.
Evi1 belongs to the PRDM family of genes. The features of the PRDM3 (MDS-Evi1) gene are 
highly analogous to the PRDM2 (RIZ) and PRDM1 (Blimp-1) genes, in which each express 
a truncated protein missing the PR domain.  It has been demonstrated that another member of 
this family of proteins PRDM1 interacts with the histone methyltransferases G9a.  In Chapter 
5 we analyze whether Evi1 may also interact with histone methyltransferases.  The findings 
indicate that Evi1 indeed physically interacts with methyltransfereases, however the interactions 
are selective as it interacts with SUV39H1 and G9a but not with Set9.  The binding domain of 
SUV39h1 has been mapped to involve SET domain, a common motif found in several different 
methyltransferases.  As the binding does not interfere with SUV39H1 enzymatic activity, we 
showed that upon interaction with SUV39H1, Evi1 is able to exhibits methylation activity. 
Further analysis showed that the complex of SUV39H1/Evi1 can be found bound to histone 
tails.  Since specific methylation of histone tails is involved in transcriptional repression, we 
could demonstrate that presence of SUV39H1 enhances Evi1 transcriptional repression in a 
dose dependent manner.  These results establish Evi1 as a transcriptional regulator that is able 
to form higher order complexes with histone methyltransferases and may cause transcriptional 
repression of putative target genes during tumorgenesis.  
The general discussion described in Chapter 6 summarizes our findings and provides possible 
explanation for the role of Evi1in leukemic development.  
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EVI1 (Afkorting voor: Ecotropic Viral Integration site 1) is een nucleair eiwit met specifieke 
domeinen (zogenaamde zinkvingers) die kunnen binden aan DNA. EVI1 is oorspronkelijk 
geïdentificeerd als een eiwit dat betrokken is bij de ontwikkeling van leukemie in de muis. 
Daarnaast is abnormale expressie van EVI1 in de hematopoietische voorlopercellen, als gevolg 
van bijvoorbeeld chromosomale translocaties, (is) aangetoond in patiënten met myelodysplastisch 
syndroom (MDS) en acute myeloïde leukemie (AML). Deze bevindingen suggereren dat EVI1 
mogelijk een rol speelt bij de ontwikkeling en progressie van leukemie. Patiënten met verhoogde 
expressie van EVI1 reageren over het algemeen relatief slecht op de huidige therapieën.
Alhoewel de exacte rol van EVI1 nog onduidelijk is lijkt het eiwit betrokken te zijn bij 
transcriptionele genregulatie. Ondanks dat EVI1 expressie noodzakelijk is voor embryonale 
ontwikkeling, blijkt het niveau van EVI1 minder essentieel later in  de ontwikkeling.
Hoofdstuk 1 geeft een overzicht van de normale bloedcelvorming, in het bijzonder de erythroïde 
en myeloïde bloedcelontwikkeling. De rol en functie van de belangrijkste transcriptiefactoren 
in deze twee specifieke bloedcel lijnen worden bediscussieerd. In dit hoofdstuk wordt EVI1 
besproken met betrekking tot 1) leukemieontwikkeling, 2) interactie met andere eiwitten en 3) de 
EVI1-fusie eiwitten die worden gevonden in humane leukemieën. Tot besluit, wordt de regulatie 
van gentranscriptie door histon modificatie beschreven.
Cellulaire transformatie als gevolg van verhoogde expressie van EVI1 is aangetoond in in vitro 
modelsystemen. Echter, het effect van abnormaal verhoogde expressie van EVI1 in in vivo 
systemen was nog niet bestudeerd. Om deze in vivo effecten te onderzoeken hebben we een 
nieuw EVI1 transgeen muizenmodel gegenereerd en geanalyseerd, hetgeen staat beschreven 
in Hoofdstuk 2. Door EVI1, in dit conditionele muizenmodel, specifiek tot expressie te laten 
komen in de erythroïde bloedcellen, tonen we aan dat  EVI lethaal is voor bijna 40% van de 
muizenembryo’s. De foetale levers van muizen met verhoogde EVI1 expressie vertoonden een 
anemie, d.w.z. een duidelijk verlaagde hoeveelheid aan rode bloedcellen. De rode bloedcellen 
die aanwezig waren vertoonden een abnormale erythroïde ontwikkeling, gekarakteriseerd door 
karakteristieke grote displastische cellen. De capaciteit van de rode cellen om te differentiëren is 
ook gestoord aangezien er een duidelijke reductie in kolonie vormende cellen werd aangetoond 
wanneer de cellen uit de foetale levers in vitro werden gekweekt. Verhoogde EVI1 expressie 
resulteerde ook in abnormale expressie van verschillende erythoïd- specifieke genen. De genen 
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die coderen voor de transcriptiefactoren Pu.1 en c-Myb kwamen verhoogd tot expressie, terwijl 
betaglobine (major) en AlaS verlaagd waren. Geen veranderingen in expressie werden aangetoond 
voor de erythroïd-specifieke genen die coderen voor Gata1 en erythropoietine receptor. We tonen 
aan dat verhoogde EVI1 expressie in een in vivo muizenmodel de normale ontwikkeling van 
erythroïde cellen in het embryonale stadium verstoord. In Hoofdstuk 3 onderzochten we de 
effecten van EVI1 in vroege erythroïde voorloper cellen door de in hoofdstuk 3 beschreven 
transgene EVI1 muizen te kruisen met muizen waarbij het Cre-gen onder controle staat van de 
Epo-receptor promoter. Dubbel transgene embryo’s vertonen een ernstig fenotype, namelijk veel 
celdood van foetale lever cellen, een sterke afname van het aantal erythroïde voorloper cellen, 
onvermogen van voorlopercellen om te differentiëren en dysplasie. 
Hoofdstuk 4 beschrijft de identificatie en analyse, met het zogenaamde two-hybrid systeem, 
van een nieuw eiwit dat aan EVI1 bindt. Dit eiwit, Mbd3b behoort tot een familie van eiwitten 
dat specifiek bindt aan gemethyleerd DNA. Het is onderdeel van een groter complex (NuRD) 
dat betrokken is bij de modificatie van histonen en kan daarbij de expressie van genen verlagen 
door middel van deacetylering. EVI1 wordt over het algemeen gezien als een transcriptionele 
repressor. Het feit dat EVI1 kan binden aan het NuRD complex suggereert dat EVI1 de expressie 
van specifieke genen mogelijk verlaagd als gevolg van de NuRD functie. EVI1 en Mbd3b 
binden door middel van specifieke domeinen in EVI1, de zogaande zinkvingers, en het methyl 
bindingsdomein van Mbd3b. Met biochemische analyses werd aangetoond dat de binding tussen 
EVI1 en Mbd3b optreedt in vivo en dat beide eiwitten zich bevinden in specifieke nucleaire 
structuren. Ondanks dat de exacte functie van deze structuren onbekend is, zouden het mogelijk 
de plaatsen aangeven waar EVI1 aan het DNA bindt. Het NuRD complex zou als gevolg van de 
interactie van EVI1 met Mbd3d naar deze specifieke plaatsen worden getransporteerd. Middels 
specifieke in vitro transcriptie analyses tonen we aan dat de directe interactie tussen EVI1 en 
Mbd3b inderdaad transcriptionele repressie tot gevolg heeft. Deze resultaten zouden kunnen 
suggereren dat EVI1 zijn leukemische transformatie ontleent aan de binding met Mbd3b dat, als 
onderdeel van het NuRD complex, resulteert in de modificatie van het chromatine.
EVI1 behoort tot de familie van zogenaamde PRDM (PR domein-bevattende) eiwitten. De 
eigenschappen van het PRDM3 (MDS-EVI1) gen zijn analoog aan de genen die coderen voor 
PRDM2 (RIZ) en PRDM1 (BLIMP-1), waarbij naast het volledige gen product ook een verkort 
eiwit tot expressie kan komen, zonder het PR domein. In het verleden is aangetoond dat PRDM1 
bindt aan de histon methyltransferase G9a. In Hoofdstuk 5 hebben we onderzocht of EVI1 ook 
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bindt aan histon methyltransferases. We hebben aangetoond dat EVI1 inderdaad een selectieve 
interactie aangaat met twee specifieke methyltransferases, SUV39H1 en G9a. EVI1 bindt echter 
niet aan een ander methyltransferase Set9. Het zogenaamde SET domein, een domein dat 
frequent wordt gevonden bij methyltransferases, van SUV39h1, is noodzakelijk voor de binding 
aan EVI1. Deze binding interfereert niet met de normale enzymatische functie van SUV39h1 
en we laten zien dat EVI1 door middel van de interactie met SUV39h1 methyltransferase 
activiteit krijgt.  We hebben tevens laten zien dat het EVI1/SUV39h1 complex aan histonen 
bindt. Specifieke methylering van histonen resulteert in transcriptionele repressie. We hebben 
aangetoond dat de transcriptionele repressie van EVI1 versterkt naar mate er meer SUV39h1 
aanwezig is. Onze resultaten impliceren dat EVI1 onderdeel is van complexen van eiwitten 
met methyltransferase activiteit. Deze activiteit is mogelijk betrokken bij de remming van de 
transcriptie van EVI1-gereguleerde genen en EVI1-gemedieerde tumorgenese.
De algemene discussie beschreven in Hoofdstuk 6 geeft een samenvatting van de bevindingen 
en belicht de rol van EVI1 in leukemie ontwikkeling naar aanleiding van de bevindingen 
beschreven in dit proefschrift.
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List of abbreviations
293T   Human primary embryonal kidney cells
32D   Growth factor-dependent mouse bone marrow cells
7-AAD   7-amino actinomycin D
AML   Acute myeloid leukemia
BFU-e   Burst forming unit erythroid
cDNA   Complementary deoxyribonucleic acid
CD 71   Transferrin receptor
CFU-e   Colony forming unit erythroid
c-kit (CD117)  Stem cell factor receptor
COS-7   African green monkey kidney cell line
DNA   Deoxyribonucleic acid
E   Embryonic day
EGFP   Enhanced green fluorescence protein
Epo   Erythropoietin
Evi   Ecotropic integration site
FACS   Fluorescence-activated cell sorter
FCS   Fetal calf serum
FITC   Fluorescein isothiocyanate
GST   Glutathione S-transferase
HDAC   Histone deacetylase
HSC   Hematopoietic stem cell
HTMase  Histone methyltransferases assay
IL   Interluekin
IP   Immuno precipitation
kb    Kilo base
kD   Kilo Dalton
LCR   Locus control region
MDS   Myelodysplastic syndrome
MEL   Mouse erythroleukemia
ONPG   o-nitrophenyl-β-d-galactopyranoside
mRNA   Messenger ribonucleic acid
PCR   Polymerase chain reaction
ϕE    Retrovirus producer cells based on the 293T cell line
SCF   Stem cell factor
TAP   Tandem Affinity Purification
TER119  Erythroid cell marker
TRITC   Tetramethylrhodamine isothiocyanate
WB   Western blotting
Y2H   Yeast-two hybrid
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